<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for female pattern hair loss - van Zuuren, EJ - 2016 | Cochrane Library</title> <meta content="Interventions for female pattern hair loss - van Zuuren, EJ - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007628.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for female pattern hair loss - van Zuuren, EJ - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007628.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007628.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for female pattern hair loss" name="citation_title"/> <meta content="Esther J van Zuuren" name="citation_author"/> <meta content="Leiden University Medical Center" name="citation_author_institution"/> <meta content="E.J.van_Zuuren@lumc.nl" name="citation_author_email"/> <meta content="Zbys Fedorowicz" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Jan Schoones" name="citation_author"/> <meta content="Leiden University Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD007628.pub4" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/05/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007628.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007628.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007628.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Alopecia [*therapy]; Drug Administration Schedule; Finasteride [*therapeutic use]; Hair [*drug effects, growth &amp; development]; Low‐Level Light Therapy; Minoxidil [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007628.pub4&amp;doi=10.1002/14651858.CD007628.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="IYhCEbRn";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007628\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007628\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007628\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007628\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ru","pt","ms","hr","fr","zh_HANT","fa","th"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007628.pub4",title:"Interventions for female pattern hair loss",firstPublishedDate:"May 26, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007628.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007628.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007628.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007628.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007628.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007628.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007628.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007628.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007628.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007628.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>15041 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007628.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-sec-0348"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-sec-0043"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-sec-0044"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-sec-0052"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-sec-0053"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-sec-0082"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-sec-0337"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/appendices#CD007628-sec-0353"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/table_n/CD007628StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/table_n/CD007628StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for female pattern hair loss</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/information#CD007628-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Esther J van Zuuren</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/information#CD007628-cr-0003">Zbys Fedorowicz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007628.pub4/information#CD007628-cr-0004">Jan Schoones</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/information/en#CD007628-sec-0370">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 May 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007628.pub4">https://doi.org/10.1002/14651858.CD007628.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007628-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007628-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007628-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007628-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007628-abs-0004">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD007628-abs-0003">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD007628-abs-0018">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007628-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007628-abs-0001" lang="en"> <section id="CD007628-sec-0001"> <h3 class="title" id="CD007628-sec-0001">Background</h3> <p>Female pattern hair loss (FPHL), or androgenic alopecia, is the most common type of hair loss affecting women. It is characterised by progressive shortening of the duration of the growth phase of the hair with successive hair cycles, and progressive follicular miniaturisation with conversion of terminal to vellus hair follicles (terminal hairs are thicker and longer, while vellus hairs are soft, fine, and short). The frontal hair line may or may not be preserved. Hair loss can have a serious psychological impact on women. </p> </section> <section id="CD007628-sec-0002"> <h3 class="title" id="CD007628-sec-0002">Objectives</h3> <p>To determine the efficacy and safety of the available options for the treatment of female pattern hair loss in women. </p> </section> <section id="CD007628-sec-0003"> <h3 class="title" id="CD007628-sec-0003">Search methods</h3> <p>We updated our searches of the following databases to July 2015: the Cochrane Skin Group Specialised Register, CENTRAL in the Cochrane Library (2015, Issue 6), MEDLINE (from 1946), EMBASE (from 1974), PsycINFO (from 1872), AMED (from 1985), LILACS (from 1982), PubMed (from 1947), and Web of Science (from 1945). We also searched five trial registries and checked the reference lists of included and excluded studies. </p> </section> <section id="CD007628-sec-0004"> <h3 class="title" id="CD007628-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials that assessed the efficacy of interventions for FPHL in women. </p> </section> <section id="CD007628-sec-0005"> <h3 class="title" id="CD007628-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial quality, extracted data and carried out analyses. </p> </section> <section id="CD007628-sec-0006"> <h3 class="title" id="CD007628-sec-0006">Main results</h3> <p>We included 47 trials, with 5290 participants, of which 25 trials were new to this update. Only five trials were at 'low risk of bias', 26 were at 'unclear risk', and 16 were at 'high risk of bias'. </p> <p>The included trials evaluated a wide range of interventions, and 17 studies evaluated minoxidil. Pooled data from six studies indicated that a greater proportion of participants (157/593) treated with minoxidil (2% and one study with 1%) reported a moderate to marked increase in their hair regrowth when compared with placebo (77/555) (risk ratio (RR) = 1.93, 95% confidence interval (CI) 1.51 to 2.47; moderate quality evidence). These results were confirmed by the investigator‐rated assessments in seven studies with 1181 participants (RR 2.35, 95% CI 1.68 to 3.28; moderate quality evidence). Only one study reported on quality of life (QoL) (260 participants), albeit inadequately (low quality evidence). There was an important increase of 13.18 in total hair count per cm² in the minoxidil group compared to the placebo group (95% CI 10.92 to 15.44; low quality evidence) in eight studies (1242 participants). There were 40/407 adverse events in the twice daily minoxidil 2% group versus 28/320 in the placebo group (RR 1.24, 95% CI 0.82 to 1.87; low quality evidence). There was also no statistically significant difference in adverse events between any of the individual concentrations against placebo. </p> <p>Four studies (1006 participants) evaluated minoxidil 2% versus 5%. In one study, 25/57 participants in the minoxidil 2% group experienced moderate to greatly increased hair regrowth versus 22/56 in the 5% group (RR 1.12, 95% CI 0.72 to 1.73). In another study, 209 participants experienced no difference based on a visual analogue scale (P = 0.062; low quality evidence). The assessments of the investigators based on three studies (586 participants) were in agreement with these findings (moderate quality evidence). One study assessed QoL (209 participants) and reported limited data (low quality evidence). Four trials (1006 participants) did not show a difference in number of adverse events between the two concentrations (RR 1.02, 95% CI 0.91 to 1.20; low quality evidence). Both concentrations did not show a difference in increase in total hair count at end of study in three trials with 631 participants (mean difference (MD) −2.12, 95% CI −5.47 to 1.23; low quality evidence). </p> <p>Three studies investigated finasteride 1 mg compared to placebo. In the finasteride group 30/67 participants experienced improvement compared to 33/70 in the placebo group (RR 0.95, 95% CI 0.66 to 1.37; low quality evidence). This was consistent with the investigators' assessments (RR 0.77, 95% CI 0.31 to 1.90; low quality evidence). QoL was not assessed. Only one study addressed adverse events (137 participants) (RR 1.03, 95% CI 0.45 to 2.34; low quality evidence). In two studies (219 participants) there was no clinically meaningful difference in change of hair count, whilst one study (12 participants) favoured finasteride (low quality evidence). </p> <p>Two studies (141 participants) evaluated low‐level laser comb therapy compared to a sham device. According to the participants, the low‐level laser comb was not more effective than the sham device (RR 1.54, 95% CI 0.96 to 2.49; and RR 1.18, 95% CI 0.74 to 1.89; moderate quality evidence). However, there was a difference in favour of low‐level laser comb for change from baseline in hair count (MD 17.40, 95% CI 9.74 to 25.06; and MD 17.60, 95% CI 11.97 to 23.23; low quality evidence). These studies did not assess QoL and did not report adverse events per treatment arm and only in a generic way (low quality evidence). Low‐level laser therapy against sham comparisons in two separate studies also showed an increase in total hair count but with limited further data. </p> <p>Single studies addressed the other comparisons and provided limited evidence of either the efficacy or safety of these interventions, or were unlikely to be examined in future trials. </p> </section> <section id="CD007628-sec-0007"> <h3 class="title" id="CD007628-sec-0007">Authors' conclusions</h3> <p>Although there was a predominance of included studies at unclear to high risk of bias, there was evidence to support the efficacy and safety of topical minoxidil in the treatment of FPHL (mainly moderate to low quality evidence). Furthermore, there was no difference in effect between the minoxidil 2% and 5% with the quality of evidence rated moderate to low for most outcomes. Finasteride was no more effective than placebo (low quality evidence). There were inconsistent results in the studies that evaluated laser devices (moderate to low quality evidence), but there was an improvement in total hair count measured from baseline. </p> <p>Further randomised controlled trials of other widely‐used treatments, such as spironolactone, finasteride (different dosages), dutasteride, cyproterone acetate, and laser‐based therapy are needed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007628-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007628-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD007628-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD007628-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007628-abs-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007628-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007628-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007628-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD007628-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007628-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD007628-abs-0019">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007628-abs-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007628-abs-0013">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007628-abs-0005" lang="en"> <h3>Treatments for female pattern hair loss</h3> <p><b>Review question</b> </p> <p>Which treatments are effective and safe for female pattern hair loss (FPHL)?</p> <p><b>Background</b> </p> <p>The most common type of hair loss in women is FPHL, also known as androgenic alopecia. Unlike men, women do not go bald, but have hair thinning predominantly over the top and front of the head. It can occur at any time, from puberty until later in life. However, it occurs more frequently in postmenopausal women. </p> <p>The diagnosis is supported by careful history taking (including family history). Other causes should be considered; therefore, a clinical examination and laboratory tests may be necessary. FPHL can have a significant impact on self‐consciousness, and the damage to a woman's self‐confidence can affect her quality of life (QoL), leading to feelings of unattractiveness, shame, discomfort, emotional stress, and low self‐esteem. </p> <p><b>Study characteristics</b> </p> <p>We examined the available evidence up to 7 July 2015. Forty‐seven studies, which included 5290 women, met the inclusion criteria of this Cochrane review. The mean age of participants in the studies varied from 27 to 57 years. We assessed over half of the included studies as at unclear risk of bias, 16 as high risk, and only five studies as low risk of bias. Funding was provided in 26 of the 47 studies, mainly by pharmaceutical companies. </p> <p><b>Key results</b> </p> <p>This Cochrane review found that minoxidil is more effective than placebo. In six studies, the proportion of women that experienced at least moderate hair regrowth was twice as high in the minoxidil group compared to the placebo group. This was confirmed by the investigators assessments in seven studies. In eight studies, there was an important increase in total hair count per cm² in the minoxidil group compared to the placebo group. QoL was only assessed in one study and it was unclear from the data if there was an important improvement. The number of adverse events was similar for both groups. These were mostly mild, consisting of itch, skin irritation, dermatitis, and additional hair growth on areas other than the scalp. </p> <p>Four studies compared minoxidil (2%) to minoxidil (5%), but none of the studies indicated any benefit of the higher concentration over the lower concentration. The number of adverse events did not differ between the two groups. Minoxidil should not be used in pregnant or lactating women. </p> <p>Three studies compared finasteride to placebo. Finasteride is only approved in men for treatment of hair loss as well as for enlarged prostate. In one of the three studies the opinion of both the participants and investigators were evaluated but finasteride was shown to be no more effective than placebo. Hair count improved only in the finasteride group in a small study with 12 participants, but not in the other two studies (219 participants). Adverse events were only addressed in one study and these were similar in both groups. The investigators of these studies did not assess QoL. </p> <p>Laser comb therapy did not appear to be more effective than sham therapy according to the participants in two studies with 141 participants. Nonetheless an important increase in hair growth was reported in both these studies. QoL was not addressed, and adverse events were not reported per intervention group, making these data less usable. </p> <p>Individual studies investigated most of the other interventions and comparisons, and we could not make any firm conclusions about the efficacy or safety of these other interventions. </p> <p>Although it is generally acknowledged that renewed hair shedding occurs relatively soon after discontinuation of treatment, none of the included studies reported data on the sustainability of the treatment effect, nor on the possible impact of hair regrowth, reflected by a decrease in time spent by women on hair styling or the use of wigs. </p> <p><b>Quality of the evidence</b> </p> <p>We rated the quality of evidence for most outcomes as moderate or low. The lower quality of evidence was mainly caused by risk of bias in studies (e.g. no blinding) or a small sample size making the results less precise. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007628-sec-0348" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007628-sec-0348"></div> <h3 class="title" id="CD007628-sec-0349">Implications for practice</h3> <section id="CD007628-sec-0349"> <p>Based on only those studies that are most likely to have provided reliable results (i.e. reproducible, repeatable, and therefore valid), and selecting the most rigorously described and conducted studies, we conclude that there is mainly moderate to low quality evidence to support the efficacy of only one of the interventions for female pattern hair loss (FPHL), notably minoxidil. </p> <p>Minoxidil (2%) topical solution twice daily appears to be effective and safe, and minoxidil (5%) used once daily may be as effective as minoxidil (2%) used twice daily, which is likely to result in improved adherence. However, the higher concentration of minoxidil (5%) is only registered for therapeutic management of FPHL in a small number of countries worldwide. </p> <p>Although finasteride continues to be prescribed for treatment of women with FPHL, this therapeutic option does not appear to be supported by current research based on randomised controlled trials. Low‐level laser therapy options are attracting interest but the results so far have been inconsistent. </p> <p>Clinical decision‐making on the choice of intervention for FPHL should be based on high‐level evidence if it is available, but in the absence of such evidence for any other specific intervention, these decisions should continue to be guided by clinical experience and peoples' individual characteristics and preferences until further evidence for these other interventions becomes available. </p> <p>In view of the fact that there may be a delay before any treatment effect can be noticed, and as most of the available treatments fail to achieve the desired end result, cosmetic aids and hair transplant surgery need to be included in the decision‐making process. Furthermore, physicians should also try to address the psychosocial impact, coping mechanisms, and QoL issues when treating women with FPHL. </p> </section> <h3 class="title" id="CD007628-sec-0350">Implications for research</h3> <section id="CD007628-sec-0350"> <p>It is widely perceived that 2% minoxidil is more effective than the 1% concentration, and this is reflected in the fact that the 2% concentration is most frequently registered worldwide for FPHL. However, the results from one study included in this review indicate that 1% minoxidil does not appear any less effective than 2% minoxidil and is also associated with a potentially lower number of adverse events. There was also evidence (mainly moderate to low quality) that 5% minoxidil once daily was as effective as 2% minoxidil twice daily; a factor which may be important in improving adherence in future clinical trials. </p> <p>There is also an urgent need for high‐quality, well‐designed, and rigorously‐reported studies of other widely‐used treatments, such as spironolactone, finasteride (at different dosages), dutasteride, cyproterone acetate, and laser‐based therapy. Conceivably, some studies listed in the '<a href="./references#CD007628-sec-0379" title="">Characteristics of ongoing studies</a>' section of this review will be able to provide answers to these remaining questions in the future. </p> <p>There was wide variability in the conduct and the quality of reporting of many trials. A major area for improvement would be in the standardisation of outcome reporting in any future research. The use of proprietary severity scales and non‐standardised scales significantly hampered our ability to combine study results for a meta‐analysis. Outcomes collected in future trials should be primarily based on a standardised scale of the participant's assessment of the treatment efficacy, and they should also have a greater emphasis on changes in QoL as a result of the interventions. Standardised and uniform scales should be developed and used for physicians' assessments, and these should reliably reflect the proportion of participants with investigator‐rated clinically significant hair regrowth and mean change in total hair count from baseline to the end of the study. Follow‐up studies addressing the sustainability of hair regrowth after discontinuation of treatment should be taken into account as they constitute an important outcome for participants. Another important patient‐reported outcome should be the impact of the hair regrowth reflected by a decrease in the time spent by women on hair styling, including the use of wigs. </p> <p>Future randomised controlled trials must be well‐designed, well‐conducted, and adequately delivered, with subsequent reporting, including high‐quality descriptions of all aspects of methodology. Rigorous reporting needs to conform to the Consolidated Standards of Reporting Trials (<a href="http://www.consort-statement.org/" target="_blank">CONSORT</a>) statement, and this will enable appraisal and interpretation of results, and accurate judgements to be made about the risk of bias and the overall quality of the evidence. Although it is uncertain whether reported quality mirrors actual study conduct, it is noteworthy that studies with unclear methodology have been shown to produce biased estimates of treatment effects (<a href="./references#CD007628-bbs2-0151" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. [PUBMED: 7823387] ">Schulz 1995</a>). Adherence to guidelines, such as the CONSORT statement, would help ensure complete reporting. </p> <p>For further research recommendations based on the EPICOT (evidence, population, intervention, comparison, outcomes, and time) format (<a href="./references#CD007628-bbs2-0116" title="BrownP , BrunnhuberK , ChalkidouK , ChalmersI , ClarkeM , FentonM , et al. How to formulate research questions. BMJ2006;333(7572):804‐6. [PUBMED: 17038740 ] ">Brown 2006</a>), see <a href="#CD007628-tbl-0010">Table 6</a>. </p> <div class="table" id="CD007628-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Research recommendations based on a gap in the evidence of the effects of interventions for female pattern hair loss (FPHL)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Core elements</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Issues to consider</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Status of research for this review</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evidence (E)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>What is the current state of the evidence?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This systematic review included 47 RCTs. There is mainly moderate to low quality evidence for the efficacy and safety of topical minoxidil 2% and 5% in the treatment of FPHL. </p> <p>Minoxidil (2%) topical solution twice daily appears to be effective and safe, and minoxidil (5%) used once daily may be as effective as minoxidil (2%) used twice daily, which may result in improved adherence. However, the higher concentration (5%) of minoxidil is only registered for the therapeutic management of FPHL in a small number of countries around the world. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Population (P)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosis, disease stage, comorbidity, risk factors, gender, age, ethnic group, specific inclusion or exclusion criteria, clinical setting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The participants should be aged 18 to 89 years.</p> <p>A distinction between women with and without a hyperandrogenic profile should be made, and between ethnic groups as well as pre‐ and postmenopausal women. </p> <p><b>Inclusion criteria </b> </p> <p> <ul id="CD007628-list-0010"> <li> <p>Women with FPHL Ludwig (3‐point) classification (<a href="./references#CD007628-bbs2-0137" title="LudwigE . Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. British Journal of Dermatology1977;97(3):247‐54. [PUBMED: 921894] ">Ludwig 1977</a>) or the Sinclair (5‐point) scale (<a href="./references#CD007628-bbs2-0153" title="SinclairR , JolleyD , MallariR , MageeJ . The reliability of horizontally sectioned scalp biopsies in the diagnosis of chronic diffuse telogen hair loss in women. Journal of the American Academy of Dermatology2004;51(2):189‐99. [PUBMED: 15280836] ">Sinclair 2004</a>). </p> </li> </ul> </p> <p><b>Exclusion criteria </b> </p> <p> <ul id="CD007628-list-0011"> <li> <p>Local scalp treatments in prior 4 weeks.</p> </li> <li> <p>Systemic treatment three months prior to study that could interfere with the study medications. </p> </li> <li> <p>Chemotherapy, radiation therapy, or laser therapy (on the scalp) within the last 6 months. </p> </li> <li> <p>Concomitant medication for treatment of hair loss.</p> </li> <li> <p>Pregnant or lactating women.</p> </li> <li> <p>Hyper‐ or hypothyroidism.</p> </li> <li> <p>Malnutrition.</p> </li> <li> <p>Liver, renal, or metabolic disease.</p> </li> <li> <p>Wearing a wig or having had a hair transplant.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type, frequency, dose, duration, prognostic factor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study duration should be at least 6 months.</p> <p>High‐quality, well‐designed, and rigorously‐reported studies of other widely used treatments, e.g. spironolactone, finasteride (at different dosages), dutasteride, cyproterone acetate, and laser‐based therapy should be included. </p> <p>Information on direct and indirect costs of the interventions should be addressed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparison (C)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type, frequency, dose, duration, prognostic factor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Direct comparison studies of the widely used treatments are warranted.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome (O)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Which clinical or patient‐related outcomes will the researcher need to measure, improve, influence, or accomplish? Which methods of </p> <p>measurement should be used?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant's assessment of the treatment efficacy and changes in quality of life using standardised questionnaires, e.g. the Women's Androgenetic Alopecia Quality of Life Questionnaire (WAA‐QOL) (<a href="./references#CD007628-bbs2-0112" title="BiondoS , SinclairR . Quality of life in Australian women with female pattern hair loss. The Open Dermatology Journal2010;4:90‐4. ">Biondo 2010</a>; <a href="./references#CD007628-bbs2-0120" title="DolteKS , GirmanCJ , HartmaierS , RobertsJ , BergfeldW , WaldstreicherJ . Development of a health‐related quality of life questionnaire for women with androgenetic alopecia. Clinical and Experimental Dermatology2000;25(8):637‐42. [PUBMED: 11167980] ">Dolte 2000</a>). Standardised and uniform scales should be developed and used for physicians' assessments, and these should reliably reflect proportion of participants with investigator‐rated clinically significant hair regrowth and mean change in total hair count from baseline to the end of the study. Studies should address the sustainability of hair regrowth after discontinuation of treatment. An important patient‐reported outcome should be the impact of the hair regrowth reflected by the time spent by women with FPHL on hair styling, including the use of wigs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time stamp (T)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Date of literature search or recommendation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 July 2015</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study type</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>What is the most appropriate study design to address the proposed question?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD007628-list-0012"> <li> <p>Randomised controlled trial (adequately powered/multicentred).</p> </li> <li> <p>Methods: concealment of allocation sequence.</p> </li> <li> <p>Blinding: participants, trialists, outcomes assessors, data analysts.</p> </li> <li> <p>Setting: hospital/university or general practice with adequate follow‐up.</p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: FPHL: female pattern hair loss.</p> </div> </div> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007628-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007628-sec-0043"></div> <div class="table" id="CD007628-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Minoxidil versus placebo</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Minoxidil (1%, 2% and 5%) compared to placebo for female pattern hair loss (FPHL)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with FPHL<br/> <b>Intervention:</b> minoxidil (1%, 2% and 5%)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with minoxidil</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>The proportion of participants with self‐rated clinically significant hair regrowth at the end of the study</b> <br/> Assessed with: 3 to 7 point Likert scales<br/> Follow‐up: range 24 weeks to 32 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.93</b> <br/> (1.51 to 2.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1148<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26.5% versus 13.9% experienced moderate to marked hair regrowth</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>139 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>268 per 1000</b> <br/> (209 to 343) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b> <br/> Assessed with: VAS, 0 = negative, 50 = neutral and 100 = positive<br/> Scale from: 0 to 100 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard deviations (SDs) were missing, therefore we could not calculate mean difference (MD). The VAS score was 54.4 for 5% minoxidil, 52.1 for 2% minoxidil, and 46.5 for placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.24</b> <br/> (0.82 to 1.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>727<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>These are the data for the minoxidil 2% versus placebo. The RR for minoxidil 1% versus placebo was 1.12 (95% CI 0.61 to 2.06) and for minoxidil 5% versus placebo 2.05 (95% CI 0.96 to 4.37) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>88 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>109 per 1000</b> <br/> (72 to 164) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of participants with investigator‐rated clinically significant hair regrowth at the end of the study</b> <br/> Assessed with: 4 to 7 point Likert scales<br/> Follow‐up: range 24 weeks to 32 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.35</b> <br/> (1.68 to 3.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1181<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>18.4% versus 7.7% had at least moderate hair regrowth</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>181 per 1000</b> <br/> (129 to 253) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in total hair count</b> <br/> Follow‐up: range 24 weeks to 32 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in total hair count ranged from <b>−3.25 to 20.4 hairs/cm</b>² </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in total hair count in the intervention group was <b>13.18 hairs/cm</b> ²<b>higher</b> (10.92 higher to 15.44 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1242<br/> (8 RCTs)<sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The impact of excluding <a href="./references#CD007628-bbs2-0036" title="PriceVH , MenefeeE . Quantitative estimation of hair growth. I. androgenetic alopecia in women: effect of minoxidil. Journal of Investigative Dermatology1990;95(6):683‐7. [PUBMED: 2250110] ">Price 1990</a> from this analysis had a marginal effect on the overall pooled result (RR 12.96, 95% 10.69 to 15.24) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Degree of hair shedding from baseline to the end of the study</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>380<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> very low<sup>10,11,12</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007628-bbs2-0034" title="Pazoki‐ToroudiH , BabakoohiS , NilforoushzadehMA , Nassiri‐KashaniM , ShizarpourM , AjamiM , et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed2012;10(5):276‐82. [PUBMED: 23163069] ">Pazoki‐Toroudi 2012</a>: MD ‐37.85 hairs, 95% CI −54.22 to −21.48; P &lt; 0.00001) in favour of minoxidil. Number of participants reporting decrease: <a href="./references#CD007628-bbs2-0046" title="WhitingDA , JacobsonC . Treatment of female androgenetic alopecia with minoxidil 2%. International Journal of Dermatology1992;31(11):800‐4. [PUBMED: 1428436] ">Whiting 1992</a>: RR 1.34, 95% CI 0.68 to 2.66; <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a>: RR 1.13, 95% CI 0.95 to 1.33 </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cosmetic appearance of the hair or participant satisfaction</b> <br/> Assessed with: VAS with 0 = no benefit, 50 = moderate benefit, and 100 = great benefit<br/> Scale from: 0 to 100 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS score was 60.0 (27.6) for 5% minoxidil, 50.5 (35.5) for 2% minoxidil and 41.8 (29.9) for placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality (or pattern) of hair regrowth (e.g. thickness)</b> <br/> Assessed with: Savin Female Density scale and target area hair width was 0.87 (1.315) mm/cm² </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>372<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>2,13</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Investigators in <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> reported statistically significant differences in hair density for both minoxidil concentrations compared to placebo. <a href="./references#CD007628-bbs2-0028" title="NCT01325350 . Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01325350 (accessed 14 January 2016). ">NCT01325350</a>: MD 0.80, 95% CI 0.36 to 1.24; P = 0.004 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio; <b>GRADE:</b> Grading of Recommendations Assessment, Development and Evaluation; <b>FPHL:</b> female pattern hair loss;<b>RCT</b> : randomised controlled trial; <b>MD:</b> mean difference; <b>VAS:</b> visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded 1 level for serious risk of bias as we judged 5/6 studies' key domains of risk of bias, i.e. sequence generation, allocation concealment, and blinding as 'unclear'. <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a> was at 'low risk'.<br/> <sup>2</sup>Downgraded 1 level for serious imprecision due to small sample size, not meeting optimal information size.<br/> <sup>3</sup>Downgraded 1 level for serious risk of bias due to high drop‐out rate and per‐protocol analysis.<br/> <sup>4</sup>Downgraded 1 level for serious risk of bias as all 4 studies were at unclear to high risk of bias.<br/> <sup>5</sup>Downgraded 1 level for serious imprecision due to low occurrence of events.<br/> <sup>6</sup><a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> had 3 treatment arms.<br/> <sup>7</sup>Downgraded 1 level for serious risk of bias as we judged 6/7 studies' key domains of risk of bias, i.e. sequence generation, allocation concealment, and blinding as 'unclear'. <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a> was at 'low risk'.<br/> <sup>8</sup>Downgraded 1 level for serious risk of bias as we judged 7/8 studies' key domains of risk of bias, i.e. sequence generation, allocation concealment, and blinding as 'unclear'. <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a> was at 'low risk'.<br/> <sup>9</sup><a href="./references#CD007628-bbs2-0036" title="PriceVH , MenefeeE . Quantitative estimation of hair growth. I. androgenetic alopecia in women: effect of minoxidil. Journal of Investigative Dermatology1990;95(6):683‐7. [PUBMED: 2250110] ">Price 1990</a> was an outlier, with a small sample size (N = 8). There was possible publication bias, single participant with large treatment effect, and the result may be due to natural sampling variation.<br/> <sup>10</sup>Downgraded 1 level for serious risk of bias as in 2/3 studies' key domains of risk of bias, i.e. sequence generation, allocation concealment, and blinding were judged 'unclear'. <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a> was at 'low risk'.<br/> <sup>11</sup>Downgraded 1 level for serious inconsistency as only <a href="./references#CD007628-bbs2-0034" title="Pazoki‐ToroudiH , BabakoohiS , NilforoushzadehMA , Nassiri‐KashaniM , ShizarpourM , AjamiM , et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed2012;10(5):276‐82. [PUBMED: 23163069] ">Pazoki‐Toroudi 2012</a> showed a difference in favour of minoxidil whilst the other 2 studies did not.<br/> <sup>12</sup>Downgraded 1 level for serious imprecision due to wide CIs, and the optimal information size is not met.<br/> <sup>13</sup>Downgraded 1 level for serious risk of bias due to attrition bias in <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> and unclear risk of selection, performance, and detection bias in <a href="./references#CD007628-bbs2-0028" title="NCT01325350 . Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01325350 (accessed 14 January 2016). ">NCT01325350</a>. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007628-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Minoxidil 2% versus minoxidil 5%</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Minoxidil 2% compared to minoxidil 5% for female pattern hair loss (FPHL)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with FPHL <br/> <b>Intervention:</b> minoxidil 2%<br/> <b>Comparison:</b> minoxidil 5% </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with minoxidil 5%</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with minoxidil 2%</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of participants with self‐rated clinically significant hair regrowth</b> <br/> Assessed with: 7 point Likert scale in <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>, VAS scale 0‐100 in <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> <br/> Follow‐up: range 24 weeks to 48 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>322<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a> moderate to greatly increased hair regrowth in minoxidil 2% group versus 5% RR 1.12, 95% CI 0.72 to 1.73. VAS in <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> 62.9 (16.7 standard deviation (SD)) versus 68.1 (17.9 SD), authors' reported P = 0.062 </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b> <br/> Assessed with: VAS<br/> Scale from: 0 to 100 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>209<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Investigators reported "no statistically significant difference in impact of hair loss on quality of life between the two intervention groups" </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.02</b> <br/> (0.91 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1006<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Excluding <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> from the analysis, reduced the degree of heterogeneity, with minimal impact on the pooled results </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>369 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>376 per 1000</b> <br/> (335 to 442) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of participants with investigator‐rated clinically significant hair regrowth</b> <br/> Assessed with: 7 point Likert scales in <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a> and <a href="./references#CD007628-bbs2-0039" title="ShengY‐Y , RuiW‐L , XuF , QiS‐S , HuR‐M , MiaoY , et al. A randomized controlled clinical study on 2% and 5% topical minoxidil solution in the treatment of female pattern hair loss [Chinese]. Journal of Clinical Dermatology2014;43(10):583‐5. [EMBASE: 2015699887] ">Sheng 2014</a>. VAS scale in <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> <br/> Follow‐up: range 24 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>586<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>These outcomes in the 3 studies were in agreement with the participant assessments that there was no difference between the 2 concentrations of minoxidil </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline to study conclusion in total hair count</b> <br/> Follow‐up: range 26 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline to study conclusion in total hair count ranged from <b>23.7 to 31.9 hairs/cm</b>² </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline to study conclusion in total hair count in the intervention group was <b>2.12 hairs/cm</b> ²<b>lower</b> (5.47 lower to 1.23 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>631<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference between the 2 concentrations of minoxidil</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Degree of hair shedding from baseline to the end of the study</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed in any of the studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cosmetic appearance of the hair or participant satisfaction</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>322<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3/4 in <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a> were more satisfied after minoxidil 2% versus &gt; 50% on 5%. In <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> the scores on the VAS were 50.5 (SD 32.5) in the 2% group versus 60.0 (SD 27.6) in the 5% group </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality (or pattern) of hair regrowth (e.g. thickness)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>322<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No differences in both studies between the treatment arms</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio; <b>GRADE:</b> Grading of Recommendations Assessment, Development and Evaluation; <b>FPHL:</b> female pattern hair loss;<b>RCT</b> : randomised controlled trial; <b>MD:</b> mean difference; <b>VAS:</b> visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded 1 level for serious risk of imprecision, due to wide CIs in <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>.<br/> <sup>2</sup>Downgraded 1 level for serious risk of bias due to the fact participants were not blinded in <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>.<br/> <sup>3</sup>Downgraded 1 level for serious risk of bias due to high drop‐out rate and per‐protocol analysis.<br/> <sup>4</sup>Downgraded 1 level for serious imprecision due to small sample size, and not meeting the optimal information size.<br/> <sup>5</sup>Downgraded 1 level for serious inconsistency, due to <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> showing (as only study) a statistically significant difference in favour of minoxidil 2%.<br/> <sup>6</sup>Downgraded 1 level for serious risk of bias as blinding was unclear in 3/4 studies.<br/> <sup>7</sup>Downgraded 1 level for serious risk of bias, due to the fact the blinding of the investigators was not assured in <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a> and <a href="./references#CD007628-bbs2-0039" title="ShengY‐Y , RuiW‐L , XuF , QiS‐S , HuR‐M , MiaoY , et al. A randomized controlled clinical study on 2% and 5% topical minoxidil solution in the treatment of female pattern hair loss [Chinese]. Journal of Clinical Dermatology2014;43(10):583‐5. [EMBASE: 2015699887] ">Sheng 2014</a>.<br/> <sup>8</sup>Downgraded 1 level for serious risk of imprecision, due to wide CIs, and the optimal information size is not met.<br/> <sup>9</sup>Downgraded 1 level for serious risk of bias, due to the fact that outcome assessors in <a href="./references#CD007628-bbs2-0025" title="DoshiU , IsraelM , KendallC , QuizaC , SacavageS , TyndallD , et al. Effectiveness of once daily 5% minoxidil topical foam in the treatment of women with thinning hair due to female pattern hair loss (FPHL). Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB112. [EMBASE: 71895204] NCT01145625 . A Phase 3 multi‐center parallel design clinical trial to compare the efficacy and safety of 5% Minoxidil Foam vs. 2% Minoxidil Solution in females for the treatment of female pattern hair loss ‐ androgenetic alopecia (MINALO3004, NCT01145625). clinicaltrials.gov/ct2/show/NCT01145625 (accessed 14 January 2016). ">NCT01145625</a> were not blinded.<br/> <sup>10</sup>Downgraded 1 level for serious imprecision, due to low sample sizes not meeting optimal information sizes. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007628-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Finasteride versus placebo</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Finasteride compared to placebo for female pattern hair loss (FPHL)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with FPHL<br/> <b>Intervention:</b> finasteride<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with finasteride</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>The proportion of participants with self‐rated clinically significant hair regrowth at the end of the study</b> <br/> Assessed with: Questionnaire (Barber 1998)<br/> Follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.95</b> <br/> (0.66 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Finasteride was no more effective than placebo</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>471 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>448 per 1000</b> <br/> (311 to 646) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed in any of the studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> <br/> Follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.03</b> <br/> (0.45 to 2.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>786 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>809 per 1000</b> <br/> (354 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of participants with investigator‐rated clinically significant hair regrowth</b> <br/> Assessed with: 7‐point rating scale (‐3 = greatly decreased to +3 = greatly increased)<br/> Follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.77</b> <br/> (0.31 to 1.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Finasteride was no more effective than placebo, this is consistent with the assessments of the participants </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>186 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b> <br/> (58 to 353) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change from baseline to study conclusion in total hair count</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>231<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In two of the studies (<a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a> and <a href="./references#CD007628-bbs2-0047" title="WhitingDA , WaldstreicherJ , SanchezM , KaufmanKD . Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women. Journal of Investigative Dermatology. Symposium Proceedings1999;4(3):282‐4. [PUBMED: 10674382] ">Whiting 1999</a>) there was no clinically meaningful difference whilst in <a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a> there was a difference of around 17 hairs in favour of finasteride </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Degree of hair shedding from baseline to the end of the study</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>1,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Although the investigators in <a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a> provided no data, they reported that there was no statistically significant difference in the slowing down of hair loss between the two groups </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cosmetic appearance of the hair or participant satisfaction</b> <br/> Follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.78</b> <br/> (0.40 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>229 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>178 per 1000</b> <br/> (91 to 350) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality (or pattern) of hair regrowth (e.g. thickness)</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed in any of the studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio; <b>GRADE:</b> Grading of Recommendations Assessment, Development and Evaluation; <b>FPHL:</b> female pattern hair loss;<b>RCT</b>: randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded 1 level for serious risk of bias as we judged key domains of risk of bias, i.e. sequence generation, allocation concealment, and blinding as 'unclear'.<br/> <sup>2</sup>Downgraded 1 level for serious imprecision due to wide CIs, small sample size, and not meeting the optimal information size.<br/> <sup>3</sup>Downgraded 1 level for serious risk of bias as in 2 studies key domains of risk of bias, i.e. sequence generation, allocation concealment, and blinding were judged 'unclear'. Furthermore in <a href="./references#CD007628-bbs2-0047" title="WhitingDA , WaldstreicherJ , SanchezM , KaufmanKD . Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women. Journal of Investigative Dermatology. Symposium Proceedings1999;4(3):282‐4. [PUBMED: 10674382] ">Whiting 1999</a> the drop‐out ratio was &gt; 30% and the analysis was per‐protocol.<br/> <sup>4</sup>Downgraded 1 level for serious inconsistency as in <a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a> and <a href="./references#CD007628-bbs2-0047" title="WhitingDA , WaldstreicherJ , SanchezM , KaufmanKD . Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women. Journal of Investigative Dermatology. Symposium Proceedings1999;4(3):282‐4. [PUBMED: 10674382] ">Whiting 1999</a> there was no meaningful difference, while <a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a> did show a difference of around 19 hairs in favour of finasteride.<br/> <sup>5</sup>Downgraded 1 level for serious imprecision due to small sample size not meeting the optimal information size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007628-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Low‐level laser comb versus sham device</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Low‐level laser comb compared to sham device for female pattern hair loss (FPHL)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with FPHL<br/> <b>Intervention:</b> low‐level laser comb<br/> <b>Comparison:</b> sham device </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with sham device</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with low‐level laser comb</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of participants with self‐rated clinically significant hair regrowth</b> <br/> Assessed with: 5 point Likert scale. However, minimally improved and improved data are combined by investigators<br/> Follow‐up: mean 26 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>141<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The participants did not consider the low‐level laser comb to be more effective than the sham device (RR 1.54, 95% CI 0.96 to 2.49 for <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a> and RR 1.18, 95% CI 0.74 to 1.89 for <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed in any of the studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> <br/> Follow‐up: mean 26 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>141<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The investigators reported that there were "laser comb‐related adverse events: dry skin (5.1%), pruritus (2.5%), scalp tenderness (1.3%), irritation (1.3%) &amp; a warm sensation at the site (1.3%)" </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with investigator‐rated clinically significant hair regrowth</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed in any of the studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline to study conclusion in total hair count</b> <br/> Follow‐up: mean 26 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were statistically significant differences in favour of low‐level laser comb. MD 17.40 hairs, 95% CI 9.74 to 25.06 (<a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>); MD 17.60 hairs, 95% CI 11.97 to 23.23 (<a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Degree of hair shedding from baseline to the end of the study</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed in any of the studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cosmetic appearance of the hair or participant satisfaction</b> <br/> Follow‐up: mean 26 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>141<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minimally improved or improved thickness or fullness of the hair: RR 1.46, 95% CI 0.86 to 2.49 for <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a> and RR 1.33, 95% CI 0.76 to 2.33 for <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality (or pattern) of hair regrowth (e.g. thickness)</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed in any of the studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio; <b>ITT:</b> intention‐to‐treat; <b>GRADE:</b> Grading of Recommendations Assessment, Development and Evaluation; <b>FPHL:</b> female pattern hair loss;<b>RCT</b> : randomised controlled trial; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Not downgraded for risk of bias, due to the fact we recalculated the RR for the intention‐to‐treat (ITT) population, whilst in both studies (<a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>; <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>) these were analysed as per‐protocol.<br/> <sup>2</sup>Downgraded 1 level for serious imprecision, due to wide CIs for both studies, due to small sample size, and not meeting optimal information size.<br/> <sup>3</sup>Downgraded 1 level for serious risk of bias, due to the fact there was a drop‐out rate of 19.2% in <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a> and 9.5% in <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>, and data analysis was per‐protocol. Furthermore, the trials did not provide exact data of adverse events per treatment arm.<br/> <sup>4</sup>Downgraded 1 level for imprecision, due to small sample size, and not meeting optimal information size.<br/> <sup>5</sup>Downgraded 1 level for serious risk of bias, due to the fact there was a drop‐out rate of 19.2% in <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a> and 9.5% in <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>, and data analysis was per‐protocol. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007628-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007628-sec-0044"></div> <p>We have listed unfamiliar terms in the 'Glossary of terms' (<a href="#CD007628-tbl-0005">Table 1</a>). </p> <div class="table" id="CD007628-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of terms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Term</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alopecia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loss of hair from head or body</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anagen hair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active, growing hair</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anagen phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active growth phase of hair follicles (2 to 7 years)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Catagen phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Involution phase of the hair follicle</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ferritin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron‐containing proteins that are widely distributed in animals, plants, and micro‐organisms. Their major function is to store iron in a non‐toxic bioavailable form </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follicular miniaturisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The follicles produce hair that is thinner and thinner, until they either stop producing hair or produce hair that is so fine it is barely noticeable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hepatotoxic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical‐driven liver damage</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperandrogenism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Condition characterised by excessive production/secretion of androgens</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypertrichosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excessive (terminal and vellus) hair in non‐androgen dependent body sites; varies in people with different ethnic background without any pathological findings </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hirsutism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excessive hairiness on women in those parts of the body where terminal hair does not normally occur or is minimal ‐ for example, beard or chest hair </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ludwig scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Classification of female pattern hair loss (FPHL) stages I to III (minimal, moderate, intense) (<a href="./references#CD007628-bbs2-0137" title="LudwigE . Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. British Journal of Dermatology1977;97(3):247‐54. [PUBMED: 921894] ">Ludwig 1977</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐alpha‐reductase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An enzyme that converts testosterone, the male sex hormone, into the more potent hormone, dihydrotestosterone </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sinclair scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐point scale (1 = normal, 5 = advanced hair loss) used to assess FPHL (<a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telogen hair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dormant, inactive hair</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telogen phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resting phase of the hair follicle (3 months)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telogen effluvium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Massive hair loss resulting from the early entry of hairs into the telogen phase</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terminal hair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thicker, longer, and pigmented hair</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tincture¹</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An alcoholic extract of a drug derived from a plant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vasodilation¹</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Widening of the blood vessels</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vellus hair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short, fine, light‐coloured, and barely noticeable hair that develops on most of a person's body from childhood </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: FPHL: female pattern hair loss.<br/> ¹Definition taken from: <a href="./references#CD007628-bbs2-0138" title="MartinA (editor) . Concise Colour Medical Dictionary. 2nd edition. Oxford University Press, 1998. ">Martin 1998</a> </p> </div> </div> <section id="CD007628-sec-0045"> <h3 class="title" id="CD007628-sec-0045">Description of the condition</h3> <section id="CD007628-sec-0046"> <h4 class="title">Definition and clinical features</h4> <p>Female pattern hair loss (FPHL) is an increasingly common clinical problem in women (<a href="./references#CD007628-bbs2-0110" title="BienováM , KucerováM , FiuraskováM , HajdúchM , KolárZ . Androgenetic alopecia and current methods of treatment. Acta Dermatovenerologica Alpina, Pannonica, et Adriatica2005;14(1):5‐8. [PUBMED: 15818439] ">Bienová 2005</a>; <a href="./references#CD007628-bbs2-0125" title="GanDC , SinclairRD . Prevalence of male and female pattern hair loss in Maryborough. Journal of Investigative Dermatology. Symposium Proceedings2005;10(3):184‐9. [PUBMED: 16382660] ">Gan 2005</a>; <a href="./references#CD007628-bbs2-0130" title="HoffmannR , HappleR . Current understanding of androgenetic alopecia. Part I: etiopathogenesis. European Journal of Dermatology2000;10(4):319‐27. [PUBMED: 10846263] ">Hoffmann 2000</a>), with over 21 million affected in the USA alone (<a href="./references#CD007628-bbs2-0134" title="LeavittM . Understanding and management of female pattern alopecia. Facial Plastic Surgery2008;24(4):414‐27. [PUBMED: 19034818] ">Leavitt 2008</a>). However, as the androgen‐dependent (male hormone) nature of the condition has not been clearly established, it has been proposed that in women the commonly‐used term 'androgenic alopecia' (AGA) should be replaced by 'female pattern hair loss' (FPHL) (<a href="./references#CD007628-bbs2-0142" title="OlsenEA . Female pattern hair loss. Journal of the American Academy of Dermatology2001;45(3 Suppl):S70‐80. [PUBMED: 11511856] ">Olsen 2001</a>; <a href="./references#CD007628-bbs2-0166" title="YipL , RufautN , SinclairR . Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: An update of what we now know. Australasian Journal of Dermatology2011;52(2):81‐8. [PUBMED: 21605090] ">Yip 2011</a>). Both terms can be found in the literature and are often used interchangeably. </p> <p>Hair growth occurs in cycles of various phases: anagen is the growth phase; catagen is the involuting or regressing phase; and telogen, the resting or quiescent phase (<a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>). FPHL is characterised by the production of shorter and finer hairs due to progressive miniaturisation of hair follicles, so fine vellus hairs are produced instead of thicker terminal hairs (<a href="./references#CD007628-bbs2-0159" title="TrüebRM . Molecular mechanisms of androgenetic alopecia. Experimental Gerontology2002;37(8‐9):981‐90. [PUBMED: 12213548] ">Trüeb 2002</a>). Hair shedding can vary in intensity over time and from individual to individual. The onset of hair loss may precede menarche in young women or occur as late as the sixth decade of life (<a href="./references#CD007628-bbs2-0142" title="OlsenEA . Female pattern hair loss. Journal of the American Academy of Dermatology2001;45(3 Suppl):S70‐80. [PUBMED: 11511856] ">Olsen 2001</a>; <a href="./references#CD007628-bbs2-0143" title="OlsenEA , MessengerAG , ShapiroJ , BergfeldWF , HordinskyMK , RobertsJL , et al. Evaluation and treatment of male and female pattern hair loss. Journal of the American Academy of Dermatology2005;52(2):301‐11. [PUBMED: 15692478] ">Olsen 2005</a>; <a href="./references#CD007628-bbs2-0166" title="YipL , RufautN , SinclairR . Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: An update of what we now know. Australasian Journal of Dermatology2011;52(2):81‐8. [PUBMED: 21605090] ">Yip 2011</a>). Women who present to their doctor with a reduction in hair density often have thinning and widening of the area of hair loss on the central part of the scalp, which includes a breach of the frontal hairline. This sequence of symptoms is generally described as a 'Christmas tree' pattern (<a href="./references#CD007628-bbs2-0114" title="Blume‐PeytaviU , BlumeyerA , TostiA , FinnerA , MarmolV , TrakatelliM , et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. British Journal of Dermatology2011;164(1):5‐15. [PUBMED: 20795997] ">Blume‐Peytavi 2011b</a>; <a href="./references#CD007628-bbs2-0144" title="OlsenEA . Female pattern hair loss. In: Blume‐PeytaviU , TostiA , WhitingDA , TrüebRM editor(s). Hair Growth and Disorders. Berlin, Heidelberg: Springer Verlag, 2008:171‐86. ">Olsen 2008</a>) (see <a href="#CD007628-fig-0001">Figure 1</a> and <a href="#CD007628-fig-0002">Figure 2</a>). The frontal hairline may or may not be preserved; however, as with male pattern hair loss, the degree of loss of hair from the temples does not necessarily correlate with the presence or severity of mid‐frontal scalp hair loss (<a href="./references#CD007628-bbs2-0078" title="SinclairR , WewerinkeM , JolleyD . Treatment of female pattern hair loss with oral antiandrogens. British Journal of Dermatology2005;152(3):466‐73. [EMBASE: 2005182968] ">Sinclair 2005</a>; <a href="./references#CD007628-bbs2-0166" title="YipL , RufautN , SinclairR . Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: An update of what we now know. Australasian Journal of Dermatology2011;52(2):81‐8. [PUBMED: 21605090] ">Yip 2011</a>). </p> <div class="figure" id="CD007628-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Stage 1 on Ludwig scale (mild female pattern hair loss). Copyright © 2011 Department of Dermatology, Leiden University Medical Centre: reproduced with permission." data-id="CD007628-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Stage 1 on Ludwig scale (mild female pattern hair loss). Copyright © 2011 Department of Dermatology, Leiden University Medical Centre: reproduced with permission. </p> </div> </div> </div> <div class="figure" id="CD007628-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Stage 3 on Ludwig scale (severe female pattern hair loss). Copyright © 2011 Department of Dermatology, Leiden University Medical Centre: reproduced with permission." data-id="CD007628-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Stage 3 on Ludwig scale (severe female pattern hair loss). Copyright © 2011 Department of Dermatology, Leiden University Medical Centre: reproduced with permission. </p> </div> </div> </div> <p>The clinical evaluation and definition of the pattern of hair loss in women with FPHL has traditionally relied on the Ludwig (three‐point) classification (<a href="./references#CD007628-bbs2-0137" title="LudwigE . Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. British Journal of Dermatology1977;97(3):247‐54. [PUBMED: 921894] ">Ludwig 1977</a>); however, a five‐point grading scale has been introduced more recently (<a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>; <a href="./references#CD007628-bbs2-0153" title="SinclairR , JolleyD , MallariR , MageeJ . The reliability of horizontally sectioned scalp biopsies in the diagnosis of chronic diffuse telogen hair loss in women. Journal of the American Academy of Dermatology2004;51(2):189‐99. [PUBMED: 15280836] ">Sinclair 2004</a>). In all three Ludwig stages, there is hair loss in increasing severity on the front and top of the scalp, with relative preservation of the frontal hairline; the back and sides may or may not be involved (<a href="./references#CD007628-bbs2-0137" title="LudwigE . Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. British Journal of Dermatology1977;97(3):247‐54. [PUBMED: 921894] ">Ludwig 1977</a>). In the five‐point mid‐frontal grading scale (visual analogue scale (VAS)), stage one represents the normal female hair pattern; stage two, mild hair loss; and the other stages, more severe hair loss (<a href="./references#CD007628-bbs2-0125" title="GanDC , SinclairRD . Prevalence of male and female pattern hair loss in Maryborough. Journal of Investigative Dermatology. Symposium Proceedings2005;10(3):184‐9. [PUBMED: 16382660] ">Gan 2005</a>). </p> <p>The diagnosis of FPHL in women is supported by a history of gradual thinning of the scalp hair over a period of months to years, which is characterised by a diffuse reduction of hair density over the crown and mid‐frontal scalp region (<a href="./references#CD007628-bbs2-0107" title="Atanaskova MesinkovskaN , BergfeldWF . Hair: What is new in diagnosis and management? Female pattern hair loss update: Diagnosis and treatment. Dermatologic Clinics2013;31(1):119‐27. [PUBMED: 23159181] ">Atanaskova Mesinkovska 2013</a>; <a href="./references#CD007628-bbs2-0113" title="BirchMP , LallaSC , MessengerAG . Female pattern hair loss. Clinical and Experimental Dermatology2002;27(5):383‐8. [PUBMED: 12190638] ">Birch 2002</a>; <a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>; <a href="./references#CD007628-bbs2-0140" title="MessengerAG , SinclairR . Follicular miniaturization in female pattern hair loss: clinicopathological correlations. British Journal of Dermatology2006;155(5):926‐30. [PUBMED: 17034520] ">Messenger 2006</a>). In women with FPHL, a family history may not be as clearly defined as in men with AGA (<a href="./references#CD007628-bbs2-0143" title="OlsenEA , MessengerAG , ShapiroJ , BergfeldWF , HordinskyMK , RobertsJL , et al. Evaluation and treatment of male and female pattern hair loss. Journal of the American Academy of Dermatology2005;52(2):301‐11. [PUBMED: 15692478] ">Olsen 2005</a>), and although there is often a positive association between family history and FPHL or AGA, a negative history should not specifically preclude a diagnosis of FPHL (<a href="./references#CD007628-bbs2-0114" title="Blume‐PeytaviU , BlumeyerA , TostiA , FinnerA , MarmolV , TrakatelliM , et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. British Journal of Dermatology2011;164(1):5‐15. [PUBMED: 20795997] ">Blume‐Peytavi 2011b</a>). A detailed history, including any family history of FPHL or AGA, and a thorough clinical examination should be undertaken, and this needs to include examination for features of hyperandrogenism (<a href="./references#CD007628-bbs2-0107" title="Atanaskova MesinkovskaN , BergfeldWF . Hair: What is new in diagnosis and management? Female pattern hair loss update: Diagnosis and treatment. Dermatologic Clinics2013;31(1):119‐27. [PUBMED: 23159181] ">Atanaskova Mesinkovska 2013</a>; <a href="./references#CD007628-bbs2-0114" title="Blume‐PeytaviU , BlumeyerA , TostiA , FinnerA , MarmolV , TrakatelliM , et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. British Journal of Dermatology2011;164(1):5‐15. [PUBMED: 20795997] ">Blume‐Peytavi 2011b</a>; <a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>). Clinical evaluation should include examination of the scalp skin, hair density, and facial (including eyebrows and eyelashes) and body hair, as well as signs of acne, hirsutism, or both. If the medical history suggests hyperandrogenism, an examination for cliteromegaly should also be undertaken (<a href="./references#CD007628-bbs2-0114" title="Blume‐PeytaviU , BlumeyerA , TostiA , FinnerA , MarmolV , TrakatelliM , et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. British Journal of Dermatology2011;164(1):5‐15. [PUBMED: 20795997] ">Blume‐Peytavi 2011b</a>; <a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>). </p> <p>Women with menstrual cycle disturbances or those exhibiting marked acne, hirsutism, or both, should be investigated fully (<a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>). The tests include the free androgen index test (FAI), and measurement of the levels of sex hormone‐binding globulin (SHBG) and prolactin (<a href="./references#CD007628-bbs2-0114" title="Blume‐PeytaviU , BlumeyerA , TostiA , FinnerA , MarmolV , TrakatelliM , et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. British Journal of Dermatology2011;164(1):5‐15. [PUBMED: 20795997] ">Blume‐Peytavi 2011b</a>). More details on laboratory testing and excluding other causes of FPHL are found in the S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women, and adolescents (<a href="./references#CD007628-bbs2-0114" title="Blume‐PeytaviU , BlumeyerA , TostiA , FinnerA , MarmolV , TrakatelliM , et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. British Journal of Dermatology2011;164(1):5‐15. [PUBMED: 20795997] ">Blume‐Peytavi 2011b</a>). Polycystic ovary syndrome is the most common cause of hyperandrogenism, and although virilizing tumours may be implicated, they tend to be rare and characterised by recent onset and rapidly progressing severe hair loss, among other features (<a href="./references#CD007628-bbs2-0114" title="Blume‐PeytaviU , BlumeyerA , TostiA , FinnerA , MarmolV , TrakatelliM , et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. British Journal of Dermatology2011;164(1):5‐15. [PUBMED: 20795997] ">Blume‐Peytavi 2011b</a>; <a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>; <a href="./references#CD007628-bbs2-0154" title="SinclairR , PatelM , DawsonTLJr , YazdabadiA , YipL , PerezA , et al. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. British Journal of Dermatology2011;165(Suppl 3):12‐8. [PUBMED: 22171680] ">Sinclair 2011</a>; <a href="./references#CD007628-bbs2-0162" title="vanZuurenEJ , FedorowiczZ , CarterB , PandisN . Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.CD010334.pub2] ">van Zuuren 2015</a>). However, a lack of clinical evidence of hyperandrogenism does not necessarily rule out the presence of biochemical hyperandrogenism (<a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>). </p> <p>Loss of hair can also expose the scalp to sun damage and pose an increased risk of skin cancer (<a href="./references#CD007628-bbs2-0166" title="YipL , RufautN , SinclairR . Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: An update of what we now know. Australasian Journal of Dermatology2011;52(2):81‐8. [PUBMED: 21605090] ">Yip 2011</a>). </p> <p>Other possible causes of hair loss must be considered; thus, the differential diagnosis of FPHL should include telogen effluvium (<a href="./references#CD007628-bbs2-0078" title="SinclairR , WewerinkeM , JolleyD . Treatment of female pattern hair loss with oral antiandrogens. British Journal of Dermatology2005;152(3):466‐73. [EMBASE: 2005182968] ">Sinclair 2005</a>). Chronic telogen effluvium is defined as excessive shedding of hair for at least six months without a noticeable widening of the area of hair loss in the midfrontal scalp region (<a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>). It can occur as a primary idiopathic event; secondary to thyroid disease, systemic lupus erythematosus, or end‐stage renal disease; or it may be due to certain drugs or nutritional deficiencies (<a href="./references#CD007628-bbs2-0117" title="Camacho‐MartínezFM . Hair loss in women. Seminars in Cutaneous Medicine and Surgery2009;28(1):19‐32. [PUBMED: 19341939] ">Camacho‐Martínez 2009</a>; <a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>; <a href="./references#CD007628-bbs2-0153" title="SinclairR , JolleyD , MallariR , MageeJ . The reliability of horizontally sectioned scalp biopsies in the diagnosis of chronic diffuse telogen hair loss in women. Journal of the American Academy of Dermatology2004;51(2):189‐99. [PUBMED: 15280836] ">Sinclair 2004</a>). A sudden increase in hair loss is more consistent with a diagnosis of acute telogen effluvium, which may follow childbirth, severe systemic illness, or may be precipitated by certain medications (<a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>). Alopecia areata diffusa is characterised by diffuse, patchy hair shedding in sharply defined areas (<a href="./references#CD007628-bbs2-0134" title="LeavittM . Understanding and management of female pattern alopecia. Facial Plastic Surgery2008;24(4):414‐27. [PUBMED: 19034818] ">Leavitt 2008</a>). It usually affects women over 40 years of age, many of whom are misdiagnosed as having telogen effluvium (<a href="./references#CD007628-bbs2-0160" title="TrüebRM . Systematic approach to hair loss in women [Systematisches Vorgehen bei Frauen mit Haarausfall]. Journal der Deutschen Dermatologischen Gesellschaft2010;8(4):284‐97. [PUBMED: 20105246] ">Trüeb 2010</a>). </p> </section> <section id="CD007628-sec-0047"> <h4 class="title">Symptoms</h4> <p>Hair loss can have a significant negative psychological impact on both men and women (<a href="./references#CD007628-bbs2-0120" title="DolteKS , GirmanCJ , HartmaierS , RobertsJ , BergfeldW , WaldstreicherJ . Development of a health‐related quality of life questionnaire for women with androgenetic alopecia. Clinical and Experimental Dermatology2000;25(8):637‐42. [PUBMED: 11167980] ">Dolte 2000</a>; <a href="./references#CD007628-bbs2-0127" title="HadshiewIM , FoitzikK , ArckPC , PausR . Burden of hair loss: stress and the underestimated psychosocial impact of telogen effluvium and androgenetic alopecia. Journal of Investigative Dermatology2004;123(3):455‐7. [PUBMED: 15304082] ">Hadshiew 2004</a>; <a href="./references#CD007628-bbs2-0136" title="LevyLL , EmerJJ . Female pattern alopecia: current perspectives. International Journal of Women's Health2013;5:541‐56. [PUBMED: 24039457] ">Levy 2013</a>; <a href="./references#CD007628-bbs2-0154" title="SinclairR , PatelM , DawsonTLJr , YazdabadiA , YipL , PerezA , et al. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. British Journal of Dermatology2011;165(Suppl 3):12‐8. [PUBMED: 22171680] ">Sinclair 2011</a>). However, because hair has important social and psychological relevance to women, they tend to suffer more than men. A woman's hair is within her control to create her femininity, beauty, and sexuality. It is an "essential part of self‐identity (or 'body‐image')" (<a href="./references#CD007628-bbs2-0118" title="CashTF . The psychology of hair loss and its implications for patient care. Clinics in Dermatology2001;19(2):161‐6. [PUBMED: 11397595 ] ">Cash 2001</a>). For many people, hair is a "physical attribute that expresses individuality, and it is central to feelings of attractiveness or unattractiveness" (<a href="./references#CD007628-bbs2-0118" title="CashTF . The psychology of hair loss and its implications for patient care. Clinics in Dermatology2001;19(2):161‐6. [PUBMED: 11397595 ] ">Cash 2001</a>). In women it can be a source of concern in terms of feeling removed from what is considered a 'normal' female appearance (<a href="./references#CD007628-bbs2-0118" title="CashTF . The psychology of hair loss and its implications for patient care. Clinics in Dermatology2001;19(2):161‐6. [PUBMED: 11397595 ] ">Cash 2001</a>). </p> <p>Studies have revealed that women with FPHL experience increased levels of self‐consciousness, feelings of unattractiveness, shame, discomfort, and emotional stress; some of which can lead to social withdrawal (<a href="./references#CD007628-bbs2-0118" title="CashTF . The psychology of hair loss and its implications for patient care. Clinics in Dermatology2001;19(2):161‐6. [PUBMED: 11397595 ] ">Cash 2001</a>; <a href="./references#CD007628-bbs2-0147" title="ReidEE , HaleyAC , BorovickaJH , RademakerA , WestDP , ColavincenzoM , et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. Journal of the American Academy of Dermatology2011;66(3):e97‐102. [PUBMED: 21601948] ">Reid 2011</a>; <a href="./references#CD007628-bbs2-0161" title="van derDonkJ , PasschierJ , Knegt‐JunkC , van derWegen‐KeijserMH , NieboerC , StolzE , et al. Psychological characteristics of women with androgenetic alopecia: a controlled study. British Journal of Dermatology1991;125(3):248‐52. [PUBMED: 1911317] ">van der Donk 1991</a>). The Women's Androgenetic Alopecia Quality of Life Questionnaire (WAA‐QOL) is a validated instrument, which has been used to assess the impact of FPHL on quality of life (QoL) in women (<a href="./references#CD007628-bbs2-0120" title="DolteKS , GirmanCJ , HartmaierS , RobertsJ , BergfeldW , WaldstreicherJ . Development of a health‐related quality of life questionnaire for women with androgenetic alopecia. Clinical and Experimental Dermatology2000;25(8):637‐42. [PUBMED: 11167980] ">Dolte 2000</a>). However, recent research has indicated that the severity of a woman's hair loss is not a reliable predictor of QoL or perception of severity in hair loss (<a href="./references#CD007628-bbs2-0147" title="ReidEE , HaleyAC , BorovickaJH , RademakerA , WestDP , ColavincenzoM , et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. Journal of the American Academy of Dermatology2011;66(3):e97‐102. [PUBMED: 21601948] ">Reid 2011</a>). People may often rate their hair loss more severely than a dermatologist (<a href="./references#CD007628-bbs2-0111" title="BiondoS , GobleD , SinclairR . Women who present with female pattern hair loss tend to underestimate the severity of their hair loss. British Journal of Dermatology2004;150(4):750‐2. [PUBMED: 15099373] ">Biondo 2004</a>); therefore, clinicians should be alert to the possible impact of a woman's perception of hair loss on her QoL. </p> </section> <section id="CD007628-sec-0048"> <h4 class="title">Epidemiology and causes</h4> <p>Although FPHL is the most common type of hair loss in women, estimates of its true prevalence vary widely (<a href="./references#CD007628-bbs2-0159" title="TrüebRM . Molecular mechanisms of androgenetic alopecia. Experimental Gerontology2002;37(8‐9):981‐90. [PUBMED: 12213548] ">Trüeb 2002</a>). The fact that investigators tend to use different diagnostic criteria (and usually don’t describe them clearly) may contribute to the variation in prevalence figures. However, it is generally recognised that the prevalence of FPHL increases with age (<a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>). The prevalence of FPHL among women aged between 20 to 29 years increases from 12% to approximately 60% for women aged 80 and over (<a href="./references#CD007628-bbs2-0125" title="GanDC , SinclairRD . Prevalence of male and female pattern hair loss in Maryborough. Journal of Investigative Dermatology. Symposium Proceedings2005;10(3):184‐9. [PUBMED: 16382660] ">Gan 2005</a>; <a href="./references#CD007628-bbs2-0166" title="YipL , RufautN , SinclairR . Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: An update of what we now know. Australasian Journal of Dermatology2011;52(2):81‐8. [PUBMED: 21605090] ">Yip 2011</a>). It is reported to be lower in Asian women, and although prevalence is considered to be less in African women, very limited data are available to support this contention (<a href="./references#CD007628-bbs2-0114" title="Blume‐PeytaviU , BlumeyerA , TostiA , FinnerA , MarmolV , TrakatelliM , et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. British Journal of Dermatology2011;164(1):5‐15. [PUBMED: 20795997] ">Blume‐Peytavi 2011b</a>). </p> <p>Genetic predisposition as well as hormonal factors are involved in the cause of FPHL (<a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>). Most women with FPHL do not have signs and symptoms of androgen excess, and systemic androgen levels are, in general, normal (<a href="./references#CD007628-bbs2-0107" title="Atanaskova MesinkovskaN , BergfeldWF . Hair: What is new in diagnosis and management? Female pattern hair loss update: Diagnosis and treatment. Dermatologic Clinics2013;31(1):119‐27. [PUBMED: 23159181] ">Atanaskova Mesinkovska 2013</a>; <a href="./references#CD007628-bbs2-0114" title="Blume‐PeytaviU , BlumeyerA , TostiA , FinnerA , MarmolV , TrakatelliM , et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. British Journal of Dermatology2011;164(1):5‐15. [PUBMED: 20795997] ">Blume‐Peytavi 2011b</a>; <a href="./references#CD007628-bbs2-0143" title="OlsenEA , MessengerAG , ShapiroJ , BergfeldWF , HordinskyMK , RobertsJL , et al. Evaluation and treatment of male and female pattern hair loss. Journal of the American Academy of Dermatology2005;52(2):301‐11. [PUBMED: 15692478] ">Olsen 2005</a>; <a href="./references#CD007628-bbs2-0166" title="YipL , RufautN , SinclairR . Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: An update of what we now know. Australasian Journal of Dermatology2011;52(2):81‐8. [PUBMED: 21605090] ">Yip 2011</a>). In these women, the local conversion of testosterone into dihydrotestosterone in the hair follicles is supposed to initiate terminal to vellus transformation (<a href="./references#CD007628-bbs2-0146" title="PriceVH . Androgenetic alopecia in women. Journal of Investigative Dermatology. Symposium Proceedings2003;8(1):24‐7. [PUBMED: 12894991 ] ">Price 2003</a>). </p> <p>A complex pattern of inheritance and a number of genes are considered to be associated with FPHL (<a href="./references#CD007628-bbs2-0106" title="AliI , DawberRPR , WojnarowskaFT . The role of the androgen receptor gene CAG repeat polymorphism and X‐chromosome inactivation pattern in postmenopausal female pattern hair loss. British Journal of Dermatology2008;159(Suppl 1):8‐9. ">Ali 2008</a>; <a href="./references#CD007628-bbs2-0107" title="Atanaskova MesinkovskaN , BergfeldWF . Hair: What is new in diagnosis and management? Female pattern hair loss update: Diagnosis and treatment. Dermatologic Clinics2013;31(1):119‐27. [PUBMED: 23159181] ">Atanaskova Mesinkovska 2013</a>; <a href="./references#CD007628-bbs2-0123" title="El‐SamahyMH , ShaheenMA , SaddikDE , Abdel FattahNS , El‐SawiMA , MahranMZ , et al. Evaluation of androgen receptor gene as a candidate gene in female androgenetic alopecia. International Journal of Dermatology2009;48(6):584‐7. [PUBMED: 19538365] ">El‐Samahy 2009</a>; <a href="./references#CD007628-bbs2-0149" title="RichetiF , KochiC , RochaMN , Sant'Anna CorrêaC , LazzariniR , GuazzelliRM , et al. Increased androgen receptor messenger RNA in frontal‐parietal hair follicles of women with androgenetic alopecia. Genetics and Molecular Research2013;12(2):1834‐40. [PUBMED: 23479164 ] ">Richeti 2013</a>; <a href="./references#CD007628-bbs2-0154" title="SinclairR , PatelM , DawsonTLJr , YazdabadiA , YipL , PerezA , et al. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. British Journal of Dermatology2011;165(Suppl 3):12‐8. [PUBMED: 22171680] ">Sinclair 2011</a>; <a href="./references#CD007628-bbs2-0164" title="WestbergL , BaghaeiF , RosmondR , HellstrandM , LandénM , JanssonM , et al. Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. Journal of Clinical Endocrinology &amp; Metabolism2001;86(6):2562‐8. [PUBMED: 11397855] ">Westberg 2001</a>; <a href="./references#CD007628-bbs2-0166" title="YipL , RufautN , SinclairR . Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: An update of what we now know. Australasian Journal of Dermatology2011;52(2):81‐8. [PUBMED: 21605090] ">Yip 2011</a>). A variation of the androgen receptor gene has been identified in postmenopausal women, leading to increased serum levels of androgens (<a href="./references#CD007628-bbs2-0106" title="AliI , DawberRPR , WojnarowskaFT . The role of the androgen receptor gene CAG repeat polymorphism and X‐chromosome inactivation pattern in postmenopausal female pattern hair loss. British Journal of Dermatology2008;159(Suppl 1):8‐9. ">Ali 2008</a>). In premenopausal women, certain variants of the androgen receptor gene and the oestrogen receptor beta gene seem to be involved (<a href="./references#CD007628-bbs2-0164" title="WestbergL , BaghaeiF , RosmondR , HellstrandM , LandénM , JanssonM , et al. Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. Journal of Clinical Endocrinology &amp; Metabolism2001;86(6):2562‐8. [PUBMED: 11397855] ">Westberg 2001</a>). The role of oestrogens (female sex hormones) are probably of equal importance to that of androgens, but whether oestrogens have a stimulatory or an inhibitory effect is still a matter of debate (<a href="./references#CD007628-bbs2-0166" title="YipL , RufautN , SinclairR . Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: An update of what we now know. Australasian Journal of Dermatology2011;52(2):81‐8. [PUBMED: 21605090] ">Yip 2011</a>).   </p> <p>Low ferritin (iron‐containing proteins) levels have been suggested as possible contributory factors in FPHL (<a href="./references#CD007628-bbs2-0133" title="KantorJ , KesslerLJ , BrooksDG , CotsarelisG . Decreased serum ferritin is associated with alopecia in women. Journal of Investigative Dermatology2003;121(5):985‐8. [PUBMED: 14708596] ">Kantor 2003</a>), although a more recent study did not support this (<a href="./references#CD007628-bbs2-0145" title="OlsenAE , ReedKB , CacchioPB , CaudillL . Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. Journal of the American Academy of Dermatology2010;63(6):991‐9. [PUBMED: 20947203] ">Olsen 2010</a>). </p> <p>"The demonstration of thyroid hormone receptor expression in hair follicle cells indicates that thyroid hormone may affect hair growth directly" (<a href="./references#CD007628-bbs2-0139" title="MessengerAG . Thyroid hormone and hair growth. British Journal of Dermatology2000;142(4):633‐4. [PUBMED: 10792210] ">Messenger 2000</a>). In view of the "similarity between hair loss in hypothyroidism and FPHL, the implications may extend to other forms of hair loss besides that seen in thyroid deficiency" (<a href="./references#CD007628-bbs2-0139" title="MessengerAG . Thyroid hormone and hair growth. British Journal of Dermatology2000;142(4):633‐4. [PUBMED: 10792210] ">Messenger 2000</a>). </p> </section> </section> <section id="CD007628-sec-0049"> <h3 class="title" id="CD007628-sec-0049">Description of the intervention</h3> <p>Current treatment options for women with FPHL are either topical (applied to the scalp) or systemic (taken orally). </p> <p> <ul id="CD007628-list-0001"> <li> <p>Topical: minoxidil, aminexil, oestrogens, or alfatradiol (<a href="./references#CD007628-bbs2-0107" title="Atanaskova MesinkovskaN , BergfeldWF . Hair: What is new in diagnosis and management? Female pattern hair loss update: Diagnosis and treatment. Dermatologic Clinics2013;31(1):119‐27. [PUBMED: 23159181] ">Atanaskova Mesinkovska 2013</a>; <a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>; <a href="./references#CD007628-bbs2-0143" title="OlsenEA , MessengerAG , ShapiroJ , BergfeldWF , HordinskyMK , RobertsJL , et al. Evaluation and treatment of male and female pattern hair loss. Journal of the American Academy of Dermatology2005;52(2):301‐11. [PUBMED: 15692478] ">Olsen 2005</a>). </p> </li> <li> <p>Systemic: hormonal contraception, cyproterone acetate, finasteride, spironolactone, and flutamide (<a href="./references#CD007628-bbs2-0107" title="Atanaskova MesinkovskaN , BergfeldWF . Hair: What is new in diagnosis and management? Female pattern hair loss update: Diagnosis and treatment. Dermatologic Clinics2013;31(1):119‐27. [PUBMED: 23159181] ">Atanaskova Mesinkovska 2013</a>; <a href="./references#CD007628-bbs2-0110" title="BienováM , KucerováM , FiuraskováM , HajdúchM , KolárZ . Androgenetic alopecia and current methods of treatment. Acta Dermatovenerologica Alpina, Pannonica, et Adriatica2005;14(1):5‐8. [PUBMED: 15818439] ">Bienová 2005</a>; <a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>; <a href="./references#CD007628-bbs2-0143" title="OlsenEA , MessengerAG , ShapiroJ , BergfeldWF , HordinskyMK , RobertsJL , et al. Evaluation and treatment of male and female pattern hair loss. Journal of the American Academy of Dermatology2005;52(2):301‐11. [PUBMED: 15692478] ">Olsen 2005</a>). </p> </li> </ul> </p> <p>Minoxidil is an antihypertensive vasodilator (<a href="./references#CD007628-bbs2-0107" title="Atanaskova MesinkovskaN , BergfeldWF . Hair: What is new in diagnosis and management? Female pattern hair loss update: Diagnosis and treatment. Dermatologic Clinics2013;31(1):119‐27. [PUBMED: 23159181] ">Atanaskova Mesinkovska 2013</a>). The topical formulation is available in three concentrations (1%, 2%, and 5%), with the 2% concentration applied once daily and the 5% either once or twice daily as the most commonly prescribed treatments (<a href="./references#CD007628-bbs2-0107" title="Atanaskova MesinkovskaN , BergfeldWF . Hair: What is new in diagnosis and management? Female pattern hair loss update: Diagnosis and treatment. Dermatologic Clinics2013;31(1):119‐27. [PUBMED: 23159181] ">Atanaskova Mesinkovska 2013</a>; <a href="./references#CD007628-bbs2-0115" title="BlumeyerA , TostiA , MessengerA , ReygagneP , delMarmolV , SpulsPI , et al. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men. Journal of the German Society of Dermatology2011;9(Suppl 6):S1‐57. [PUBMED: 21980982] ">Blumeyer 2011</a>; <a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>). Minoxidil as a 1% concentration is less frequently used, and in most countries, the 5% concentration is only registered for the treatment of AGA in men (<a href="./references#CD007628-bbs2-0150" title="RogersNE , AvramMR . Medical treatments for male and female pattern hair loss. Journal of the American Academy of Dermatology2008;59(4):547‐66. [PUBMED: 18793935] ">Rogers 2008</a>). Common side‐effects include scalp irritation and hypertrichosis on the cheeks and forehead (<a href="./references#CD007628-bbs2-0150" title="RogersNE , AvramMR . Medical treatments for male and female pattern hair loss. Journal of the American Academy of Dermatology2008;59(4):547‐66. [PUBMED: 18793935] ">Rogers 2008</a>). Minoxidil is contraindicated in pregnant and lactating women (<a href="./references#CD007628-bbs2-0150" title="RogersNE , AvramMR . Medical treatments for male and female pattern hair loss. Journal of the American Academy of Dermatology2008;59(4):547‐66. [PUBMED: 18793935] ">Rogers 2008</a>). </p> <p>Aminexil is a derivative of minoxidil, which is available as a shampoo and in vials (<a href="./references#CD007628-bbs2-0115" title="BlumeyerA , TostiA , MessengerA , ReygagneP , delMarmolV , SpulsPI , et al. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men. Journal of the German Society of Dermatology2011;9(Suppl 6):S1‐57. [PUBMED: 21980982] ">Blumeyer 2011</a>), but it has not been approved by either the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). </p> <p>Twice daily applications of 1% to 5% tincture of progesterone (a major hormone in the female menstrual cycle) can be used, but not in concentrations greater than 2%, or more than 2 mL per day, as it may cause menstrual irregularities. Topical oestrogens include fulvestrant twice daily or topical estradiol valerate 0.03% once daily (<a href="./references#CD007628-bbs2-0008" title="GassmuellerJ , HoffmannR , WebsterA . Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof‐of‐concept studies. British Journal of Dermatology2008;158(1):109‐15. [PUBMED: 17986309] ">Gassmueller 2008</a>; <a href="./references#CD007628-bbs2-0010" title="GeorgalaS , KatoulisAC , GeorgalaC , MoussatouV , BoziE , StavrianeasNG . Topical estrogen therapy for androgenetic alopecia in menopausal females. Dermatology2004;208(2):178‐9. [PUBMED: 15057016] ">Georgala 2004</a>). Alfatradiol is a 5‐alpha‐reductase inhibitor, but it is not freely available in many countries (<a href="./references#CD007628-bbs2-0001" title="Blume‐PeytaviU , KunteC , KrispA , Garcia BartelsN , EllwangerU , HoffmannR . Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women [Vergleich der Wirksamkeit und Sicherheit von Minoxidil und Alfatradiol bei der topischen Behandlung der androgenetischen Alopezie der Frau]. Journal der Deutschen Dermatologischen Gesellschaft2007;5(5):391‐5. [PUBMED: 17451383] ">Blume‐Peytavi 2007</a>). </p> <p>Systemic treatments that focus on antiandrogenic therapy include cyproterone acetate, spironolactone, finasteride, and flutamide (<a href="./references#CD007628-bbs2-0107" title="Atanaskova MesinkovskaN , BergfeldWF . Hair: What is new in diagnosis and management? Female pattern hair loss update: Diagnosis and treatment. Dermatologic Clinics2013;31(1):119‐27. [PUBMED: 23159181] ">Atanaskova Mesinkovska 2013</a>; <a href="./references#CD007628-bbs2-0110" title="BienováM , KucerováM , FiuraskováM , HajdúchM , KolárZ . Androgenetic alopecia and current methods of treatment. Acta Dermatovenerologica Alpina, Pannonica, et Adriatica2005;14(1):5‐8. [PUBMED: 15818439] ">Bienová 2005</a>; <a href="./references#CD007628-bbs2-0115" title="BlumeyerA , TostiA , MessengerA , ReygagneP , delMarmolV , SpulsPI , et al. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men. Journal of the German Society of Dermatology2011;9(Suppl 6):S1‐57. [PUBMED: 21980982] ">Blumeyer 2011</a>; <a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>). As all of these treatments carry the risk of malformation in male foetuses, effective contraceptive advice should be provided to women of childbearing age (<a href="./references#CD007628-bbs2-0115" title="BlumeyerA , TostiA , MessengerA , ReygagneP , delMarmolV , SpulsPI , et al. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men. Journal of the German Society of Dermatology2011;9(Suppl 6):S1‐57. [PUBMED: 21980982] ">Blumeyer 2011</a>; <a href="./references#CD007628-bbs2-0143" title="OlsenEA , MessengerAG , ShapiroJ , BergfeldWF , HordinskyMK , RobertsJL , et al. Evaluation and treatment of male and female pattern hair loss. Journal of the American Academy of Dermatology2005;52(2):301‐11. [PUBMED: 15692478] ">Olsen 2005</a>). </p> <p>Cyproterone acetate treatment is often used as a combination therapy of 2 mg in oral contraceptives plus cyproterone acetate up to 100 mg/day on days five to 15 of the menstrual cycle (<a href="./references#CD007628-bbs2-0115" title="BlumeyerA , TostiA , MessengerA , ReygagneP , delMarmolV , SpulsPI , et al. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men. Journal of the German Society of Dermatology2011;9(Suppl 6):S1‐57. [PUBMED: 21980982] ">Blumeyer 2011</a>; <a href="./references#CD007628-bbs2-0117" title="Camacho‐MartínezFM . Hair loss in women. Seminars in Cutaneous Medicine and Surgery2009;28(1):19‐32. [PUBMED: 19341939] ">Camacho‐Martínez 2009</a>). Important side‐effects are depression, weight gain, breast tenderness, and loss of libido (<a href="./references#CD007628-bbs2-0134" title="LeavittM . Understanding and management of female pattern alopecia. Facial Plastic Surgery2008;24(4):414‐27. [PUBMED: 19034818] ">Leavitt 2008</a>). </p> <p>Finasteride can be prescribed in varying doses, between 1 and 5 mg, and is generally well‐tolerated, but some women may experience breast tenderness and increased libido (<a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>). Furthermore, it is not registered by the FDA or EMA for use in women. </p> <p>Spironolactone (a diuretic, which is also used as an antiandrogen) in a dose of 50 to 200 mg/day, is one of the most frequently prescribed medications for FPHL in the USA (<a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>; <a href="./references#CD007628-bbs2-0134" title="LeavittM . Understanding and management of female pattern alopecia. Facial Plastic Surgery2008;24(4):414‐27. [PUBMED: 19034818] ">Leavitt 2008</a>). Well known side‐effects are electrolyte imbalance, cycle disturbances, fatigue, drowsiness, urticaria, breast tenderness, hypotension, and haematological disturbances (<a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>). Therefore, especially in the first weeks or months, blood pressure and electrolyte screening should be monitored (<a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>). </p> <p>Flutamide is not a first‐line drug due to its potentially severe hepatotoxic effects, but it has been used as a last‐resort treatment (<a href="./references#CD007628-bbs2-0165" title="YazdabadiA , SinclairR . Treatment of female pattern hair loss with the androgen receptor antagonist flutamide. Australasian Journal of Dermatology2011;52(2):132‐4. [PUBMED: 21605098] ">Yazdabadi 2011</a>). </p> <p>There has also been a steadily increasing interest in a variety of low‐level laser treatment options over recent years (<a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>; <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>; <a href="./references#CD007628-bbs2-0019" title="LanzafameRJ , BlancheRR , ChiacchieriniRP , KazmirekER , SklarJA . The growth of human scalp hair in females using visible red light laser and LED sources. Lasers in Surgery and Medicine2014;46(8):601‐7. [PUBMED: 25124964] ">Lanzafame 2014</a>). </p> <p>Other considered treatments include food and herbal supplements, hair transplantation, and less frequently used medical treatments (e.g. dutasteride, cimetidine, tretinoin, and ketoconazole) (<a href="./references#CD007628-bbs2-0107" title="Atanaskova MesinkovskaN , BergfeldWF . Hair: What is new in diagnosis and management? Female pattern hair loss update: Diagnosis and treatment. Dermatologic Clinics2013;31(1):119‐27. [PUBMED: 23159181] ">Atanaskova Mesinkovska 2013</a>; <a href="./references#CD007628-bbs2-0115" title="BlumeyerA , TostiA , MessengerA , ReygagneP , delMarmolV , SpulsPI , et al. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men. Journal of the German Society of Dermatology2011;9(Suppl 6):S1‐57. [PUBMED: 21980982] ">Blumeyer 2011</a>; <a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>). Cosmetic aids are other important management options and include hairstyling techniques, hair replacements, camouflage products, and hair accessories (<a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>; <a href="./references#CD007628-bbs2-0132" title="InuiS , InoueT , ItamiS . Effect of hairpieces on perceived quality of life in female pattern hair loss patients: questionnaire based study. Journal of Dermatology2013;40(8):671. [PUBMED: 23734854 ] ">Inui 2013</a>). </p> <p>As soon as treatment is stopped, shedding of hair may resume within weeks <a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>). Women with FPHL need thoughtful evaluation and management as well as reassurance (<a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>; <a href="./references#CD007628-bbs2-0146" title="PriceVH . Androgenetic alopecia in women. Journal of Investigative Dermatology. Symposium Proceedings2003;8(1):24‐7. [PUBMED: 12894991 ] ">Price 2003</a>), especially when current options for the treatment of this condition do not appear to demonstrate any long‐term or permanent benefits.  </p> </section> <section id="CD007628-sec-0050"> <h3 class="title" id="CD007628-sec-0050">How the intervention might work</h3> <p>Strategies to improve scalp hair density include prolongation of anagen duration, reversal of terminal to vellus transformation, or generation of de novo hair induction from the inter‐follicular epidermis (<a href="./references#CD007628-bbs2-0124" title="EllisJA , SinclairR , HarrapSB . Androgenic alopecia: pathogenesis and potential for therapy. Expert Reviews in Molecular Medicine2002;4(22):1‐11. [PUBMED: 14585162] ">Ellis 2002</a>). Minoxidil has a direct effect on the proliferation and differentiation of follicular keratinocytes (epidermal cells), leading to a prolongation of the anagen phase (<a href="./references#CD007628-bbs2-0150" title="RogersNE , AvramMR . Medical treatments for male and female pattern hair loss. Journal of the American Academy of Dermatology2008;59(4):547‐66. [PUBMED: 18793935] ">Rogers 2008</a>). In essence, it encourages hair to move from the resting stage to the active growth stage (<a href="./references#CD007628-bbs2-0150" title="RogersNE , AvramMR . Medical treatments for male and female pattern hair loss. Journal of the American Academy of Dermatology2008;59(4):547‐66. [PUBMED: 18793935] ">Rogers 2008</a>). Potassium channels found in human hair follicles may play a role in this process, but the exact mechanism of action is still unclear (<a href="./references#CD007628-bbs2-0152" title="ShorterK , FarjoNP , PicksleySM , RandallVA . Human hair follicles contain two forms of ATP‐sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB Journal2008;22(6):1725‐36. [PUBMED: 18258787] ">Shorter 2008</a>). Aminexil, a derivative of minoxidil, has a similar mode of action (<a href="./references#CD007628-bbs2-0115" title="BlumeyerA , TostiA , MessengerA , ReygagneP , delMarmolV , SpulsPI , et al. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men. Journal of the German Society of Dermatology2011;9(Suppl 6):S1‐57. [PUBMED: 21980982] ">Blumeyer 2011</a>). </p> <p>Cyproterone acetate is a progestin (synthetic hormone) with antiandrogen action. It acts by blocking androgen receptors, which prevents androgens (male hormones) from binding to these receptors and suppresses luteinizing hormone (which in turn reduces testosterone levels) (<a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>; <a href="./references#CD007628-bbs2-0134" title="LeavittM . Understanding and management of female pattern alopecia. Facial Plastic Surgery2008;24(4):414‐27. [PUBMED: 19034818] ">Leavitt 2008</a>). It is often combined with oral contraceptives, especially ethinyl estradiol 35 μg with 2 mg cyproterone acetate (<a href="./references#CD007628-bbs2-0115" title="BlumeyerA , TostiA , MessengerA , ReygagneP , delMarmolV , SpulsPI , et al. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men. Journal of the German Society of Dermatology2011;9(Suppl 6):S1‐57. [PUBMED: 21980982] ">Blumeyer 2011</a>; <a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>; <a href="./references#CD007628-bbs2-0134" title="LeavittM . Understanding and management of female pattern alopecia. Facial Plastic Surgery2008;24(4):414‐27. [PUBMED: 19034818] ">Leavitt 2008</a>). Spironolactone reduces the activity of 5‐alpha‐reductase, inhibits the biosynthesis of androgens, and has a direct antagonistic effect on androgen receptors (<a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>; <a href="./references#CD007628-bbs2-0134" title="LeavittM . Understanding and management of female pattern alopecia. Facial Plastic Surgery2008;24(4):414‐27. [PUBMED: 19034818] ">Leavitt 2008</a>). Finasteride is a selective inhibitor of 5‐alpha‐reductase, which reduces the conversion of testosterone into dihydrotestosterone (DHT) (<a href="./references#CD007628-bbs2-0110" title="BienováM , KucerováM , FiuraskováM , HajdúchM , KolárZ . Androgenetic alopecia and current methods of treatment. Acta Dermatovenerologica Alpina, Pannonica, et Adriatica2005;14(1):5‐8. [PUBMED: 15818439] ">Bienová 2005</a>; <a href="./references#CD007628-bbs2-0150" title="RogersNE , AvramMR . Medical treatments for male and female pattern hair loss. Journal of the American Academy of Dermatology2008;59(4):547‐66. [PUBMED: 18793935] ">Rogers 2008</a>), thereby lowering serum and scalp levels of DHT, while increasing scalp levels of testosterone. Low‐level laser treatment options may increase anagen hairs by stimulating epidermal stem cells in the hair follicle bulge (<a href="./references#CD007628-bbs2-0107" title="Atanaskova MesinkovskaN , BergfeldWF . Hair: What is new in diagnosis and management? Female pattern hair loss update: Diagnosis and treatment. Dermatologic Clinics2013;31(1):119‐27. [PUBMED: 23159181] ">Atanaskova Mesinkovska 2013</a>; <a href="./references#CD007628-bbs2-0108" title="AvciP , GuptaGK , ClarkJ , WikonkalN , HamblinMR . Low‐level laser (light) therapy (LLLT) for treatment of hair loss. Lasers in Surgery and Medicine2014;46(2):144‐51. [PUBMED: 23970445] ">Avci 2013</a>). </p> </section> <section id="CD007628-sec-0051"> <h3 class="title" id="CD007628-sec-0051">Why it is important to do this review</h3> <p>Although a range of options are available for the treatment of FPHL, it is unclear how effective they are and if any have a long‐term beneficial effect. Many of these interventions may have important and undesirable side‐effects. This Cochrane review is needed to clarify the best approach to treating this condition, to provide reliable decision‐making information to clinicians and people with the condition about the benefits and harms of available treatments, and to be the basis for recommendations for future research. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007628-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007628-sec-0052"></div> <p>To determine the efficacy and safety of the available options for the treatment of female pattern hair loss in women. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007628-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007628-sec-0053"></div> <section id="CD007628-sec-0054"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007628-sec-0055"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs).</p> </section> <section id="CD007628-sec-0056"> <h4 class="title">Types of participants</h4> <p>Any woman of any age who had been diagnosed with female pattern hair loss (FPHL) or androgenic alopecia (AGA) by a dermatologist or clinician. We included women with increased circulating androgens, whether due to physiological causes, polycystic ovary syndrome, or any other causes. However, we excluded women with androgen‐producing adrenal or ovary tumours. </p> </section> <section id="CD007628-sec-0057"> <h4 class="title">Types of interventions</h4> <p>We considered any intervention for FPHL or AGA.</p> </section> <section id="CD007628-sec-0058"> <h4 class="title">Types of outcome measures</h4> <section id="CD007628-sec-0059"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007628-list-0002"> <li> <p>The proportion of participants with self‐rated clinically significant hair regrowth at the end of the study. </p> </li> <li> <p>Change in quality of life (QoL) using any validated and recognised generic or disease‐specific instrument, e.g. the Women's Androgenetic Alopecia Quality of Life Questionnaire (WAA‐QOL) (<a href="./references#CD007628-bbs2-0120" title="DolteKS , GirmanCJ , HartmaierS , RobertsJ , BergfeldW , WaldstreicherJ . Development of a health‐related quality of life questionnaire for women with androgenetic alopecia. Clinical and Experimental Dermatology2000;25(8):637‐42. [PUBMED: 11167980] ">Dolte 2000</a>). </p> </li> <li> <p>Adverse effects: safety, tolerability, and any reported adverse events.</p> </li> </ul> </p> </section> <section id="CD007628-sec-0060"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007628-list-0003"> <li> <p>Proportion of participants with investigator‐rated clinically significant hair regrowth at the end of the study. </p> </li> <li> <p>Mean change in total hair count from baseline to the end of the study.</p> </li> <li> <p>Degree of hair shedding from baseline to the end of the study.</p> </li> <li> <p>Cosmetic appearance of the hair or participant satisfaction.</p> </li> <li> <p>Change in quality (or pattern) of hair regrowth (e.g. thickness).</p> </li> </ul> </p> <p>We defined 'clinically significant' outcomes as, for example, a single level change on the Sinclair scale (<a href="./references#CD007628-bbs2-0140" title="MessengerAG , SinclairR . Follicular miniaturization in female pattern hair loss: clinicopathological correlations. British Journal of Dermatology2006;155(5):926‐30. [PUBMED: 17034520] ">Messenger 2006</a>; <a href="./references#CD007628-bbs2-0153" title="SinclairR , JolleyD , MallariR , MageeJ . The reliability of horizontally sectioned scalp biopsies in the diagnosis of chronic diffuse telogen hair loss in women. Journal of the American Academy of Dermatology2004;51(2):189‐99. [PUBMED: 15280836] ">Sinclair 2004</a>). We accepted all outcomes measures that used a recognised generic or validated scale (e.g. Ludwig scale, Sinclair scale). </p> </section> </section> </section> <section id="CD007628-sec-0061"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant RCTs regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD007628-sec-0062"> <h4 class="title">Electronic searches</h4> <p>Jan Schoones (JS) updated the following searches to 7 July 2015. Prior searches were done by JS and Skin Group's Information Specialist. </p> <p> <ul id="CD007628-list-0004"> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (2015, Issue 6) using the search strategy in <a href="./appendices#CD007628-sec-0354">Appendix 1</a>. </p> </li> <li> <p>MEDLINE via Ovid (from 1946) using the strategy in <a href="./appendices#CD007628-sec-0355">Appendix 2</a>. </p> </li> <li> <p>EMBASE via Ovid (from 1974) using the strategy in <a href="./appendices#CD007628-sec-0356">Appendix 3</a>. </p> </li> <li> <p>PsycInfo via Ovid (from 1872) using the strategy in <a href="./appendices#CD007628-sec-0355">Appendix 2</a>. </p> </li> <li> <p>PubMed (from 1947) using the strategy in <a href="./appendices#CD007628-sec-0357">Appendix 4</a>. </p> </li> <li> <p>Web of Science (from 1945) using the strategy in <a href="./appendices#CD007628-sec-0358">Appendix 5</a>. </p> </li> </ul> </p> <p>The Skin Group's Information Specialist updated the following searches to 15 July 2015. </p> <p> <ul id="CD007628-list-0005"> <li> <p>The Cochrane Skin Group Specialised Register using the following terms: (androgen* AND alopecia) OR (female AND pattern AND hair AND loss) OR (female and baldness) or (female AND pattern AND alopecia). </p> </li> <li> <p>AMED via Ovid (Allied and Complementary Medicine, from 1985) using the strategy in <a href="./appendices#CD007628-sec-0359">Appendix 6</a>. </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database, from 1982) using the strategy in <a href="./appendices#CD007628-sec-0360">Appendix 7</a>. </p> </li> </ul> </p> <section id="CD007628-sec-0063"> <h5 class="title">Trial registries</h5> <p>We searched the following trial registries on 24 July 2015 (Esther J van Zuuren (EvZ) and JS) using the search terms: androgenic alopecia, androgenetic alopecia, and FPHL. </p> <p> <ul id="CD007628-list-0006"> <li> <p>The ISRCTN registry (<a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>). </p> </li> <li> <p>The US National Institutes of Health Ongoing Trials Register (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>). </p> </li> <li> <p>The Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>). </p> </li> <li> <p>The World Health Organization International Clinical Trials Registry platform (<a href="http://www.who.int/trialsearch" target="_blank">www.who.int/trialsearch</a>). </p> </li> <li> <p>The EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/" target="_blank">www.clinicaltrialsregister.eu/</a>). </p> </li> </ul> </p> </section> </section> <section id="CD007628-sec-0064"> <h4 class="title">Searching other resources</h4> <section id="CD007628-sec-0065"> <h5 class="title">Adverse effects</h5> <p>We did not perform a separate search for adverse effects of the target intervention. However, we did examine data on adverse effects from the included studies we identified. </p> </section> <section id="CD007628-sec-0066"> <h5 class="title">References from published studies</h5> <p>We examined the bibliographies of the included and excluded studies for further references to potentially eligible RCTs. </p> </section> <section id="CD007628-sec-0067"> <h5 class="title">Correspondence</h5> <p>We contacted the trial investigators and asked them to provide missing data or clarify study details (see <a href="#CD007628-tbl-0006">Table 2</a>). </p> <div class="table" id="CD007628-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Contact with investigators</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Additional</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0050" title="BezzolaP , SorbelliniE . The role of microinflammation and apoptosis in androgenic alopecia: New therapeutical strategies [Il ruolo della microinfiammazione e dell' apoptosi nella alopecia androgenetica: Nouve strategie terapeutiche]. Journal of Plastic Dermatology2009;5(1):47‐58. [EMBASE: 2009226819] ">Bezzola 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no separate data for women. The primary outcome was diameter of hair, not one of the outcomes for this review. We excluded this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0001" title="Blume‐PeytaviU , KunteC , KrispA , Garcia BartelsN , EllwangerU , HoffmannR . Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women [Vergleich der Wirksamkeit und Sicherheit von Minoxidil und Alfatradiol bei der topischen Behandlung der androgenetischen Alopezie der Frau]. Journal der Deutschen Dermatologischen Gesellschaft2007;5(5):391‐5. [PUBMED: 17451383] ">Blume‐Peytavi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IPD (individual patient data) were unavailable. We included this study.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. </p> <p>We received a response on 16 November 2011: "The allocation concealment was performed using sequentially numbered, sealed, opaque envelopes, and kept by the project manager of the CRC." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0003" title="Bureau JP, GinouvesP , GuilbaudJ , RouxME . Essential oils and low‐intensity electromagnetic pulses in the treatment of androgen‐dependent alopecia. Advances in Therapy2003;20(4):220‐9. [PUBMED: 14669818] ">Bureau 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We could contact one of the investigators, who was unable to provide separate data on women. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0004" title="CarminaE , LoboRA . Treatment of hyperandrogenic alopecia in women. Fertility and Sterility2003;79(1):91‐5. [PUBMED: 12524069] ">Carmina 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0005" title="DeVillezRL , JacobsJP , SzpunarCA , WarnerML . Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Archives of Dermatology1994;130(3):303‐7. [PUBMED: 8129407] ">DeVillez 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0006" title="DraelosZD , JacobsonEL , KimH , KimM , JacobsonMK . A pilot study evaluating the efficacy of topically applied niacin derivatives for treatment of female pattern alopecia. Journal of Cosmetic Dermatology2005;4(4):258‐61. [PUBMED: 17168873] ">Draelos 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0056" title="FarellaV , MelliMC , GiorginiS . Mucopolysaccharides and depolymerized nucleic acids in the treatment of androgenic alopecia [Mucopolisaccaridi e acidi nucleici depolimerizzati nella alopecia androgenetica, studio clinico in doppio cieco]. Dermatologia Oggi1991;6(3):39‐46. [EMBASE: 1992071835] ">Farella 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Italian Cochrane Centre translated and assessed this study, but it was a controlled clinical trial (CCT), so we excluded it. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0007" title="FischerTW , BurmeisterG , SchmidtHW , ElsnerP . Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. British Journal of Dermatology2004;150(2):341‐5. [PUBMED: 14996107] ">Fischer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We received information that allowed a change in the assessment for several domains from unclear to low risk of bias. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0008" title="GassmuellerJ , HoffmannR , WebsterA . Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof‐of‐concept studies. British Journal of Dermatology2008;158(1):109‐15. [PUBMED: 17986309] ">Gassmueller 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We received information that allowed a change in assessment for several domains from unclear to low risk of bias. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0010" title="GeorgalaS , KatoulisAC , GeorgalaC , MoussatouV , BoziE , StavrianeasNG . Topical estrogen therapy for androgenetic alopecia in menopausal females. Dermatology2004;208(2):178‐9. [PUBMED: 15057016] ">Georgala 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0009" title="GehringW , GloorM . Use of the phototrichogram to assess the stimulation of hair growth ‐ An in vitro study of women with androgenetic alopecia [Das Phototrichogramm als Verfahren zur Beurteilung haarwachstumsfördernder Präparate am beispiel einer Kombination von Hirsefruchtextrakt, L‐Cystin und Calcium panthonthenat‐Ergebnisse einer in vivo Untersuchung bei Frauen mit androgenetischem Haarausfall]. H+G Zeitschrift fur Hautkrankheiten2000;75(7‐8):419‐23. [EMBASE: 2000344799] ">Gehring 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0058" title="GolpourM , RabbaniH , FarzinD , AziziF . Comparing the effectiveness of local solution of minoxidil and caffeine 2.5% with local solution of minoxidil 2.5% in treatment of androgenetic alopecia. Journal of Mazandaran University of Medical Sciences2013;23(106):29‐36. [EMBASE: 2014593395] ">Golpour 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. One review author, ZF, translated this study, which only included males, so we excluded this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0011" title="GuerreroAR , MedinaKR , KahnMC , GuerreroMJ . Usefulness and safety of 0.025 percent 17‐alpha‐estradiol versus 2 percent minoxidil in the treatment of androgenetic alopecia [Utilidad y seguridad del 17‐alfa‐estradiol 0,025 por ciento versus minoxidil 2 por ciento en el tratamiento de la alopecia androgenetica]. Revista Chilena de Dermatologia2009;25(1):21‐5. ">Guerrero 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. The data was mixed in terms of gender. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0012" title="HongCK , HanTY , KangHC , AhnSW , AhnJY , SeoSJ . The efficacy and safety of a combination cytopurine/pentadecanoic glyceride topical solution on androgenetic alopecia: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(12):1233‐9. ">Hong 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation/concealment and blinding. The data was mixed in terms of gender. We included this study. <a href="http://mailto:hongck@cau.ac.kr" target="_blank"><span class="__cf_email__" data-cfemail="6c0403020b0f072c0f0d19420d0f42071e">[email protected]</span></a>; <a href="http://dermahan@gmail.com" target="_blank"><span class="__cf_email__" data-cfemail="2f4b4a5d424e474e416f48424e4643014c4042">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0013" title="JacobsJP , SzpunarCA , WarnerML . Use of topical minoxidil therapy for androgenetic alopecia in women. International Journal of Dermatology1993;32(10):758‐62. [PUBMED: 8225725] ">Jacobs 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were unable to contact the study investigators. We included this study.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>; <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation/concealment and blinding. We included this study. <a href="http://dm@hairmax.com" target="_blank"><span class="__cf_email__" data-cfemail="395d54795158504b545841175a5654">[email protected]</span></a>; Leonard Stillman. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation/concealment and blinding. We included this study. <a href="http://drkeene@hairrestore.com" target="_blank"><span class="__cf_email__" data-cfemail="ea8e98818f8f848faa828b8398988f999e85988fc4898587">[email protected]</span></a>; <a href="http://andyg@appliedbiology.com" target="_blank"><span class="__cf_email__" data-cfemail="b2d3dcd6cbd5f2d3c2c2dedbd7d6d0dbdddeddd5cb9cd1dddf">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0017" title="KimJH , YSM , ChoiJE , SonSW . Study of the efficacy of Korean red ginseng in the treatment of androgenic alopecia. Journal of Ginseng Research2009;33(3):223‐8. ">Kim 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding.</p> <p><a href="http://skin4u@korea.ac.kr" target="_blank"><span class="__cf_email__" data-cfemail="70031b191e4405301b1f0215115e11135e1b02">[email protected]</span></a>. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0018" title="KimH , ChoiJW , KimJY , ShinJW , LeeSJ , HuhCH . Low‐level light therapy for androgenetic alopecia: a 24‐week, randomized, double‐blind, sham device‐controlled multicenter trial. Dermatologic Surgery2013;39(8):1177‐83. [PUBMED: 23551662] ">Kim 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation, but not for concealment and blinding. We did not receive separate data for women. We included this study. <a href="http://chhuh@snu.ac.kr" target="_blank"><span class="__cf_email__" data-cfemail="593a31312c31192a372c77383a77322b">[email protected]</span></a>; <a href="http://seokjong@knu.ac.kr" target="_blank"><span class="__cf_email__" data-cfemail="6516000a0e0f0a0b02250e0b104b04064b0e17">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0019" title="LanzafameRJ , BlancheRR , ChiacchieriniRP , KazmirekER , SklarJA . The growth of human scalp hair in females using visible red light laser and LED sources. Lasers in Surgery and Medicine2014;46(8):601‐7. [PUBMED: 25124964] ">Lanzafame 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation, as well as losses to follow‐up.</p> <p><a href="http://raymond.lanzafame@gmail.com" target="_blank"><span class="__cf_email__" data-cfemail="c8baa9b1a5a7a6ace6a4a9a6b2a9aea9a5ad88afa5a9a1a4e6aba7a5">[email protected]</span></a>. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0020" title="LeFloc'hC , ChenitiA , ConnétableS , PiccardiN , VincenziC , TostiA . Effect of a nutritional supplement on hair loss in women. Journal of Cosmetic Dermatology2015;14(1):76‐82. [PUBMED: 25573272] ">Le Floc'h 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. <a href="http://npiccardi@rd.loreal.com" target="_blank"><span class="__cf_email__" data-cfemail="aec0dec7cdcdcfdccac7eedcca80c2c1dccbcfc280cdc1c3">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0065" title="LiMC , ShuW , WangHY , WangXS . Randomized double‐blind placebo‐controlled evaluation of topical minoxidil in the treatment of female androgonetic alopecia. Chinese Journal of Dermatology1996;29:223‐5. ">Li 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We excluded this study as it was a CCT.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0022" title="MazzarellaF , LoconsoleF , CammisaA , MastrolonardoM , VenaGA . Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16‐month therapy course. Journal of Dermatological Treatment1997;8(3):189‐92. [EMBASE: 1997295968] ">Mazzarella 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. The data was mixed in terms of gender. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0023" title="MinozziM , UnferV , ConstabileL . Androgenetic alopecia in postmenopausal women [Alopecia androgenetica in post‐menopausa]. Giornale Italiano di Ostetricia e Ginecologia1997;19(6):341‐4. [EMBASE: 1997225861] ">Minozzi 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0033" title="OuraH , IinoM , IdetaR , NakazawaY , KishimotoJ , AraseS . Efficacy of adenosine on female pattern hair loss and male androgenetic alopecia. Journal of Investigative Dermatology2008;128(Suppl 1):S151. OuraH , IinoM , NakazawaY , TajimaM , IdetaR , NakayaY , et al. Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: a pilot, double‐blind, randomized, placebo‐controlled trial. Journal of Dermatology2008;35(12):763‐7. [PUBMED: 19239555] ">Oura 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0034" title="Pazoki‐ToroudiH , BabakoohiS , NilforoushzadehMA , Nassiri‐KashaniM , ShizarpourM , AjamiM , et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed2012;10(5):276‐82. [PUBMED: 23163069] ">Pazoki‐Toroudi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. <a href="http://hpazooki@farabi.tums.ac.ir" target="_blank"><span class="__cf_email__" data-cfemail="82eaf2e3f8edede9ebc2e4e3f0e3e0ebacf6f7eff1ace3e1acebf0">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0036" title="PriceVH , MenefeeE . Quantitative estimation of hair growth. I. androgenetic alopecia in women: effect of minoxidil. Journal of Investigative Dermatology1990;95(6):683‐7. [PUBMED: 2250110] ">Price 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We received no response from the investigator. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We received no response from the investigator. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0039" title="ShengY‐Y , RuiW‐L , XuF , QiS‐S , HuR‐M , MiaoY , et al. A randomized controlled clinical study on 2% and 5% topical minoxidil solution in the treatment of female pattern hair loss [Chinese]. Journal of Clinical Dermatology2014;43(10):583‐5. [EMBASE: 2015699887] ">Sheng 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation/concealment and blinding. We included this study. <a href="http://dxq93216@medmail.com.cn" target="_blank"><span class="__cf_email__" data-cfemail="02667a733b31303334426f67666f636b6e2c616d6f2c616c">[email protected]</span></a>; <a href="http://felix_sheng@medmail.com.cn" target="_blank"><span class="__cf_email__" data-cfemail="93f5f6fffaebcce0fbf6fdf4d3fef6f7fef2faffbdf0fcfebdf0fd">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0040" title="ShinHS , LeeSH , KimDH , AnJS , KwonOS , EunHC . The efficacy and safety of AP‐FHG0604T on female pattern hair loss: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(2):119‐26. ">Shin 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation/concealment. We included this study. </p> <p><a href="http://hceun@snu.ac.kr" target="_blank"><span class="__cf_email__" data-cfemail="e78f84829289a7948992c98684c98c95">[email protected]</span></a>; <a href="http://reslab@naver.com" target="_blank"><span class="__cf_email__" data-cfemail="b5c7d0c6d9d4d7f5dbd4c3d0c79bd6dad8">[email protected]</span></a> (Dr Shin Hyoseung); <a href="http://oskwon@snu.ac.kr" target="_blank"><span class="__cf_email__" data-cfemail="8ee1fde5f9e1e0cefde0fba0efeda0e5fc">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0077" title="SinclairR . Treatment of androgenetic alopecia in women with oral antiandrogen therapy. Annales de Dermatologie et de Venereologie2002;129(Suppl 1 Pt 1):1S324. ">Sinclair 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Information provided to us enabled a change from unclear to high risk of bias. We excluded this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0041" title="ThomE . Efficacy and tolerability of Hairgain® in individuals with hair loss: a placebo‐controlled, double‐blind study. Journal of International Medical Research2001;29(1):2‐6. [EMBASE: 2001114261] ">Thom 2001</a>/<a href="./references#CD007628-bbs2-0042" title="ThomE . Nourkrin: objective and subjective effects and tolerability in persons with hair loss. Journal of International Medical Research2006;34(5):514‐9. [EMBASE: 2006563255] ">Thom 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The data was mixed in terms of gender. We received no response from the investigator. We included this study. <a href="http://erling.thom@parexel.com" target="_blank"><span class="__cf_email__" data-cfemail="3653445a5f585118425e595b76465744534e535a1855595b">[email protected]</span></a>; <a href="http://info@pharmamedico.com" target="_blank"><span class="__cf_email__" data-cfemail="026b6c646d42726a63706f636f67666b616d2c616d6f">[email protected]</span></a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The information we received allowed us to change the assessment for several domains from unclear to low risk of bias. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0044" title="UkşalÜ , BayramF , UtaşS , ÇolakR , BorluM . Comparision of low dose finasteride, flutamide and spirolactone in female androgenetic alopecia. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S238. ">Ukşal 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study, but there were missing data. We received no response from the investigator. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0045" title="VexiauP , ChaspouxC , BoudouP , FietJ , JouaniqueC , HardyN , et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12‐month randomized trial. British Journal of Dermatology2002;146(6):992‐9. [PUBMED: 12072067] ">Vexiau 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We received information regarding the hyperandrogenic profile of the women. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0094" title="ACTRN12607000027415 . Double blind placebo controlled trial into the treatment of female pattern hair loss with spironolactone and minoxidil. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=81787 (accessed 14 January 2016). ">ACTRN12607000027415</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date. <a href="http://yazdaa27@gmail.com" target="_blank"><span class="__cf_email__" data-cfemail="b8c1d9c2dcd9d98a8ff8dfd5d9d1d496dbd7d5">[email protected]</span></a>; <a href="http://Rod.SINCLAIR@svhm.org.au" target="_blank"><span class="__cf_email__" data-cfemail="3664595218657f78757a777f647645405e5b18594451185743">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0095" title="EUCTR2013‐002740‐85‐ES . A Pilot Randomized, Double‐blind, Placebo‐controlled Clinical Trial to Obtain Preliminary Data on Efficacy and Safety in the Application of PRGF‐Endoret by Mesotherapy, in the Treatment of Male and Female Androgenetic Alopecia of Over 6 Months Duration. www.clinicaltrialsregister.eu/ctr‐search/search?query=EUCTR2013‐002740‐85‐ES (accessed 16 January 2016). ">EUCTR2013‐002740‐85‐ES</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date nor if these are the same studies. <a href="http://eduardoanitua@eduardoanitua.com" target="_blank"><span class="__cf_email__" data-cfemail="254041504457414a444b4c515044654041504457414a444b4c5150440b464a48">[email protected]</span></a>; <a href="http://virginia.cuadrado@bti-implant.es" target="_blank">virginia.cuadrado@bti‐implant.es</a>; <a href="http://alopecia.ccdermatologico@gmail.com" target="_blank"><span class="__cf_email__" data-cfemail="3f5e53504f5a5c565e115c5c5b5a4d525e4b50535058565c507f58525e5653115c5052">[email protected]</span></a>. Are EUCTR2013‐002740‐85‐ES and NCT01885676 the same studies, as everything is the same, except contact persons (same inclusion, same number of patients, same treatments, same sponsor) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0096" title="NCT00175617 . Efficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT00175617 (accessed 14 January 2016). ">NCT00175617</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date. <a href="http://andreas.finner@vch.ca" target="_blank"><span class="__cf_email__" data-cfemail="e786898395828694c9818e89898295a791848fc98486">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0097" title="NCT00197379 . The Effect of 0.5% Roxithromycin Lotion for Androgenetic Alopecia. clinicaltrials.gov/ct2/show/NCT00197379 (accessed 14 January 2016). ">NCT00197379</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date. <a href="http://itoutai@hama-med.ac.jp" target="_blank">itoutai@hama‐med.ac.jp</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0098" title="NCT00418249 . Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women. clinicaltrials.gov/ct2/show/NCT00418249 (accessed 14 January 2016). ">NCT00418249</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date. <a href="http://mailto:rlurie%40bezeqint.net" target="_blank"><span class="__cf_email__" data-cfemail="e99b859c9b808ca98b8c938c9880879dc7878c9d">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0025" title="DoshiU , IsraelM , KendallC , QuizaC , SacavageS , TyndallD , et al. Effectiveness of once daily 5% minoxidil topical foam in the treatment of women with thinning hair due to female pattern hair loss (FPHL). Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB112. [EMBASE: 71895204] NCT01145625 . A Phase 3 multi‐center parallel design clinical trial to compare the efficacy and safety of 5% Minoxidil Foam vs. 2% Minoxidil Solution in females for the treatment of female pattern hair loss ‐ androgenetic alopecia (MINALO3004, NCT01145625). clinicaltrials.gov/ct2/show/NCT01145625 (accessed 14 January 2016). ">NCT01145625</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation/concealment. LinkedIn Professor Kendall, and U Doshi and website Johnson &amp; Johnson. Received from both Johnson &amp; Johnson international as NL reply they forwarded it to responsible party, however, no response </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0026" title="NCT01189279 . Safety and pharmacokinetics study of new formulation of Bimatoprost in patients with alopecia. clinicaltrials.gov/ct2/show/NCT01189279 (accessed 14 January 2016). ">NCT01189279</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date. <a href="http://clinicaltrials@allergan.com" target="_blank"><span class="__cf_email__" data-cfemail="1f7c737671767c7e736b6d767e736c5f7e73737a6d787e71317c7072">[email protected]</span></a>, international and Dutch website </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0027" title="NCT01226459 . A Phase 3 Multi‐Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia). clinicaltrials.gov/ct2/show/NCT01226459 (accessed 14 January 2016). ">NCT01226459</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0028" title="NCT01325350 . Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01325350 (accessed 14 January 2016). ">NCT01325350</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allergan through website twice, no reply.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0029" title="NCT01655108 . Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients. clinicaltrials.gov/ct2/show/NCT01655108 (accessed 14 January 2016). ">NCT01655108</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation/concealment and blinding and received all possible data of the submitted paper. <a href="http://izelda@unb.br" target="_blank"><span class="__cf_email__" data-cfemail="94fdeef1f8f0f5d4e1faf6baf6e6">[email protected]</span></a>, Barbara Uzel: <a href="http://barbara.uzel@gmail.com" target="_blank"><span class="__cf_email__" data-cfemail="ef8d8e9d8d8e9d8ec19a958a83af88828e8683c18c8082">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0100" title="NCT01662089 . The Efficacy in Treatment of Female Pattern Hair Loss Using 5% Minoxidil Solution Combinded With Zinc Supplement. clinicaltrials.gov/ct2/show/NCT01662089 (accessed 14 January 2016). ">NCT01662089</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date. <a href="http://mailto:rattapongthuangtong%40yahoo.com?subject=NCT01662089, SirirajH-004, The Efficacy in Treatment of Female Pattern Hair Loss Using 5% Minoxidil Solution Combinded With Zinc Supplement" target="_blank"><span class="__cf_email__" data-cfemail="7f0d1e0b0b1e0f1011180b170a1e11180b1011183f061e171010511c1012">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0101" title="NCT01686295 . 24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness. clinicaltrials.gov/ct2/show/NCT01686295 (accessed 14 January 2016). ">NCT01686295</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date. <a href="http://mailto:candresen%40tklresearch.com?subject=NCT01686295, CS940112, 24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness" target="_blank"><span class="__cf_email__" data-cfemail="7714161913051204121937031c1b051204121605141f5914181a">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0102" title="NCT01885676 . Plasma Rich in Growth Factors (PRGF‐Endoret) in the Treatment of Androgenetic Alopecia. clinicaltrials.gov/ct2/show/NCT01885676 (accessed 14 January 2016). ">NCT01885676</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date. <a href="http://mailto:eduardoanitua%40eduardoanitua.com?subject=NCT01885676, BTI-01D-EC/12/ALO, Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia" target="_blank"><span class="__cf_email__" data-cfemail="503534253122343f313e39242531103534253122343f313e392425317e333f3d">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0030" title="NCT01900041 . A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01900041 (accessed 14 January 2016). ">NCT01900041</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation and flow chart. We included this study. </p> <p><a href="http://Larissa.Cheredeeva@merz.ru" target="_blank"><span class="__cf_email__" data-cfemail="622e03100b1111034c210a0710070607071403220f0710184c1017">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0031" title="NCT01967277 . A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy. clinicaltrials.gov/ct2/show/NCT01967277 (accessed 14 January 2016). ">NCT01967277</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. concealment and blinding (but not sequence generation). We included this study. <a href="http://pschnoor@capillus.com" target="_blank"><span class="__cf_email__" data-cfemail="661615050e08090914260507160f0a0a13154805090b">[email protected]</span></a>, <a href="http://mailto:info@capillus.com" target="_blank"><span class="__cf_email__" data-cfemail="620b0c040d220103120b0e0e17114c010d0f">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0103" title="NCT02074943 . Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia. clinicaltrials.gov/ct2/show/NCT02074943 (accessed 14 January 2016). ">NCT02074943</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no further information regarding publication date, and the study is not yet finished. <a href="http://mailto:Jerry.Shapiro%40vch.ca?subject=NCT02074943, H13-03126, Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia" target="_blank"><span class="__cf_email__" data-cfemail="3e745b4c4c47106d565f4e574c517e485d56105d5f">[email protected]</span></a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CCT: controlled clinical trial (quasi‐randomised).</p> </div> </div> </section> </section> </section> <section id="CD007628-sec-0068"> <h3 class="title" id="CD007628-sec-0068">Data collection and analysis</h3> <p>We followed the previously published protocol (<a href="./references#CD007628-bbs2-0167" title="CusmanichCC , HannonCW , AndrioloRB , LimaHC . Interventions for androgenic alopecia in women. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007628.pub2] ">Cusmanich 2009</a>) for this Cochrane review. This is the first update of the original published Cochrane review (<a href="./references#CD007628-bbs2-0168" title="vanZuurenEJ , FedorowiczZ , CarterB , AndrioloRB , SchoonesJ . Interventions for female pattern hair loss. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD007628.pub3] ">van Zuuren 2012</a>). </p> <section id="CD007628-sec-0069"> <h4 class="title">Selection of studies</h4> <p>Two review authors (EvZ and Zbys Fedorowicz (ZF)) assessed the titles and abstracts identified from the searches. We only included RCTs that evaluated FPHL in women in this Cochrane review. The two review authors independently assessed each included study to determine whether the predefined selection criteria were met, and they resolved any differences of opinion through discussion within the review team. We have listed the excluded studies and the reasons for their exclusion in the '<a href="./references#CD007628-sec-0377" title="">Characteristics of excluded studies</a>' section of the review. </p> </section> <section id="CD007628-sec-0070"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (EvZ and ZF) extracted data using a previously developed data extraction form, and resolved any disagreements on data extraction by consensus. We contacted the trial authors and asked them to provide missing data where possible. Two review authors (EvZ and ZF) checked and entered the data into Review Manager (RevMan) (<a href="./references#CD007628-bbs2-0148" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager (RevMan) 2014</a>). </p> </section> <section id="CD007628-sec-0071"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (EvZ and ZF) independently assessed the risk of bias in the included studies following the domain‐based evaluation described in Chapter 8 of the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007628-bbs2-0129" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. Chichester, UK: John Wiley &amp; Sons, Ltd. ">Higgins 2011</a>). They compared the evaluations, and resolved any inconsistencies by discussion. </p> <p>We rated the following domains separately for each of the included studies as either 'low risk of bias', 'high risk of bias', or 'unclear' if the risk of bias was uncertain or unknown. </p> <p> <ul id="CD007628-list-0007"> <li> <p>Whether the allocation sequence was adequately generated ('sequence generation').</p> </li> <li> <p>Whether the allocation was adequately concealed ('allocation concealment').</p> </li> <li> <p>Whether knowledge of the allocated interventions was adequately prevented during the study ('blinding'). </p> </li> <li> <p>Whether incomplete outcome data were adequately addressed.</p> </li> <li> <p>Whether reports of the study were free of suggestion of selective outcome reporting.</p> </li> <li> <p>Whether the study was apparently free of other sources of bias that could put it at high risk of bias, e.g. baseline imbalance. </p> </li> </ul> </p> <p>We have reported these assessments in the 'Risk of bias' table for each individual study in the '<a href="./references#CD007628-sec-0376" title="">Characteristics of included studies</a>' section of the review. </p> <p>We also categorised and reported the overall risk of bias of each of the included studies according to the following. </p> <p> <ul id="CD007628-list-0008"> <li> <p>Low risk of bias (plausible bias unlikely to seriously alter the results) if all criteria were met. </p> </li> <li> <p>Unclear risk of bias (plausible bias that raises some doubt about the results) if one or more criteria were assessed as unclear. </p> </li> <li> <p>High risk of bias (plausible bias that seriously weakens confidence in the results) if one or more criteria were not met. </p> </li> </ul> </p> <p>We reported these assessments in the '<a href="#CD007628-sec-0091">Risk of bias in included studies</a>' section. </p> </section> <section id="CD007628-sec-0072"> <h4 class="title">Measures of treatment effect</h4> <p>We presented continuous outcomes on the original scale as reported in each individual study. In future updates, if included studies report similar outcomes using different scales, we will standardise these by dividing the estimated coefficient by its standard deviation (SD), to allow us to make comparisons between scales. </p> <p>We presented dichotomous outcomes data as risk ratios (RR). We reported all outcome data with their associated 95% confidence intervals (CIs) and analysed them in RevMan (<a href="./references#CD007628-bbs2-0148" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager (RevMan) 2014</a>) using the Mantel‐Haenszel test, unless we stated otherwise. </p> </section> <section id="CD007628-sec-0073"> <h4 class="title">Unit of analysis issues</h4> <section id="CD007628-sec-0074"> <h5 class="title">Cross‐over studies</h5> <p>We included one cross‐over study (<a href="./references#CD007628-bbs2-0001" title="Blume‐PeytaviU , KunteC , KrispA , Garcia BartelsN , EllwangerU , HoffmannR . Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women [Vergleich der Wirksamkeit und Sicherheit von Minoxidil und Alfatradiol bei der topischen Behandlung der androgenetischen Alopezie der Frau]. Journal der Deutschen Dermatologischen Gesellschaft2007;5(5):391‐5. [PUBMED: 17451383] ">Blume‐Peytavi 2007</a>), but as this study did not report any wash‐out period, we only included data from the first treatment period. </p> </section> <section id="CD007628-sec-0075"> <h5 class="title">Multi‐armed studies</h5> <p>For continuous outcomes, we included participants from the control arms of within multi‐arm studies approximately equally in the pair‐wise comparisons with the active intervention arms. The mean and SD summary statistics for the placebo participants remained unchanged. </p> </section> </section> <section id="CD007628-sec-0076"> <h4 class="title">Dealing with missing data</h4> <p>We successfully contacted the investigators of several included trials (see <a href="#CD007628-tbl-0006">Table 2</a>). We re‐analysed the data according to a treatment by allocation principle, whenever possible, and according to Section 16.2.2 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007628-bbs2-0129" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. Chichester, UK: John Wiley &amp; Sons, Ltd. ">Higgins 2011</a>). If study authors did not report data and had conducted a per‐protocol analysis, we inspected the degree of imbalance in the dropout rate between the trial arms to determine the potential impact of bias. In the absence of a treatment by allocation population, we used an available case population and reported this accordingly. </p> </section> <section id="CD007628-sec-0077"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by examining the characteristics of the studies, the similarity between the types of participants, and the interventions. Also, we determined the degree of heterogeneity between the studies using the I² statistic. We reported heterogeneity as important if it was at least moderate to substantial by an I² statistic value of greater than 60% (<a href="./references#CD007628-bbs2-0129" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. Chichester, UK: John Wiley &amp; Sons, Ltd. ">Higgins 2011</a>). If we could explain this by clinical reasoning and could make a coherent argument for combining the studies, we entered these into a meta‐analysis. In cases where we could not adequately explain the heterogeneity, we did not pool the data. </p> <p>The clinical diversity between the studies included in this review, as well as the limited number of studies that we could combine for each intervention, only allowed us to make assessments of heterogeneity between the studies for two of the comparisons. </p> </section> <section id="CD007628-sec-0078"> <h4 class="title">Assessment of reporting biases</h4> <p>We performed assessments of reporting bias following the recommendations on testing for funnel plot asymmetry (<a href="./references#CD007628-bbs2-0122" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. [PUBMED: 9310563] ">Egger 1997</a>), as described in Section 10.4.3.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007628-bbs2-0129" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. Chichester, UK: John Wiley &amp; Sons, Ltd. ">Higgins 2011</a>), for primary and secondary outcomes where we performed meta‐analysis (at least three studies needed). We only presented funnel plots where there was some evidence of asymmetry in the plots. We explored the possible sources of asymmetry with an additional sensitivity analysis. </p> </section> <section id="CD007628-sec-0079"> <h4 class="title">Data synthesis</h4> <p>Two review authors (EvZ and ZF) analysed the data in RevMan (<a href="./references#CD007628-bbs2-0148" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager (RevMan) 2014</a>) and reported them in accordance with the advice in Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007628-bbs2-0129" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. Chichester, UK: John Wiley &amp; Sons, Ltd. ">Higgins 2011</a>). We only performed a meta‐analysis if we were able to identify an adequate number of studies (n ≥ 3) that investigated similar interventions and reported data that exhibited not less than moderate heterogeneity (<a href="./references#CD007628-bbs2-0158" title="TreadwellJR , TregearSJ , RestonJT , TurkelsonCM . A system for rating the stability and strength of medical evidence. BMC Medical Research Methodology2006;6:52. [PUBMED: 17052350] ">Treadwell 2006</a>). We used a fixed‐effect model to pool the data into a meta‐analysis, and we fitted a random‐effects model as part of a sensitivity analysis to explore the degree of heterogeneity between studies. </p> </section> <section id="CD007628-sec-0080"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We analysed the different concentrations of the interventions as subgroups by comparing the RRs and 95% CI. If we observed differences in effect estimates between the subgroups, we analysed these separately. </p> <p>In future updates of this Cochrane review and if a sufficient number of studies examining similar comparisons are available, we will consider if any further subgroup analyses are warranted, for example, age groups, pre‐ and postmenopausal, ethnic background, and the presence of hyperandrogenism. </p> </section> <section id="CD007628-sec-0081"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses to assess the robustness of the results of this review; thus, we repeated all fixed‐effect meta‐analyses using random‐effects models. We conducted an additional sensitivity analysis, which excluded one study (<a href="./references#CD007628-bbs2-0036" title="PriceVH , MenefeeE . Quantitative estimation of hair growth. I. androgenetic alopecia in women: effect of minoxidil. Journal of Investigative Dermatology1990;95(6):683‐7. [PUBMED: 2250110] ">Price 1990</a>) with suspected reporting bias in comparison one, i.e. minoxidil versus placebo, and a further sensitivity analysis in comparison two i.e. minoxidil (2%) versus minoxidil (5%), which excluded one study, which had twice the number of adverse events in the 5% treatment arm (<a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007628-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007628-sec-0082"></div> <section id="CD007628-sec-0083"> <h3 class="title">Description of studies</h3> <section id="CD007628-sec-0084"> <h4 class="title">Results of the search</h4> <p>Our earlier searches retrieved 334 references to studies plus 10 references from other sources. The updated searches provided 563 references to studies in addition to 30 ongoing studies (of which seven appear to be completed and had data available on <a href="http://www.clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> and we could include, and 11 were terminated or completed but no data available which are listed under <a href="./references#CD007628-sec-0378" title="">Characteristics of studies awaiting classification</a>) (see <a href="#CD007628-fig-0003">Figure 3</a>). The total number of references retrieved for both sets of searches was therefore 937. There were 923 records after removal of duplicates. After examination of the titles and abstracts, we excluded 813 of these references from the review. We obtained full‐text copies of the remaining 110 records for further evaluation. We translated several studies that were not published in the English language — two in Chinese (<a href="./references#CD007628-bbs2-0065" title="LiMC , ShuW , WangHY , WangXS . Randomized double‐blind placebo‐controlled evaluation of topical minoxidil in the treatment of female androgonetic alopecia. Chinese Journal of Dermatology1996;29:223‐5. ">Li 1996</a>; <a href="./references#CD007628-bbs2-0039" title="ShengY‐Y , RuiW‐L , XuF , QiS‐S , HuR‐M , MiaoY , et al. A randomized controlled clinical study on 2% and 5% topical minoxidil solution in the treatment of female pattern hair loss [Chinese]. Journal of Clinical Dermatology2014;43(10):583‐5. [EMBASE: 2015699887] ">Sheng 2014</a>), two in Farsi (<a href="./references#CD007628-bbs2-0055" title="EnshaiehS , SiadatAH , ShariatS , IrajiF , NilforoushzadehMA , AsilianA . Comparison between an herbal drug and 2% minoxidil solution in the treatment of the androgenetic alopecia [Abstract P03.30]. The 14th Congress of the European Academy of Dermatology and Venereology; 2005 Oct 12‐15; London. Journal of the European Academy of Dermatology &amp; Venereology2005;19(Suppl 2):74‐5. ">Enshaieh 2005</a>; <a href="./references#CD007628-bbs2-0058" title="GolpourM , RabbaniH , FarzinD , AziziF . Comparing the effectiveness of local solution of minoxidil and caffeine 2.5% with local solution of minoxidil 2.5% in treatment of androgenetic alopecia. Journal of Mazandaran University of Medical Sciences2013;23(106):29‐36. [EMBASE: 2014593395] ">Golpour 2013</a>), three in Korean (<a href="./references#CD007628-bbs2-0012" title="HongCK , HanTY , KangHC , AhnSW , AhnJY , SeoSJ . The efficacy and safety of a combination cytopurine/pentadecanoic glyceride topical solution on androgenetic alopecia: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(12):1233‐9. ">Hong 2007</a>; <a href="./references#CD007628-bbs2-0017" title="KimJH , YSM , ChoiJE , SonSW . Study of the efficacy of Korean red ginseng in the treatment of androgenic alopecia. Journal of Ginseng Research2009;33(3):223‐8. ">Kim 2009</a>; <a href="./references#CD007628-bbs2-0040" title="ShinHS , LeeSH , KimDH , AnJS , KwonOS , EunHC . The efficacy and safety of AP‐FHG0604T on female pattern hair loss: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(2):119‐26. ">Shin 2007</a>), one in Spanish (<a href="./references#CD007628-bbs2-0011" title="GuerreroAR , MedinaKR , KahnMC , GuerreroMJ . Usefulness and safety of 0.025 percent 17‐alpha‐estradiol versus 2 percent minoxidil in the treatment of androgenetic alopecia [Utilidad y seguridad del 17‐alfa‐estradiol 0,025 por ciento versus minoxidil 2 por ciento en el tratamiento de la alopecia androgenetica]. Revista Chilena de Dermatologia2009;25(1):21‐5. ">Guerrero 2009</a>), one in German (<a href="./references#CD007628-bbs2-0009" title="GehringW , GloorM . Use of the phototrichogram to assess the stimulation of hair growth ‐ An in vitro study of women with androgenetic alopecia [Das Phototrichogramm als Verfahren zur Beurteilung haarwachstumsfördernder Präparate am beispiel einer Kombination von Hirsefruchtextrakt, L‐Cystin und Calcium panthonthenat‐Ergebnisse einer in vivo Untersuchung bei Frauen mit androgenetischem Haarausfall]. H+G Zeitschrift fur Hautkrankheiten2000;75(7‐8):419‐23. [EMBASE: 2000344799] ">Gehring 2000</a>), and three in Italian (<a href="./references#CD007628-bbs2-0056" title="FarellaV , MelliMC , GiorginiS . Mucopolysaccharides and depolymerized nucleic acids in the treatment of androgenic alopecia [Mucopolisaccaridi e acidi nucleici depolimerizzati nella alopecia androgenetica, studio clinico in doppio cieco]. Dermatologia Oggi1991;6(3):39‐46. [EMBASE: 1992071835] ">Farella 1991</a>; <a href="./references#CD007628-bbs2-0023" title="MinozziM , UnferV , ConstabileL . Androgenetic alopecia in postmenopausal women [Alopecia androgenetica in post‐menopausa]. Giornale Italiano di Ostetricia e Ginecologia1997;19(6):341‐4. [EMBASE: 1997225861] ">Minozzi 1997</a>; <a href="./references#CD007628-bbs2-0035" title="PolicarpiF , GiorginiS , FarellaV , MelliMC , CampolmiP , PanconesiE . Effects of application of a pulsed electrostatic field in male and female androgenic alopecia [Efficacia dell'applicazione di un campo elettrostatico pulsato nell'alopecia androgenetica maschile e femminile]. Annali Italiani di Dermatologia Clinica e Sperimentale1993;47(3):227‐32. [EMBASE: 1993274287] ">Policarpi 1993</a>) — prior to assessment for eligibility. </p> <div class="figure" id="CD007628-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD007628-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We excluded 35 studies reported in 41 records; six were duplicate reports of studies (see the '<a href="./references#CD007628-sec-0377" title="">Characteristics of excluded studies</a>' section). We did not include 23 ongoing studies (seven of the 30 ongoing studies were already completed) in the analyses (see the '<a href="./references#CD007628-sec-0379" title="">Characteristics of ongoing studies</a>' section), but we will include these in future updates of this review when data are available. </p> <p>Overall, we included 46 references to 47 studies but with two separate trials included in one report (<a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>; <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>). For further details, see the 'Study flow diagram' (<a href="#CD007628-fig-0003">Figure 3</a>). </p> </section> <section id="CD007628-sec-0085"> <h4 class="title">Included studies</h4> <p>This update added 25 further studies to the existing 22 studies included in the previous version of this review (<a href="./references#CD007628-bbs2-0168" title="vanZuurenEJ , FedorowiczZ , CarterB , AndrioloRB , SchoonesJ . Interventions for female pattern hair loss. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD007628.pub3] ">van Zuuren 2012</a>). The 47 studies comprised a total of 5290 participants (see the '<a href="./references#CD007628-sec-0376" title="">Characteristics of included studies</a>' section). </p> <section id="CD007628-sec-0086"> <h5 class="title">Characteristics of the trial setting and methods</h5> <p>All of the included studies were randomised controlled trials, 29 had a placebo, 14 had an active control treatment arm, and four studies included both a placebo and an active control arm. Eleven studies were conducted prior to the year 2000. The duration of most studies was between six and 12 months, with a mean of 30.4 weeks. Twenty‐two studies were conducted in Europe, 18 in the USA or Canada, two in Central‐ or South America, and 10 in Asia. </p> </section> <section id="CD007628-sec-0087"> <h5 class="title">Characteristics of the participants</h5> <p>The number of participants included in the individual studies varied widely, from six to 404 women, with a mean of 112 participants. The age of the participants ranged from 18 to 89 years, with most between 18 and 60 years and a mean of 40.5 years. All women had been diagnosed with androgenic alopecia (AGA) or female pattern hair loss (FPHL), and two studies included hyperandrogenic women (<a href="./references#CD007628-bbs2-0004" title="CarminaE , LoboRA . Treatment of hyperandrogenic alopecia in women. Fertility and Sterility2003;79(1):91‐5. [PUBMED: 12524069] ">Carmina 2003</a>; <a href="./references#CD007628-bbs2-0045" title="VexiauP , ChaspouxC , BoudouP , FietJ , JouaniqueC , HardyN , et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12‐month randomized trial. British Journal of Dermatology2002;146(6):992‐9. [PUBMED: 12072067] ">Vexiau 2002</a>). </p> </section> <section id="CD007628-sec-0088"> <h5 class="title">Characteristics of the interventions</h5> <p>The included studies evaluated a wide range of interventions: 17 studies assessed minoxidil (<a href="./references#CD007628-bbs2-0001" title="Blume‐PeytaviU , KunteC , KrispA , Garcia BartelsN , EllwangerU , HoffmannR . Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women [Vergleich der Wirksamkeit und Sicherheit von Minoxidil und Alfatradiol bei der topischen Behandlung der androgenetischen Alopezie der Frau]. Journal der Deutschen Dermatologischen Gesellschaft2007;5(5):391‐5. [PUBMED: 17451383] ">Blume‐Peytavi 2007</a>; <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>; <a href="./references#CD007628-bbs2-0005" title="DeVillezRL , JacobsJP , SzpunarCA , WarnerML . Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Archives of Dermatology1994;130(3):303‐7. [PUBMED: 8129407] ">DeVillez 1994</a>; <a href="./references#CD007628-bbs2-0013" title="JacobsJP , SzpunarCA , WarnerML . Use of topical minoxidil therapy for androgenetic alopecia in women. International Journal of Dermatology1993;32(10):758‐62. [PUBMED: 8225725] ">Jacobs 1993</a>; <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>; <a href="./references#CD007628-bbs2-0025" title="DoshiU , IsraelM , KendallC , QuizaC , SacavageS , TyndallD , et al. Effectiveness of once daily 5% minoxidil topical foam in the treatment of women with thinning hair due to female pattern hair loss (FPHL). Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB112. [EMBASE: 71895204] NCT01145625 . A Phase 3 multi‐center parallel design clinical trial to compare the efficacy and safety of 5% Minoxidil Foam vs. 2% Minoxidil Solution in females for the treatment of female pattern hair loss ‐ androgenetic alopecia (MINALO3004, NCT01145625). clinicaltrials.gov/ct2/show/NCT01145625 (accessed 14 January 2016). ">NCT01145625</a>; <a href="./references#CD007628-bbs2-0027" title="NCT01226459 . A Phase 3 Multi‐Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia). clinicaltrials.gov/ct2/show/NCT01226459 (accessed 14 January 2016). ">NCT01226459</a>; <a href="./references#CD007628-bbs2-0029" title="NCT01655108 . Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients. clinicaltrials.gov/ct2/show/NCT01655108 (accessed 14 January 2016). ">NCT01655108</a>; <a href="./references#CD007628-bbs2-0030" title="NCT01900041 . A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01900041 (accessed 14 January 2016). ">NCT01900041</a>; <a href="./references#CD007628-bbs2-0032" title="OlsenEA . Topical minoxidil in the treatment of androgenetic alopecia in women. Cutis1991;48(3):243‐8. [PUBMED: 1935254] ">Olsen 1991</a>; <a href="./references#CD007628-bbs2-0034" title="Pazoki‐ToroudiH , BabakoohiS , NilforoushzadehMA , Nassiri‐KashaniM , ShizarpourM , AjamiM , et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed2012;10(5):276‐82. [PUBMED: 23163069] ">Pazoki‐Toroudi 2012</a>; <a href="./references#CD007628-bbs2-0036" title="PriceVH , MenefeeE . Quantitative estimation of hair growth. I. androgenetic alopecia in women: effect of minoxidil. Journal of Investigative Dermatology1990;95(6):683‐7. [PUBMED: 2250110] ">Price 1990</a>; <a href="./references#CD007628-bbs2-0038" title="RietschelML , DuncanSH . Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. Journal of the American Academy of Dermatology1987;16(3 Pt 2):677‐85. [EMBASE: 1987099274] ">Rietschel 1987</a>; <a href="./references#CD007628-bbs2-0039" title="ShengY‐Y , RuiW‐L , XuF , QiS‐S , HuR‐M , MiaoY , et al. A randomized controlled clinical study on 2% and 5% topical minoxidil solution in the treatment of female pattern hair loss [Chinese]. Journal of Clinical Dermatology2014;43(10):583‐5. [EMBASE: 2015699887] ">Sheng 2014</a>; <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a>; <a href="./references#CD007628-bbs2-0045" title="VexiauP , ChaspouxC , BoudouP , FietJ , JouaniqueC , HardyN , et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12‐month randomized trial. British Journal of Dermatology2002;146(6):992‐9. [PUBMED: 12072067] ">Vexiau 2002</a>; <a href="./references#CD007628-bbs2-0046" title="WhitingDA , JacobsonC . Treatment of female androgenetic alopecia with minoxidil 2%. International Journal of Dermatology1992;31(11):800‐4. [PUBMED: 1428436] ">Whiting 1992</a>), and six studies examined the effects of finasteride (<a href="./references#CD007628-bbs2-0004" title="CarminaE , LoboRA . Treatment of hyperandrogenic alopecia in women. Fertility and Sterility2003;79(1):91‐5. [PUBMED: 12524069] ">Carmina 2003</a>; <a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a>; <a href="./references#CD007628-bbs2-0022" title="MazzarellaF , LoconsoleF , CammisaA , MastrolonardoM , VenaGA . Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16‐month therapy course. Journal of Dermatological Treatment1997;8(3):189‐92. [EMBASE: 1997295968] ">Mazzarella 1997</a>; <a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a>; <a href="./references#CD007628-bbs2-0044" title="UkşalÜ , BayramF , UtaşS , ÇolakR , BorluM . Comparision of low dose finasteride, flutamide and spirolactone in female androgenetic alopecia. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S238. ">Ukşal 1999</a>; <a href="./references#CD007628-bbs2-0047" title="WhitingDA , WaldstreicherJ , SanchezM , KaufmanKD . Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women. Journal of Investigative Dermatology. Symposium Proceedings1999;4(3):282‐4. [PUBMED: 10674382] ">Whiting 1999</a>). Two studies included cyproterone acetate in one treatment arm (<a href="./references#CD007628-bbs2-0004" title="CarminaE , LoboRA . Treatment of hyperandrogenic alopecia in women. Fertility and Sterility2003;79(1):91‐5. [PUBMED: 12524069] ">Carmina 2003</a>; <a href="./references#CD007628-bbs2-0045" title="VexiauP , ChaspouxC , BoudouP , FietJ , JouaniqueC , HardyN , et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12‐month randomized trial. British Journal of Dermatology2002;146(6):992‐9. [PUBMED: 12072067] ">Vexiau 2002</a>), and two other studies evaluated flutamide (<a href="./references#CD007628-bbs2-0004" title="CarminaE , LoboRA . Treatment of hyperandrogenic alopecia in women. Fertility and Sterility2003;79(1):91‐5. [PUBMED: 12524069] ">Carmina 2003</a>; <a href="./references#CD007628-bbs2-0044" title="UkşalÜ , BayramF , UtaşS , ÇolakR , BorluM . Comparision of low dose finasteride, flutamide and spirolactone in female androgenetic alopecia. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S238. ">Ukşal 1999</a>). Five studies investigated laser treatment (<a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>; <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>; <a href="./references#CD007628-bbs2-0018" title="KimH , ChoiJW , KimJY , ShinJW , LeeSJ , HuhCH . Low‐level light therapy for androgenetic alopecia: a 24‐week, randomized, double‐blind, sham device‐controlled multicenter trial. Dermatologic Surgery2013;39(8):1177‐83. [PUBMED: 23551662] ">Kim 2013</a>; <a href="./references#CD007628-bbs2-0019" title="LanzafameRJ , BlancheRR , ChiacchieriniRP , KazmirekER , SklarJA . The growth of human scalp hair in females using visible red light laser and LED sources. Lasers in Surgery and Medicine2014;46(8):601‐7. [PUBMED: 25124964] ">Lanzafame 2014</a>; <a href="./references#CD007628-bbs2-0031" title="NCT01967277 . A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy. clinicaltrials.gov/ct2/show/NCT01967277 (accessed 14 January 2016). ">NCT01967277</a>). Two studies examined bimatoprost (<a href="./references#CD007628-bbs2-0026" title="NCT01189279 . Safety and pharmacokinetics study of new formulation of Bimatoprost in patients with alopecia. clinicaltrials.gov/ct2/show/NCT01189279 (accessed 14 January 2016). ">NCT01189279</a>; <a href="./references#CD007628-bbs2-0028" title="NCT01325350 . Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01325350 (accessed 14 January 2016). ">NCT01325350</a>). </p> <p>A total of 17 studies addressed other interventions: alfatradiol (<a href="./references#CD007628-bbs2-0001" title="Blume‐PeytaviU , KunteC , KrispA , Garcia BartelsN , EllwangerU , HoffmannR . Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women [Vergleich der Wirksamkeit und Sicherheit von Minoxidil und Alfatradiol bei der topischen Behandlung der androgenetischen Alopezie der Frau]. Journal der Deutschen Dermatologischen Gesellschaft2007;5(5):391‐5. [PUBMED: 17451383] ">Blume‐Peytavi 2007</a>); essential oil (<a href="./references#CD007628-bbs2-0003" title="Bureau JP, GinouvesP , GuilbaudJ , RouxME . Essential oils and low‐intensity electromagnetic pulses in the treatment of androgen‐dependent alopecia. Advances in Therapy2003;20(4):220‐9. [PUBMED: 14669818] ">Bureau 2003</a>); 0.5% octyl nicotinate and 5.0% myristyl nicotinate (<a href="./references#CD007628-bbs2-0006" title="DraelosZD , JacobsonEL , KimH , KimM , JacobsonMK . A pilot study evaluating the efficacy of topically applied niacin derivatives for treatment of female pattern alopecia. Journal of Cosmetic Dermatology2005;4(4):258‐61. [PUBMED: 17168873] ">Draelos 2005</a>); topical melatonin‐alcohol solution (<a href="./references#CD007628-bbs2-0007" title="FischerTW , BurmeisterG , SchmidtHW , ElsnerP . Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. British Journal of Dermatology2004;150(2):341‐5. [PUBMED: 14996107] ">Fischer 2004</a>); topical fulvestrant solution (<a href="./references#CD007628-bbs2-0008" title="GassmuellerJ , HoffmannR , WebsterA . Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof‐of‐concept studies. British Journal of Dermatology2008;158(1):109‐15. [PUBMED: 17986309] ">Gassmueller 2008</a>); an oral combination product of millet seed extract, L‐cystine, and calcium pantothenate (<a href="./references#CD007628-bbs2-0009" title="GehringW , GloorM . Use of the phototrichogram to assess the stimulation of hair growth ‐ An in vitro study of women with androgenetic alopecia [Das Phototrichogramm als Verfahren zur Beurteilung haarwachstumsfördernder Präparate am beispiel einer Kombination von Hirsefruchtextrakt, L‐Cystin und Calcium panthonthenat‐Ergebnisse einer in vivo Untersuchung bei Frauen mit androgenetischem Haarausfall]. H+G Zeitschrift fur Hautkrankheiten2000;75(7‐8):419‐23. [EMBASE: 2000344799] ">Gehring 2000</a>); oestrogen ointment (<a href="./references#CD007628-bbs2-0010" title="GeorgalaS , KatoulisAC , GeorgalaC , MoussatouV , BoziE , StavrianeasNG . Topical estrogen therapy for androgenetic alopecia in menopausal females. Dermatology2004;208(2):178‐9. [PUBMED: 15057016] ">Georgala 2004</a>; <a href="./references#CD007628-bbs2-0011" title="GuerreroAR , MedinaKR , KahnMC , GuerreroMJ . Usefulness and safety of 0.025 percent 17‐alpha‐estradiol versus 2 percent minoxidil in the treatment of androgenetic alopecia [Utilidad y seguridad del 17‐alfa‐estradiol 0,025 por ciento versus minoxidil 2 por ciento en el tratamiento de la alopecia androgenetica]. Revista Chilena de Dermatologia2009;25(1):21‐5. ">Guerrero 2009</a>); cytopurine/pentadecanoic glyceride (<a href="./references#CD007628-bbs2-0012" title="HongCK , HanTY , KangHC , AhnSW , AhnJY , SeoSJ . The efficacy and safety of a combination cytopurine/pentadecanoic glyceride topical solution on androgenetic alopecia: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(12):1233‐9. ">Hong 2007</a>); red ginseng powder capsules (<a href="./references#CD007628-bbs2-0017" title="KimJH , YSM , ChoiJE , SonSW . Study of the efficacy of Korean red ginseng in the treatment of androgenic alopecia. Journal of Ginseng Research2009;33(3):223‐8. ">Kim 2009</a>); nutritional supplement (<a href="./references#CD007628-bbs2-0020" title="LeFloc'hC , ChenitiA , ConnétableS , PiccardiN , VincenziC , TostiA . Effect of a nutritional supplement on hair loss in women. Journal of Cosmetic Dermatology2015;14(1):76‐82. [PUBMED: 25573272] ">Le Floc'h 2015</a>); systemic oestrogens (<a href="./references#CD007628-bbs2-0023" title="MinozziM , UnferV , ConstabileL . Androgenetic alopecia in postmenopausal women [Alopecia androgenetica in post‐menopausa]. Giornale Italiano di Ostetricia e Ginecologia1997;19(6):341‐4. [EMBASE: 1997225861] ">Minozzi 1997</a>); oral gelatin cystine and lotion based on gelatine cystine and <i>Serenoa repens</i> (<a href="./references#CD007628-bbs2-0024" title="MorgantiP , FabriziG , JamesB , BrunoC . Effect of gelatin‐cystine and serenoa repens extract on free radicals level and hair growth. Journal of Applied Cosmetology1998;16(3):57‐64. [EMBASE: 1998406625] ">Morganti 1998</a>); 0.75% adenosine lotion (<a href="./references#CD007628-bbs2-0033" title="OuraH , IinoM , IdetaR , NakazawaY , KishimotoJ , AraseS . Efficacy of adenosine on female pattern hair loss and male androgenetic alopecia. Journal of Investigative Dermatology2008;128(Suppl 1):S151. OuraH , IinoM , NakazawaY , TajimaM , IdetaR , NakayaY , et al. Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: a pilot, double‐blind, randomized, placebo‐controlled trial. Journal of Dermatology2008;35(12):763‐7. [PUBMED: 19239555] ">Oura 2008</a>); the application of a pulsed electrostatic field (<a href="./references#CD007628-bbs2-0035" title="PolicarpiF , GiorginiS , FarellaV , MelliMC , CampolmiP , PanconesiE . Effects of application of a pulsed electrostatic field in male and female androgenic alopecia [Efficacia dell'applicazione di un campo elettrostatico pulsato nell'alopecia androgenetica maschile e femminile]. Annali Italiani di Dermatologia Clinica e Sperimentale1993;47(3):227‐32. [EMBASE: 1993274287] ">Policarpi 1993</a>); AP‐FHG0604T (plant extracts; <a href="./references#CD007628-bbs2-0040" title="ShinHS , LeeSH , KimDH , AnJS , KwonOS , EunHC . The efficacy and safety of AP‐FHG0604T on female pattern hair loss: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(2):119‐26. ">Shin 2007</a>) and spironolactone (<a href="./references#CD007628-bbs2-0044" title="UkşalÜ , BayramF , UtaşS , ÇolakR , BorluM . Comparision of low dose finasteride, flutamide and spirolactone in female androgenetic alopecia. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S238. ">Ukşal 1999</a>). Several trials compared and evaluated a number of these interventions in the different treatment arms. </p> </section> <section id="CD007628-sec-0089"> <h5 class="title">Characteristics of the outcome measures</h5> <p>Half of the included studies evaluated 'hair regrowth' as assessed by the participants (<a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>; <a href="./references#CD007628-bbs2-0003" title="Bureau JP, GinouvesP , GuilbaudJ , RouxME . Essential oils and low‐intensity electromagnetic pulses in the treatment of androgen‐dependent alopecia. Advances in Therapy2003;20(4):220‐9. [PUBMED: 14669818] ">Bureau 2003</a>; <a href="./references#CD007628-bbs2-0004" title="CarminaE , LoboRA . Treatment of hyperandrogenic alopecia in women. Fertility and Sterility2003;79(1):91‐5. [PUBMED: 12524069] ">Carmina 2003</a>; <a href="./references#CD007628-bbs2-0005" title="DeVillezRL , JacobsJP , SzpunarCA , WarnerML . Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Archives of Dermatology1994;130(3):303‐7. [PUBMED: 8129407] ">DeVillez 1994</a>; <a href="./references#CD007628-bbs2-0012" title="HongCK , HanTY , KangHC , AhnSW , AhnJY , SeoSJ . The efficacy and safety of a combination cytopurine/pentadecanoic glyceride topical solution on androgenetic alopecia: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(12):1233‐9. ">Hong 2007</a>; <a href="./references#CD007628-bbs2-0013" title="JacobsJP , SzpunarCA , WarnerML . Use of topical minoxidil therapy for androgenetic alopecia in women. International Journal of Dermatology1993;32(10):758‐62. [PUBMED: 8225725] ">Jacobs 1993</a>; <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>; <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>; <a href="./references#CD007628-bbs2-0018" title="KimH , ChoiJW , KimJY , ShinJW , LeeSJ , HuhCH . Low‐level light therapy for androgenetic alopecia: a 24‐week, randomized, double‐blind, sham device‐controlled multicenter trial. Dermatologic Surgery2013;39(8):1177‐83. [PUBMED: 23551662] ">Kim 2013</a>; <a href="./references#CD007628-bbs2-0020" title="LeFloc'hC , ChenitiA , ConnétableS , PiccardiN , VincenziC , TostiA . Effect of a nutritional supplement on hair loss in women. Journal of Cosmetic Dermatology2015;14(1):76‐82. [PUBMED: 25573272] ">Le Floc'h 2015</a>; <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>; <a href="./references#CD007628-bbs2-0022" title="MazzarellaF , LoconsoleF , CammisaA , MastrolonardoM , VenaGA . Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16‐month therapy course. Journal of Dermatological Treatment1997;8(3):189‐92. [EMBASE: 1997295968] ">Mazzarella 1997</a>; <a href="./references#CD007628-bbs2-0027" title="NCT01226459 . A Phase 3 Multi‐Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia). clinicaltrials.gov/ct2/show/NCT01226459 (accessed 14 January 2016). ">NCT01226459</a>; <a href="./references#CD007628-bbs2-0028" title="NCT01325350 . Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01325350 (accessed 14 January 2016). ">NCT01325350</a>; <a href="./references#CD007628-bbs2-0029" title="NCT01655108 . Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients. clinicaltrials.gov/ct2/show/NCT01655108 (accessed 14 January 2016). ">NCT01655108</a>; <a href="./references#CD007628-bbs2-0032" title="OlsenEA . Topical minoxidil in the treatment of androgenetic alopecia in women. Cutis1991;48(3):243‐8. [PUBMED: 1935254] ">Olsen 1991</a>; <a href="./references#CD007628-bbs2-0033" title="OuraH , IinoM , IdetaR , NakazawaY , KishimotoJ , AraseS . Efficacy of adenosine on female pattern hair loss and male androgenetic alopecia. Journal of Investigative Dermatology2008;128(Suppl 1):S151. OuraH , IinoM , NakazawaY , TajimaM , IdetaR , NakayaY , et al. Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: a pilot, double‐blind, randomized, placebo‐controlled trial. Journal of Dermatology2008;35(12):763‐7. [PUBMED: 19239555] ">Oura 2008</a>; <a href="./references#CD007628-bbs2-0034" title="Pazoki‐ToroudiH , BabakoohiS , NilforoushzadehMA , Nassiri‐KashaniM , ShizarpourM , AjamiM , et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed2012;10(5):276‐82. [PUBMED: 23163069] ">Pazoki‐Toroudi 2012</a>; <a href="./references#CD007628-bbs2-0035" title="PolicarpiF , GiorginiS , FarellaV , MelliMC , CampolmiP , PanconesiE . Effects of application of a pulsed electrostatic field in male and female androgenic alopecia [Efficacia dell'applicazione di un campo elettrostatico pulsato nell'alopecia androgenetica maschile e femminile]. Annali Italiani di Dermatologia Clinica e Sperimentale1993;47(3):227‐32. [EMBASE: 1993274287] ">Policarpi 1993</a>; <a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a>; <a href="./references#CD007628-bbs2-0040" title="ShinHS , LeeSH , KimDH , AnJS , KwonOS , EunHC . The efficacy and safety of AP‐FHG0604T on female pattern hair loss: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(2):119‐26. ">Shin 2007</a>; <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a>; <a href="./references#CD007628-bbs2-0046" title="WhitingDA , JacobsonC . Treatment of female androgenetic alopecia with minoxidil 2%. International Journal of Dermatology1992;31(11):800‐4. [PUBMED: 1428436] ">Whiting 1992</a>), which was the primary outcome for this review. However, none of these outcomes were measured or reported according to the definition of 'clinically significant' hair regrowth, which was prespecified for this review (see the '<a href="#CD007628-sec-0058">Types of outcome measures</a>' section). </p> <p>The outcome measures used to assess hair regrowth consisted of questionnaires that assessed these outcomes using three‐ to seven‐point scales. They included a wide range of scaling items, many of which were inadequately defined, i.e. 'none, mild, moderate improvement' or 'worsened to marked improved', and were not matched across the included studies. Three studies reported that they had applied a "modified version of a validated self‐administered hair growth questionnaire" (<a href="./references#CD007628-bbs2-0004" title="CarminaE , LoboRA . Treatment of hyperandrogenic alopecia in women. Fertility and Sterility2003;79(1):91‐5. [PUBMED: 12524069] ">Carmina 2003</a>; <a href="./references#CD007628-bbs2-0033" title="OuraH , IinoM , IdetaR , NakazawaY , KishimotoJ , AraseS . Efficacy of adenosine on female pattern hair loss and male androgenetic alopecia. Journal of Investigative Dermatology2008;128(Suppl 1):S151. OuraH , IinoM , NakazawaY , TajimaM , IdetaR , NakayaY , et al. Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: a pilot, double‐blind, randomized, placebo‐controlled trial. Journal of Dermatology2008;35(12):763‐7. [PUBMED: 19239555] ">Oura 2008</a>; <a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a>), which was developed in a previous study (<a href="./references#CD007628-bbs2-0109" title="BarberBL , KaufmanKD , KozloffRC , GirmanCJ , GuessHA . A hair growth questionnaire for use in the evaluation of therapeutic effects in men. Journal of Dermatological Treatment1998;9(3):181‐6. [EMBASE: 1998346166] ">Barber 1998</a>). The investigators provided no details of how and if their 'modified version' was tested prior to its use, and as it was originally designed for the evaluation of interventions for male pattern baldness, its validity as an assessment tool for FPHL is unclear. Two studies utilised a standard 100 mm visual analogue scale (VAS) for participant assessments of hair growth (<a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>; <a href="./references#CD007628-bbs2-0040" title="ShinHS , LeeSH , KimDH , AnJS , KwonOS , EunHC . The efficacy and safety of AP‐FHG0604T on female pattern hair loss: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(2):119‐26. ">Shin 2007</a>). Benefit from treatment was scored: 0 = "no benefit" to 100 = "great benefit". <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> was also the only included study to assess the effects of two of the interventions on quality of life (QoL), a key primary outcome for this review. The study used a six‐item VAS‐based questionnaire for these assessments, but did not indicate if the instrument had been previously tested or validated. </p> <p>A large proportion of the trials (32) assessed treatment‐associated adverse events either through questionnaires that rated the "tolerability of treatment" (<a href="./references#CD007628-bbs2-0001" title="Blume‐PeytaviU , KunteC , KrispA , Garcia BartelsN , EllwangerU , HoffmannR . Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women [Vergleich der Wirksamkeit und Sicherheit von Minoxidil und Alfatradiol bei der topischen Behandlung der androgenetischen Alopezie der Frau]. Journal der Deutschen Dermatologischen Gesellschaft2007;5(5):391‐5. [PUBMED: 17451383] ">Blume‐Peytavi 2007</a>) or "dermal reactions", such as erythema, scaling, and itching (<a href="./references#CD007628-bbs2-0008" title="GassmuellerJ , HoffmannR , WebsterA . Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof‐of‐concept studies. British Journal of Dermatology2008;158(1):109‐15. [PUBMED: 17986309] ">Gassmueller 2008</a>), or these were reported as incidental events by the participants during the course of the individual study. </p> <p>Several included studies assessed the secondary outcomes for this review, but in general, the methods of measurement and the timing of the assessments were not uniform across these studies. Over half of the studies included two of the secondary outcomes, i.e. investigator‐rated clinically significant hair regrowth and the change in total hair count from baseline to study conclusion. Eleven studies addressed hair shedding (<a href="./references#CD007628-bbs2-0004" title="CarminaE , LoboRA . Treatment of hyperandrogenic alopecia in women. Fertility and Sterility2003;79(1):91‐5. [PUBMED: 12524069] ">Carmina 2003</a>; <a href="./references#CD007628-bbs2-0011" title="GuerreroAR , MedinaKR , KahnMC , GuerreroMJ . Usefulness and safety of 0.025 percent 17‐alpha‐estradiol versus 2 percent minoxidil in the treatment of androgenetic alopecia [Utilidad y seguridad del 17‐alfa‐estradiol 0,025 por ciento versus minoxidil 2 por ciento en el tratamiento de la alopecia androgenetica]. Revista Chilena de Dermatologia2009;25(1):21‐5. ">Guerrero 2009</a>; <a href="./references#CD007628-bbs2-0012" title="HongCK , HanTY , KangHC , AhnSW , AhnJY , SeoSJ . The efficacy and safety of a combination cytopurine/pentadecanoic glyceride topical solution on androgenetic alopecia: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(12):1233‐9. ">Hong 2007</a>; <a href="./references#CD007628-bbs2-0017" title="KimJH , YSM , ChoiJE , SonSW . Study of the efficacy of Korean red ginseng in the treatment of androgenic alopecia. Journal of Ginseng Research2009;33(3):223‐8. ">Kim 2009</a>; <a href="./references#CD007628-bbs2-0020" title="LeFloc'hC , ChenitiA , ConnétableS , PiccardiN , VincenziC , TostiA . Effect of a nutritional supplement on hair loss in women. Journal of Cosmetic Dermatology2015;14(1):76‐82. [PUBMED: 25573272] ">Le Floc'h 2015</a>; <a href="./references#CD007628-bbs2-0022" title="MazzarellaF , LoconsoleF , CammisaA , MastrolonardoM , VenaGA . Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16‐month therapy course. Journal of Dermatological Treatment1997;8(3):189‐92. [EMBASE: 1997295968] ">Mazzarella 1997</a>; <a href="./references#CD007628-bbs2-0033" title="OuraH , IinoM , IdetaR , NakazawaY , KishimotoJ , AraseS . Efficacy of adenosine on female pattern hair loss and male androgenetic alopecia. Journal of Investigative Dermatology2008;128(Suppl 1):S151. OuraH , IinoM , NakazawaY , TajimaM , IdetaR , NakayaY , et al. Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: a pilot, double‐blind, randomized, placebo‐controlled trial. Journal of Dermatology2008;35(12):763‐7. [PUBMED: 19239555] ">Oura 2008</a>; <a href="./references#CD007628-bbs2-0034" title="Pazoki‐ToroudiH , BabakoohiS , NilforoushzadehMA , Nassiri‐KashaniM , ShizarpourM , AjamiM , et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed2012;10(5):276‐82. [PUBMED: 23163069] ">Pazoki‐Toroudi 2012</a>; <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a>; <a href="./references#CD007628-bbs2-0045" title="VexiauP , ChaspouxC , BoudouP , FietJ , JouaniqueC , HardyN , et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12‐month randomized trial. British Journal of Dermatology2002;146(6):992‐9. [PUBMED: 12072067] ">Vexiau 2002</a>; <a href="./references#CD007628-bbs2-0046" title="WhitingDA , JacobsonC . Treatment of female androgenetic alopecia with minoxidil 2%. International Journal of Dermatology1992;31(11):800‐4. [PUBMED: 1428436] ">Whiting 1992</a>). Twelve studies assessed cosmetic appearance and 'patient' satisfaction (<a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>; <a href="./references#CD007628-bbs2-0004" title="CarminaE , LoboRA . Treatment of hyperandrogenic alopecia in women. Fertility and Sterility2003;79(1):91‐5. [PUBMED: 12524069] ">Carmina 2003</a>; <a href="./references#CD007628-bbs2-0006" title="DraelosZD , JacobsonEL , KimH , KimM , JacobsonMK . A pilot study evaluating the efficacy of topically applied niacin derivatives for treatment of female pattern alopecia. Journal of Cosmetic Dermatology2005;4(4):258‐61. [PUBMED: 17168873] ">Draelos 2005</a>; <a href="./references#CD007628-bbs2-0017" title="KimJH , YSM , ChoiJE , SonSW . Study of the efficacy of Korean red ginseng in the treatment of androgenic alopecia. Journal of Ginseng Research2009;33(3):223‐8. ">Kim 2009</a>; <a href="./references#CD007628-bbs2-0018" title="KimH , ChoiJW , KimJY , ShinJW , LeeSJ , HuhCH . Low‐level light therapy for androgenetic alopecia: a 24‐week, randomized, double‐blind, sham device‐controlled multicenter trial. Dermatologic Surgery2013;39(8):1177‐83. [PUBMED: 23551662] ">Kim 2013</a>; <a href="./references#CD007628-bbs2-0020" title="LeFloc'hC , ChenitiA , ConnétableS , PiccardiN , VincenziC , TostiA . Effect of a nutritional supplement on hair loss in women. Journal of Cosmetic Dermatology2015;14(1):76‐82. [PUBMED: 25573272] ">Le Floc'h 2015</a>; <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>; <a href="./references#CD007628-bbs2-0029" title="NCT01655108 . Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients. clinicaltrials.gov/ct2/show/NCT01655108 (accessed 14 January 2016). ">NCT01655108</a>; <a href="./references#CD007628-bbs2-0033" title="OuraH , IinoM , IdetaR , NakazawaY , KishimotoJ , AraseS . Efficacy of adenosine on female pattern hair loss and male androgenetic alopecia. Journal of Investigative Dermatology2008;128(Suppl 1):S151. OuraH , IinoM , NakazawaY , TajimaM , IdetaR , NakayaY , et al. Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: a pilot, double‐blind, randomized, placebo‐controlled trial. Journal of Dermatology2008;35(12):763‐7. [PUBMED: 19239555] ">Oura 2008</a>; <a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a>; <a href="./references#CD007628-bbs2-0041" title="ThomE . Efficacy and tolerability of Hairgain® in individuals with hair loss: a placebo‐controlled, double‐blind study. Journal of International Medical Research2001;29(1):2‐6. [EMBASE: 2001114261] ">Thom 2001</a>; <a href="./references#CD007628-bbs2-0042" title="ThomE . Nourkrin: objective and subjective effects and tolerability in persons with hair loss. Journal of International Medical Research2006;34(5):514‐9. [EMBASE: 2006563255] ">Thom 2006</a>). </p> <p>Fourteen studies evaluated one of the secondary outcomes for this review, i.e. quality and pattern of hair regrowth (<a href="./references#CD007628-bbs2-0001" title="Blume‐PeytaviU , KunteC , KrispA , Garcia BartelsN , EllwangerU , HoffmannR . Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women [Vergleich der Wirksamkeit und Sicherheit von Minoxidil und Alfatradiol bei der topischen Behandlung der androgenetischen Alopezie der Frau]. Journal der Deutschen Dermatologischen Gesellschaft2007;5(5):391‐5. [PUBMED: 17451383] ">Blume‐Peytavi 2007</a>; <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>; <a href="./references#CD007628-bbs2-0003" title="Bureau JP, GinouvesP , GuilbaudJ , RouxME . Essential oils and low‐intensity electromagnetic pulses in the treatment of androgen‐dependent alopecia. Advances in Therapy2003;20(4):220‐9. [PUBMED: 14669818] ">Bureau 2003</a> ; <a href="./references#CD007628-bbs2-0004" title="CarminaE , LoboRA . Treatment of hyperandrogenic alopecia in women. Fertility and Sterility2003;79(1):91‐5. [PUBMED: 12524069] ">Carmina 2003</a>; <a href="./references#CD007628-bbs2-0008" title="GassmuellerJ , HoffmannR , WebsterA . Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof‐of‐concept studies. British Journal of Dermatology2008;158(1):109‐15. [PUBMED: 17986309] ">Gassmueller 2008</a>; <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>; <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>; <a href="./references#CD007628-bbs2-0017" title="KimJH , YSM , ChoiJE , SonSW . Study of the efficacy of Korean red ginseng in the treatment of androgenic alopecia. Journal of Ginseng Research2009;33(3):223‐8. ">Kim 2009</a>; <a href="./references#CD007628-bbs2-0018" title="KimH , ChoiJW , KimJY , ShinJW , LeeSJ , HuhCH . Low‐level light therapy for androgenetic alopecia: a 24‐week, randomized, double‐blind, sham device‐controlled multicenter trial. Dermatologic Surgery2013;39(8):1177‐83. [PUBMED: 23551662] ">Kim 2013</a>; <a href="./references#CD007628-bbs2-0020" title="LeFloc'hC , ChenitiA , ConnétableS , PiccardiN , VincenziC , TostiA . Effect of a nutritional supplement on hair loss in women. Journal of Cosmetic Dermatology2015;14(1):76‐82. [PUBMED: 25573272] ">Le Floc'h 2015</a>; <a href="./references#CD007628-bbs2-0028" title="NCT01325350 . Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01325350 (accessed 14 January 2016). ">NCT01325350</a>; <a href="./references#CD007628-bbs2-0029" title="NCT01655108 . Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients. clinicaltrials.gov/ct2/show/NCT01655108 (accessed 14 January 2016). ">NCT01655108</a>; <a href="./references#CD007628-bbs2-0030" title="NCT01900041 . A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01900041 (accessed 14 January 2016). ">NCT01900041</a>; <a href="./references#CD007628-bbs2-0033" title="OuraH , IinoM , IdetaR , NakazawaY , KishimotoJ , AraseS . Efficacy of adenosine on female pattern hair loss and male androgenetic alopecia. Journal of Investigative Dermatology2008;128(Suppl 1):S151. OuraH , IinoM , NakazawaY , TajimaM , IdetaR , NakayaY , et al. Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: a pilot, double‐blind, randomized, placebo‐controlled trial. Journal of Dermatology2008;35(12):763‐7. [PUBMED: 19239555] ">Oura 2008</a>). </p> <p>We examined any of the patient‐reported outcomes (PROs) presented in the included studies against the 'checklist for describing and assessing PRO's in clinical trials' (see <a href="#CD007628-tbl-0007">Table 3</a>), which is provided in Chapter 17.6.a of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007628-bbs2-0129" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. Chichester, UK: John Wiley &amp; Sons, Ltd. ">Higgins 2011</a>). </p> <div class="table" id="CD007628-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Checklist for describing and assessing patient‐reported outcomes (PROs) in clinical trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. What were PROs measuring?<br/> a. What concepts were the PROs used in the study measuring?<br/> b. What rationale (if any) for selection of concepts or constructs did the authors provide?<br/> c. Were patients involved in the selection of outcomes measured by the PROs? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2. Omissions<br/> a. Were there any important aspects of health (e.g. symptoms, function, perceptions) or quality of life (e.g. overall evaluation, satisfaction with life) that were omitted in this study from the perspectives of the patient, clinician, significant others, payers, or other administrators and decision‐makers? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3. If randomised trials and other studies measured PROs, what were the instruments' measurement strategies?<br/> a. Did investigators use instruments that yield a single indicator or index number, a profile, or a battery of instruments?<br/> b. If investigators measure PROs, did they use specific or generic measures, or both? <br/> c. Who exactly completed the instruments? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4. Did the instruments work in the way they were supposed to work ‐ validity?<br/> a. Had the instruments used been validated previously (provide reference)? Was evidence of prior validation for use in this population presented?<br/> b. Were the instruments re‐validated in this study? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5. Did the instruments work in the way they were supposed to work ‐ ability to measure change?<br/> a. Are the PROs able to detect change in patient status, even if those changes are small? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6. Can you make the magnitude of effect (if any) understandable to readers?<br/> a. Can you provide an estimate of the difference in patients achieving a threshold of function or improvement, and the associated number needed to treat (NNT)? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Table 17.6.a </p> <p>Patrick D, Guyatt GH, Acquadro C. Chapter 17: Patient‐reported outcomes. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: PRO: patient‐reported outcome.</p> </div> </div> </section> </section> <section id="CD007628-sec-0090"> <h4 class="title">Excluded studies</h4> <p>We excluded 35 studies, and reported the reasons for their exclusion in the '<a href="./references#CD007628-sec-0377" title="">Characteristics of excluded studies</a>' tables. We excluded all of these studies only after assessment of the full‐text reports. The most frequent reason for their exclusion was that they were non‐RCTs, or because they included only male participants. </p> </section> </section> <section id="CD007628-sec-0091"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed each included study for risk of bias and reported the judgements for the individual domains in the 'Risk of bias' table associated with each study. We have also presented these in the 'Risk of bias' graph in <a href="#CD007628-fig-0004">Figure 4</a> and the 'Risk of bias' summary in <a href="#CD007628-fig-0005">Figure 5</a>. </p> <div class="figure" id="CD007628-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD007628-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD007628-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD007628-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> </div> <p>We assessed the overall risk of bias for each included study, and we considered five studies to be at 'low risk of bias' as they met all criteria across all domains in the Cochrane 'Risk of bias' assessment tool (plausible bias unlikely to seriously alter the results) (<a href="./references#CD007628-bbs2-0008" title="GassmuellerJ , HoffmannR , WebsterA . Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof‐of‐concept studies. British Journal of Dermatology2008;158(1):109‐15. [PUBMED: 17986309] ">Gassmueller 2008</a>; <a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a>; <a href="./references#CD007628-bbs2-0019" title="LanzafameRJ , BlancheRR , ChiacchieriniRP , KazmirekER , SklarJA . The growth of human scalp hair in females using visible red light laser and LED sources. Lasers in Surgery and Medicine2014;46(8):601‐7. [PUBMED: 25124964] ">Lanzafame 2014</a>; <a href="./references#CD007628-bbs2-0029" title="NCT01655108 . Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients. clinicaltrials.gov/ct2/show/NCT01655108 (accessed 14 January 2016). ">NCT01655108</a>; <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a>). We categorised 16 studies as at high risk of bias (plausible bias that seriously weakens confidence in the results) because one or more domains received a judgement of high risk (<a href="./references#CD007628-bbs2-0001" title="Blume‐PeytaviU , KunteC , KrispA , Garcia BartelsN , EllwangerU , HoffmannR . Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women [Vergleich der Wirksamkeit und Sicherheit von Minoxidil und Alfatradiol bei der topischen Behandlung der androgenetischen Alopezie der Frau]. Journal der Deutschen Dermatologischen Gesellschaft2007;5(5):391‐5. [PUBMED: 17451383] ">Blume‐Peytavi 2007</a>; <a href="./references#CD007628-bbs2-0003" title="Bureau JP, GinouvesP , GuilbaudJ , RouxME . Essential oils and low‐intensity electromagnetic pulses in the treatment of androgen‐dependent alopecia. Advances in Therapy2003;20(4):220‐9. [PUBMED: 14669818] ">Bureau 2003</a>; <a href="./references#CD007628-bbs2-0004" title="CarminaE , LoboRA . Treatment of hyperandrogenic alopecia in women. Fertility and Sterility2003;79(1):91‐5. [PUBMED: 12524069] ">Carmina 2003</a>; <a href="./references#CD007628-bbs2-0006" title="DraelosZD , JacobsonEL , KimH , KimM , JacobsonMK . A pilot study evaluating the efficacy of topically applied niacin derivatives for treatment of female pattern alopecia. Journal of Cosmetic Dermatology2005;4(4):258‐61. [PUBMED: 17168873] ">Draelos 2005</a>; <a href="./references#CD007628-bbs2-0012" title="HongCK , HanTY , KangHC , AhnSW , AhnJY , SeoSJ . The efficacy and safety of a combination cytopurine/pentadecanoic glyceride topical solution on androgenetic alopecia: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(12):1233‐9. ">Hong 2007</a>; <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>; <a href="./references#CD007628-bbs2-0017" title="KimJH , YSM , ChoiJE , SonSW . Study of the efficacy of Korean red ginseng in the treatment of androgenic alopecia. Journal of Ginseng Research2009;33(3):223‐8. ">Kim 2009</a>; <a href="./references#CD007628-bbs2-0018" title="KimH , ChoiJW , KimJY , ShinJW , LeeSJ , HuhCH . Low‐level light therapy for androgenetic alopecia: a 24‐week, randomized, double‐blind, sham device‐controlled multicenter trial. Dermatologic Surgery2013;39(8):1177‐83. [PUBMED: 23551662] ">Kim 2013</a>; <a href="./references#CD007628-bbs2-0020" title="LeFloc'hC , ChenitiA , ConnétableS , PiccardiN , VincenziC , TostiA . Effect of a nutritional supplement on hair loss in women. Journal of Cosmetic Dermatology2015;14(1):76‐82. [PUBMED: 25573272] ">Le Floc'h 2015</a>; <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>; <a href="./references#CD007628-bbs2-0022" title="MazzarellaF , LoconsoleF , CammisaA , MastrolonardoM , VenaGA . Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16‐month therapy course. Journal of Dermatological Treatment1997;8(3):189‐92. [EMBASE: 1997295968] ">Mazzarella 1997</a>; <a href="./references#CD007628-bbs2-0023" title="MinozziM , UnferV , ConstabileL . Androgenetic alopecia in postmenopausal women [Alopecia androgenetica in post‐menopausa]. Giornale Italiano di Ostetricia e Ginecologia1997;19(6):341‐4. [EMBASE: 1997225861] ">Minozzi 1997</a>; <a href="./references#CD007628-bbs2-0030" title="NCT01900041 . A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01900041 (accessed 14 January 2016). ">NCT01900041</a>; <a href="./references#CD007628-bbs2-0038" title="RietschelML , DuncanSH . Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. Journal of the American Academy of Dermatology1987;16(3 Pt 2):677‐85. [EMBASE: 1987099274] ">Rietschel 1987</a>; <a href="./references#CD007628-bbs2-0045" title="VexiauP , ChaspouxC , BoudouP , FietJ , JouaniqueC , HardyN , et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12‐month randomized trial. British Journal of Dermatology2002;146(6):992‐9. [PUBMED: 12072067] ">Vexiau 2002</a>; <a href="./references#CD007628-bbs2-0047" title="WhitingDA , WaldstreicherJ , SanchezM , KaufmanKD . Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women. Journal of Investigative Dermatology. Symposium Proceedings1999;4(3):282‐4. [PUBMED: 10674382] ">Whiting 1999</a>). We rated the remaining 26 studies as at unclear risk of bias (plausible bias that raises some doubt about the result) because we assessed one or more criteria as unclear. </p> <p>Some of these assessments were, to a certain extent, based on the inadequate reporting of the criteria that are a prerequisite in the evaluation of methodological rigour, in terms of trial design and conduct. Concealment of the allocation sequence and blinding are key domains in the assessment of risk of bias, and a number of included studies provided insufficient detail to enable us to make accurate judgements. Protocol deviation, losses to follow‐up with incomplete data, and subsequent per‐protocol analyses were other important sources of potential bias in a number of the included studies. We were able to amend the judgements for a number of the domains after we successfully contacted several trial investigators. For these and further details, see the 'Risk of bias' tables in the '<a href="./references#CD007628-sec-0376" title="">Characteristics of included studies</a>' section. </p> <section id="CD007628-sec-0092"> <h4 class="title">Allocation</h4> <p>The methods used to generate the allocation sequence and how the sequence was concealed, such that participants and investigators enrolling participants could not foresee the upcoming assignment, are the most important and sensitive indicators that bias has been minimised in a clinical trial (<a href="./references#CD007628-bbs2-0151" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. [PUBMED: 7823387] ">Schulz 1995</a>). </p> <section id="CD007628-sec-0093"> <h5 class="title">Sequence generation</h5> <p>Eighteen studies described in sufficient detail the method used to generate the allocation sequence (<a href="./references#CD007628-bbs2-0001" title="Blume‐PeytaviU , KunteC , KrispA , Garcia BartelsN , EllwangerU , HoffmannR . Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women [Vergleich der Wirksamkeit und Sicherheit von Minoxidil und Alfatradiol bei der topischen Behandlung der androgenetischen Alopezie der Frau]. Journal der Deutschen Dermatologischen Gesellschaft2007;5(5):391‐5. [PUBMED: 17451383] ">Blume‐Peytavi 2007</a>; <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>; <a href="./references#CD007628-bbs2-0007" title="FischerTW , BurmeisterG , SchmidtHW , ElsnerP . Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. British Journal of Dermatology2004;150(2):341‐5. [PUBMED: 14996107] ">Fischer 2004;</a><a href="./references#CD007628-bbs2-0008" title="GassmuellerJ , HoffmannR , WebsterA . Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof‐of‐concept studies. British Journal of Dermatology2008;158(1):109‐15. [PUBMED: 17986309] ">Gassmueller 2008</a>; <a href="./references#CD007628-bbs2-0012" title="HongCK , HanTY , KangHC , AhnSW , AhnJY , SeoSJ . The efficacy and safety of a combination cytopurine/pentadecanoic glyceride topical solution on androgenetic alopecia: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(12):1233‐9. ">Hong 2007</a>; <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>; <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>; <a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a>; <a href="./references#CD007628-bbs2-0018" title="KimH , ChoiJW , KimJY , ShinJW , LeeSJ , HuhCH . Low‐level light therapy for androgenetic alopecia: a 24‐week, randomized, double‐blind, sham device‐controlled multicenter trial. Dermatologic Surgery2013;39(8):1177‐83. [PUBMED: 23551662] ">Kim 2013</a>; <a href="./references#CD007628-bbs2-0019" title="LanzafameRJ , BlancheRR , ChiacchieriniRP , KazmirekER , SklarJA . The growth of human scalp hair in females using visible red light laser and LED sources. Lasers in Surgery and Medicine2014;46(8):601‐7. [PUBMED: 25124964] ">Lanzafame 2014</a>; <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>; <a href="./references#CD007628-bbs2-0029" title="NCT01655108 . Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients. clinicaltrials.gov/ct2/show/NCT01655108 (accessed 14 January 2016). ">NCT01655108</a>; <a href="./references#CD007628-bbs2-0030" title="NCT01900041 . A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01900041 (accessed 14 January 2016). ">NCT01900041</a>; <a href="./references#CD007628-bbs2-0039" title="ShengY‐Y , RuiW‐L , XuF , QiS‐S , HuR‐M , MiaoY , et al. A randomized controlled clinical study on 2% and 5% topical minoxidil solution in the treatment of female pattern hair loss [Chinese]. Journal of Clinical Dermatology2014;43(10):583‐5. [EMBASE: 2015699887] ">Sheng 2014</a>; <a href="./references#CD007628-bbs2-0040" title="ShinHS , LeeSH , KimDH , AnJS , KwonOS , EunHC . The efficacy and safety of AP‐FHG0604T on female pattern hair loss: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(2):119‐26. ">Shin 2007</a>; <a href="./references#CD007628-bbs2-0041" title="ThomE . Efficacy and tolerability of Hairgain® in individuals with hair loss: a placebo‐controlled, double‐blind study. Journal of International Medical Research2001;29(1):2‐6. [EMBASE: 2001114261] ">Thom 2001</a>; <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a>; <a href="./references#CD007628-bbs2-0045" title="VexiauP , ChaspouxC , BoudouP , FietJ , JouaniqueC , HardyN , et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12‐month randomized trial. British Journal of Dermatology2002;146(6):992‐9. [PUBMED: 12072067] ">Vexiau 2002</a>). Therefore, we judged these studies as at low risk of bias for this domain. We considered the remaining 29 studies as at unclear risk of bias. </p> </section> <section id="CD007628-sec-0094"> <h5 class="title">Allocation concealment</h5> <p>Pharmacy‐controlled, central allocation or sequentially numbered, opaque, sealed envelopes/packets ensured that the intervention allocations could not have been foreseen in advance of, or during, enrolment in 15 studies (<a href="./references#CD007628-bbs2-0001" title="Blume‐PeytaviU , KunteC , KrispA , Garcia BartelsN , EllwangerU , HoffmannR . Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women [Vergleich der Wirksamkeit und Sicherheit von Minoxidil und Alfatradiol bei der topischen Behandlung der androgenetischen Alopezie der Frau]. Journal der Deutschen Dermatologischen Gesellschaft2007;5(5):391‐5. [PUBMED: 17451383] ">Blume‐Peytavi 2007</a>; <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>; <a href="./references#CD007628-bbs2-0007" title="FischerTW , BurmeisterG , SchmidtHW , ElsnerP . Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. British Journal of Dermatology2004;150(2):341‐5. [PUBMED: 14996107] ">Fischer 2004</a>; <a href="./references#CD007628-bbs2-0008" title="GassmuellerJ , HoffmannR , WebsterA . Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof‐of‐concept studies. British Journal of Dermatology2008;158(1):109‐15. [PUBMED: 17986309] ">Gassmueller 2008</a>; <a href="./references#CD007628-bbs2-0012" title="HongCK , HanTY , KangHC , AhnSW , AhnJY , SeoSJ . The efficacy and safety of a combination cytopurine/pentadecanoic glyceride topical solution on androgenetic alopecia: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(12):1233‐9. ">Hong 2007</a>; <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>; <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>; <a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a>; <a href="./references#CD007628-bbs2-0019" title="LanzafameRJ , BlancheRR , ChiacchieriniRP , KazmirekER , SklarJA . The growth of human scalp hair in females using visible red light laser and LED sources. Lasers in Surgery and Medicine2014;46(8):601‐7. [PUBMED: 25124964] ">Lanzafame 2014</a>; <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>; <a href="./references#CD007628-bbs2-0029" title="NCT01655108 . Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients. clinicaltrials.gov/ct2/show/NCT01655108 (accessed 14 January 2016). ">NCT01655108</a>; <a href="./references#CD007628-bbs2-0031" title="NCT01967277 . A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy. clinicaltrials.gov/ct2/show/NCT01967277 (accessed 14 January 2016). ">NCT01967277</a>; <a href="./references#CD007628-bbs2-0039" title="ShengY‐Y , RuiW‐L , XuF , QiS‐S , HuR‐M , MiaoY , et al. A randomized controlled clinical study on 2% and 5% topical minoxidil solution in the treatment of female pattern hair loss [Chinese]. Journal of Clinical Dermatology2014;43(10):583‐5. [EMBASE: 2015699887] ">Sheng 2014</a>; <a href="./references#CD007628-bbs2-0040" title="ShinHS , LeeSH , KimDH , AnJS , KwonOS , EunHC . The efficacy and safety of AP‐FHG0604T on female pattern hair loss: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(2):119‐26. ">Shin 2007</a>; <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a>), which we judged low risk of bias for this domain. The remaining trials did not report the method used to conceal the allocation sequence; thus, they received a judgment of unclear risk of bias for this domain. </p> </section> </section> <section id="CD007628-sec-0095"> <h4 class="title">Blinding</h4> <p>Thirteen studies described in sufficient detail the measures used to blind study participants and personnel from knowledge of which intervention a participant received (<a href="./references#CD007628-bbs2-0006" title="DraelosZD , JacobsonEL , KimH , KimM , JacobsonMK . A pilot study evaluating the efficacy of topically applied niacin derivatives for treatment of female pattern alopecia. Journal of Cosmetic Dermatology2005;4(4):258‐61. [PUBMED: 17168873] ">Draelos 2005</a>; <a href="./references#CD007628-bbs2-0007" title="FischerTW , BurmeisterG , SchmidtHW , ElsnerP . Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. British Journal of Dermatology2004;150(2):341‐5. [PUBMED: 14996107] ">Fischer 2004</a>; <a href="./references#CD007628-bbs2-0008" title="GassmuellerJ , HoffmannR , WebsterA . Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof‐of‐concept studies. British Journal of Dermatology2008;158(1):109‐15. [PUBMED: 17986309] ">Gassmueller 2008</a>; <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>; <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>; <a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a>; <a href="./references#CD007628-bbs2-0019" title="LanzafameRJ , BlancheRR , ChiacchieriniRP , KazmirekER , SklarJA . The growth of human scalp hair in females using visible red light laser and LED sources. Lasers in Surgery and Medicine2014;46(8):601‐7. [PUBMED: 25124964] ">Lanzafame 2014</a>; <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>; <a href="./references#CD007628-bbs2-0029" title="NCT01655108 . Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients. clinicaltrials.gov/ct2/show/NCT01655108 (accessed 14 January 2016). ">NCT01655108</a>; <a href="./references#CD007628-bbs2-0031" title="NCT01967277 . A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy. clinicaltrials.gov/ct2/show/NCT01967277 (accessed 14 January 2016). ">NCT01967277</a>; <a href="./references#CD007628-bbs2-0041" title="ThomE . Efficacy and tolerability of Hairgain® in individuals with hair loss: a placebo‐controlled, double‐blind study. Journal of International Medical Research2001;29(1):2‐6. [EMBASE: 2001114261] ">Thom 2001</a>; <a href="./references#CD007628-bbs2-0042" title="ThomE . Nourkrin: objective and subjective effects and tolerability in persons with hair loss. Journal of International Medical Research2006;34(5):514‐9. [EMBASE: 2006563255] ">Thom 2006</a>; <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a>). Blinding was achieved by identical pre‐labelled bottles, tablets, devices, or packages. As five studies were open label (<a href="./references#CD007628-bbs2-0001" title="Blume‐PeytaviU , KunteC , KrispA , Garcia BartelsN , EllwangerU , HoffmannR . Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women [Vergleich der Wirksamkeit und Sicherheit von Minoxidil und Alfatradiol bei der topischen Behandlung der androgenetischen Alopezie der Frau]. Journal der Deutschen Dermatologischen Gesellschaft2007;5(5):391‐5. [PUBMED: 17451383] ">Blume‐Peytavi 2007</a>; <a href="./references#CD007628-bbs2-0004" title="CarminaE , LoboRA . Treatment of hyperandrogenic alopecia in women. Fertility and Sterility2003;79(1):91‐5. [PUBMED: 12524069] ">Carmina 2003</a>; <a href="./references#CD007628-bbs2-0023" title="MinozziM , UnferV , ConstabileL . Androgenetic alopecia in postmenopausal women [Alopecia androgenetica in post‐menopausa]. Giornale Italiano di Ostetricia e Ginecologia1997;19(6):341‐4. [EMBASE: 1997225861] ">Minozzi 1997</a>; <a href="./references#CD007628-bbs2-0030" title="NCT01900041 . A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01900041 (accessed 14 January 2016). ">NCT01900041</a>; <a href="./references#CD007628-bbs2-0045" title="VexiauP , ChaspouxC , BoudouP , FietJ , JouaniqueC , HardyN , et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12‐month randomized trial. British Journal of Dermatology2002;146(6):992‐9. [PUBMED: 12072067] ">Vexiau 2002</a>), the outcome or outcome measurement was likely to be influenced by lack of blinding. In these studies, we judged this domain as at high risk of bias. Inadequate reporting did not permit us to make a clear judgement for this domain in the other 29 studies. </p> <p>Fifteen studies ensured blinding of outcome assessment (<a href="./references#CD007628-bbs2-0006" title="DraelosZD , JacobsonEL , KimH , KimM , JacobsonMK . A pilot study evaluating the efficacy of topically applied niacin derivatives for treatment of female pattern alopecia. Journal of Cosmetic Dermatology2005;4(4):258‐61. [PUBMED: 17168873] ">Draelos 2005</a>; <a href="./references#CD007628-bbs2-0007" title="FischerTW , BurmeisterG , SchmidtHW , ElsnerP . Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. British Journal of Dermatology2004;150(2):341‐5. [PUBMED: 14996107] ">Fischer 2004</a>; <a href="./references#CD007628-bbs2-0008" title="GassmuellerJ , HoffmannR , WebsterA . Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof‐of‐concept studies. British Journal of Dermatology2008;158(1):109‐15. [PUBMED: 17986309] ">Gassmueller 2008</a>; <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>; <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>; <a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a>; <a href="./references#CD007628-bbs2-0019" title="LanzafameRJ , BlancheRR , ChiacchieriniRP , KazmirekER , SklarJA . The growth of human scalp hair in females using visible red light laser and LED sources. Lasers in Surgery and Medicine2014;46(8):601‐7. [PUBMED: 25124964] ">Lanzafame 2014</a>; <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>; <a href="./references#CD007628-bbs2-0029" title="NCT01655108 . Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients. clinicaltrials.gov/ct2/show/NCT01655108 (accessed 14 January 2016). ">NCT01655108</a>; <a href="./references#CD007628-bbs2-0031" title="NCT01967277 . A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy. clinicaltrials.gov/ct2/show/NCT01967277 (accessed 14 January 2016). ">NCT01967277</a>; <a href="./references#CD007628-bbs2-0032" title="OlsenEA . Topical minoxidil in the treatment of androgenetic alopecia in women. Cutis1991;48(3):243‐8. [PUBMED: 1935254] ">Olsen 1991</a>; <a href="./references#CD007628-bbs2-0041" title="ThomE . Efficacy and tolerability of Hairgain® in individuals with hair loss: a placebo‐controlled, double‐blind study. Journal of International Medical Research2001;29(1):2‐6. [EMBASE: 2001114261] ">Thom 2001</a>; <a href="./references#CD007628-bbs2-0042" title="ThomE . Nourkrin: objective and subjective effects and tolerability in persons with hair loss. Journal of International Medical Research2006;34(5):514‐9. [EMBASE: 2006563255] ">Thom 2006</a>; <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a>; <a href="./references#CD007628-bbs2-0047" title="WhitingDA , WaldstreicherJ , SanchezM , KaufmanKD . Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women. Journal of Investigative Dermatology. Symposium Proceedings1999;4(3):282‐4. [PUBMED: 10674382] ">Whiting 1999</a>). In six studies, we judged that there was a high risk of detection bias mainly due to the open‐label design (<a href="./references#CD007628-bbs2-0001" title="Blume‐PeytaviU , KunteC , KrispA , Garcia BartelsN , EllwangerU , HoffmannR . Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women [Vergleich der Wirksamkeit und Sicherheit von Minoxidil und Alfatradiol bei der topischen Behandlung der androgenetischen Alopezie der Frau]. Journal der Deutschen Dermatologischen Gesellschaft2007;5(5):391‐5. [PUBMED: 17451383] ">Blume‐Peytavi 2007</a>; <a href="./references#CD007628-bbs2-0004" title="CarminaE , LoboRA . Treatment of hyperandrogenic alopecia in women. Fertility and Sterility2003;79(1):91‐5. [PUBMED: 12524069] ">Carmina 2003</a>; <a href="./references#CD007628-bbs2-0020" title="LeFloc'hC , ChenitiA , ConnétableS , PiccardiN , VincenziC , TostiA . Effect of a nutritional supplement on hair loss in women. Journal of Cosmetic Dermatology2015;14(1):76‐82. [PUBMED: 25573272] ">Le Floc'h 2015</a>; <a href="./references#CD007628-bbs2-0022" title="MazzarellaF , LoconsoleF , CammisaA , MastrolonardoM , VenaGA . Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16‐month therapy course. Journal of Dermatological Treatment1997;8(3):189‐92. [EMBASE: 1997295968] ">Mazzarella 1997</a>; <a href="./references#CD007628-bbs2-0023" title="MinozziM , UnferV , ConstabileL . Androgenetic alopecia in postmenopausal women [Alopecia androgenetica in post‐menopausa]. Giornale Italiano di Ostetricia e Ginecologia1997;19(6):341‐4. [EMBASE: 1997225861] ">Minozzi 1997</a>; <a href="./references#CD007628-bbs2-0030" title="NCT01900041 . A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01900041 (accessed 14 January 2016). ">NCT01900041</a>), whilst for the remainder (26 studies), we judged this domain as at unclear risk of bias. </p> </section> <section id="CD007628-sec-0096"> <h4 class="title">Incomplete outcome data</h4> <p>In slightly less than half of the included studies (22), incomplete outcome data appear to have been adequately addressed. The losses to follow‐up were reasonably well‐balanced across intervention groups, with similar reasons for missing data across the groups. However, in 11 studies, the high dropout rate and subsequent per‐protocol analysis of the data resulted in a judgement of high risk of bias for this domain (<a href="./references#CD007628-bbs2-0001" title="Blume‐PeytaviU , KunteC , KrispA , Garcia BartelsN , EllwangerU , HoffmannR . Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women [Vergleich der Wirksamkeit und Sicherheit von Minoxidil und Alfatradiol bei der topischen Behandlung der androgenetischen Alopezie der Frau]. Journal der Deutschen Dermatologischen Gesellschaft2007;5(5):391‐5. [PUBMED: 17451383] ">Blume‐Peytavi 2007</a>; <a href="./references#CD007628-bbs2-0003" title="Bureau JP, GinouvesP , GuilbaudJ , RouxME . Essential oils and low‐intensity electromagnetic pulses in the treatment of androgen‐dependent alopecia. Advances in Therapy2003;20(4):220‐9. [PUBMED: 14669818] ">Bureau 2003</a>; <a href="./references#CD007628-bbs2-0006" title="DraelosZD , JacobsonEL , KimH , KimM , JacobsonMK . A pilot study evaluating the efficacy of topically applied niacin derivatives for treatment of female pattern alopecia. Journal of Cosmetic Dermatology2005;4(4):258‐61. [PUBMED: 17168873] ">Draelos 2005</a>; <a href="./references#CD007628-bbs2-0012" title="HongCK , HanTY , KangHC , AhnSW , AhnJY , SeoSJ . The efficacy and safety of a combination cytopurine/pentadecanoic glyceride topical solution on androgenetic alopecia: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(12):1233‐9. ">Hong 2007</a>; <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>; <a href="./references#CD007628-bbs2-0017" title="KimJH , YSM , ChoiJE , SonSW . Study of the efficacy of Korean red ginseng in the treatment of androgenic alopecia. Journal of Ginseng Research2009;33(3):223‐8. ">Kim 2009</a>; <a href="./references#CD007628-bbs2-0018" title="KimH , ChoiJW , KimJY , ShinJW , LeeSJ , HuhCH . Low‐level light therapy for androgenetic alopecia: a 24‐week, randomized, double‐blind, sham device‐controlled multicenter trial. Dermatologic Surgery2013;39(8):1177‐83. [PUBMED: 23551662] ">Kim 2013</a>; <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>; <a href="./references#CD007628-bbs2-0022" title="MazzarellaF , LoconsoleF , CammisaA , MastrolonardoM , VenaGA . Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16‐month therapy course. Journal of Dermatological Treatment1997;8(3):189‐92. [EMBASE: 1997295968] ">Mazzarella 1997</a>; <a href="./references#CD007628-bbs2-0038" title="RietschelML , DuncanSH . Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. Journal of the American Academy of Dermatology1987;16(3 Pt 2):677‐85. [EMBASE: 1987099274] ">Rietschel 1987</a>; <a href="./references#CD007628-bbs2-0047" title="WhitingDA , WaldstreicherJ , SanchezM , KaufmanKD . Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women. Journal of Investigative Dermatology. Symposium Proceedings1999;4(3):282‐4. [PUBMED: 10674382] ">Whiting 1999</a>). </p> <p>The remaining 14 studies reported insufficient information to permit a clear judgment of the risk of bias for this domain (<a href="./references#CD007628-bbs2-0004" title="CarminaE , LoboRA . Treatment of hyperandrogenic alopecia in women. Fertility and Sterility2003;79(1):91‐5. [PUBMED: 12524069] ">Carmina 2003</a>; <a href="./references#CD007628-bbs2-0005" title="DeVillezRL , JacobsJP , SzpunarCA , WarnerML . Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Archives of Dermatology1994;130(3):303‐7. [PUBMED: 8129407] ">DeVillez 1994</a>; <a href="./references#CD007628-bbs2-0007" title="FischerTW , BurmeisterG , SchmidtHW , ElsnerP . Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. British Journal of Dermatology2004;150(2):341‐5. [PUBMED: 14996107] ">Fischer 2004</a>; <a href="./references#CD007628-bbs2-0010" title="GeorgalaS , KatoulisAC , GeorgalaC , MoussatouV , BoziE , StavrianeasNG . Topical estrogen therapy for androgenetic alopecia in menopausal females. Dermatology2004;208(2):178‐9. [PUBMED: 15057016] ">Georgala 2004</a>; <a href="./references#CD007628-bbs2-0011" title="GuerreroAR , MedinaKR , KahnMC , GuerreroMJ . Usefulness and safety of 0.025 percent 17‐alpha‐estradiol versus 2 percent minoxidil in the treatment of androgenetic alopecia [Utilidad y seguridad del 17‐alfa‐estradiol 0,025 por ciento versus minoxidil 2 por ciento en el tratamiento de la alopecia androgenetica]. Revista Chilena de Dermatologia2009;25(1):21‐5. ">Guerrero 2009</a>; <a href="./references#CD007628-bbs2-0013" title="JacobsJP , SzpunarCA , WarnerML . Use of topical minoxidil therapy for androgenetic alopecia in women. International Journal of Dermatology1993;32(10):758‐62. [PUBMED: 8225725] ">Jacobs 1993</a>; <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>; <a href="./references#CD007628-bbs2-0023" title="MinozziM , UnferV , ConstabileL . Androgenetic alopecia in postmenopausal women [Alopecia androgenetica in post‐menopausa]. Giornale Italiano di Ostetricia e Ginecologia1997;19(6):341‐4. [EMBASE: 1997225861] ">Minozzi 1997</a>; <a href="./references#CD007628-bbs2-0024" title="MorgantiP , FabriziG , JamesB , BrunoC . Effect of gelatin‐cystine and serenoa repens extract on free radicals level and hair growth. Journal of Applied Cosmetology1998;16(3):57‐64. [EMBASE: 1998406625] ">Morganti 1998</a>; <a href="./references#CD007628-bbs2-0025" title="DoshiU , IsraelM , KendallC , QuizaC , SacavageS , TyndallD , et al. Effectiveness of once daily 5% minoxidil topical foam in the treatment of women with thinning hair due to female pattern hair loss (FPHL). Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB112. [EMBASE: 71895204] NCT01145625 . A Phase 3 multi‐center parallel design clinical trial to compare the efficacy and safety of 5% Minoxidil Foam vs. 2% Minoxidil Solution in females for the treatment of female pattern hair loss ‐ androgenetic alopecia (MINALO3004, NCT01145625). clinicaltrials.gov/ct2/show/NCT01145625 (accessed 14 January 2016). ">NCT01145625</a>; <a href="./references#CD007628-bbs2-0027" title="NCT01226459 . A Phase 3 Multi‐Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia). clinicaltrials.gov/ct2/show/NCT01226459 (accessed 14 January 2016). ">NCT01226459</a>; <a href="./references#CD007628-bbs2-0028" title="NCT01325350 . Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01325350 (accessed 14 January 2016). ">NCT01325350</a>; <a href="./references#CD007628-bbs2-0030" title="NCT01900041 . A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01900041 (accessed 14 January 2016). ">NCT01900041</a>; <a href="./references#CD007628-bbs2-0044" title="UkşalÜ , BayramF , UtaşS , ÇolakR , BorluM . Comparision of low dose finasteride, flutamide and spirolactone in female androgenetic alopecia. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S238. ">Ukşal 1999</a>). </p> </section> <section id="CD007628-sec-0097"> <h4 class="title">Selective reporting</h4> <p>Protocols were available for only 13 included studies (<a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>; <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>; <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>; <a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a>; <a href="./references#CD007628-bbs2-0019" title="LanzafameRJ , BlancheRR , ChiacchieriniRP , KazmirekER , SklarJA . The growth of human scalp hair in females using visible red light laser and LED sources. Lasers in Surgery and Medicine2014;46(8):601‐7. [PUBMED: 25124964] ">Lanzafame 2014</a>; <a href="./references#CD007628-bbs2-0020" title="LeFloc'hC , ChenitiA , ConnétableS , PiccardiN , VincenziC , TostiA . Effect of a nutritional supplement on hair loss in women. Journal of Cosmetic Dermatology2015;14(1):76‐82. [PUBMED: 25573272] ">Le Floc'h 2015</a>; <a href="./references#CD007628-bbs2-0025" title="DoshiU , IsraelM , KendallC , QuizaC , SacavageS , TyndallD , et al. Effectiveness of once daily 5% minoxidil topical foam in the treatment of women with thinning hair due to female pattern hair loss (FPHL). Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB112. [EMBASE: 71895204] NCT01145625 . A Phase 3 multi‐center parallel design clinical trial to compare the efficacy and safety of 5% Minoxidil Foam vs. 2% Minoxidil Solution in females for the treatment of female pattern hair loss ‐ androgenetic alopecia (MINALO3004, NCT01145625). clinicaltrials.gov/ct2/show/NCT01145625 (accessed 14 January 2016). ">NCT01145625</a>; <a href="./references#CD007628-bbs2-0026" title="NCT01189279 . Safety and pharmacokinetics study of new formulation of Bimatoprost in patients with alopecia. clinicaltrials.gov/ct2/show/NCT01189279 (accessed 14 January 2016). ">NCT01189279</a>; <a href="./references#CD007628-bbs2-0027" title="NCT01226459 . A Phase 3 Multi‐Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia). clinicaltrials.gov/ct2/show/NCT01226459 (accessed 14 January 2016). ">NCT01226459</a>; <a href="./references#CD007628-bbs2-0028" title="NCT01325350 . Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01325350 (accessed 14 January 2016). ">NCT01325350</a>; <a href="./references#CD007628-bbs2-0029" title="NCT01655108 . Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients. clinicaltrials.gov/ct2/show/NCT01655108 (accessed 14 January 2016). ">NCT01655108</a>; <a href="./references#CD007628-bbs2-0030" title="NCT01900041 . A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01900041 (accessed 14 January 2016). ">NCT01900041</a>; <a href="./references#CD007628-bbs2-0031" title="NCT01967277 . A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy. clinicaltrials.gov/ct2/show/NCT01967277 (accessed 14 January 2016). ">NCT01967277</a>). Based on this information as well as on the details provided in the methods section of the reports, 44 of the 47 studies appear to have reported all prespecified outcomes and we therefore judged them to be free of selective reporting. We considered the remaining three studies to be at unclear risk of bias (<a href="./references#CD007628-bbs2-0023" title="MinozziM , UnferV , ConstabileL . Androgenetic alopecia in postmenopausal women [Alopecia androgenetica in post‐menopausa]. Giornale Italiano di Ostetricia e Ginecologia1997;19(6):341‐4. [EMBASE: 1997225861] ">Minozzi 1997</a>; <a href="./references#CD007628-bbs2-0044" title="UkşalÜ , BayramF , UtaşS , ÇolakR , BorluM . Comparision of low dose finasteride, flutamide and spirolactone in female androgenetic alopecia. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S238. ">Ukşal 1999</a>; <a href="./references#CD007628-bbs2-0046" title="WhitingDA , JacobsonC . Treatment of female androgenetic alopecia with minoxidil 2%. International Journal of Dermatology1992;31(11):800‐4. [PUBMED: 1428436] ">Whiting 1992</a>). One of these studies, <a href="./references#CD007628-bbs2-0044" title="UkşalÜ , BayramF , UtaşS , ÇolakR , BorluM . Comparision of low dose finasteride, flutamide and spirolactone in female androgenetic alopecia. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S238. ">Ukşal 1999</a>, was reported only as an abstract to conference proceedings, which provided insufficient information to make a clear judgement for this domain. Although <a href="./references#CD007628-bbs2-0046" title="WhitingDA , JacobsonC . Treatment of female androgenetic alopecia with minoxidil 2%. International Journal of Dermatology1992;31(11):800‐4. [PUBMED: 1428436] ">Whiting 1992</a> did not fully report the primary outcomes of participant and investigator assessments of hair regrowth, this did not appear to be intentional; and as the impact of this was unclear, we judged this domain as at unclear risk of bias. The investigators in <a href="./references#CD007628-bbs2-0023" title="MinozziM , UnferV , ConstabileL . Androgenetic alopecia in postmenopausal women [Alopecia androgenetica in post‐menopausa]. Giornale Italiano di Ostetricia e Ginecologia1997;19(6):341‐4. [EMBASE: 1997225861] ">Minozzi 1997</a> did not report all of their prespecified outcomes, but it was uncertain to what extent the lack of data for anything other than sex hormone‐binding globulin (SHBG) had any impact on their reported results; therefore, we judged this domain as at unclear risk of bias. </p> </section> <section id="CD007628-sec-0098"> <h4 class="title">Other potential sources of bias</h4> <p>We judged this domain as at 'low risk of bias' in most of the included studies (43). Although the impact of study sponsorship in <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> was unclear, the "protocol‐prohibited concomitant medications" used by a number of participants, mostly in the active intervention group, represented a high risk of bias for this domain in this study. In <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>, the baseline imbalance between the intervention groups, i.e. a higher proportion of participants with more extensive hair thinning in the 5% minoxidil group, posed a risk of bias for this domain in this study. In <a href="./references#CD007628-bbs2-0046" title="WhitingDA , JacobsonC . Treatment of female androgenetic alopecia with minoxidil 2%. International Journal of Dermatology1992;31(11):800‐4. [PUBMED: 1428436] ">Whiting 1992</a>, the potential impact of the wide range in duration (six months to 25 years) of hair loss at baseline was unclear. In <a href="./references#CD007628-bbs2-0044" title="UkşalÜ , BayramF , UtaşS , ÇolakR , BorluM . Comparision of low dose finasteride, flutamide and spirolactone in female androgenetic alopecia. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S238. ">Ukşal 1999</a>, which was reported as an abstract, we had insufficient information to permit a judgement. </p> </section> </section> <section id="CD007628-sec-0099"> <h3 class="title" id="CD007628-sec-0099">Effects of interventions</h3> <p>See: <a href="./full#CD007628-tbl-0001"><b>Summary of findings for the main comparison</b> Minoxidil versus placebo</a>; <a href="./full#CD007628-tbl-0002"><b>Summary of findings 2</b> Minoxidil 2% versus minoxidil 5%</a>; <a href="./full#CD007628-tbl-0003"><b>Summary of findings 3</b> Finasteride versus placebo</a>; <a href="./full#CD007628-tbl-0004"><b>Summary of findings 4</b> Low‐level laser comb versus sham device</a> </p> <p>Fifteen studies provided no usable or retrievable data, and did not contribute further to the results of this review (see <a href="#CD007628-tbl-0008">Table 4</a>). The main reasons why we could not use data were: studies did not report data separately for men and women, there were very limited data available in abstracts to conference proceedings, or studies did not address any of our outcomes. </p> <div class="table" id="CD007628-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Included studies with no usable or irretrievable data</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interventions and comparisons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0003" title="Bureau JP, GinouvesP , GuilbaudJ , RouxME . Essential oils and low‐intensity electromagnetic pulses in the treatment of androgen‐dependent alopecia. Advances in Therapy2003;20(4):220‐9. [PUBMED: 14669818] ">Bureau 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Essential oil solution (E2F7) and electromagnetic pulses versus placebo solution and electromagnetic pulses </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> <p>Investigators unable to provide these</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0007" title="FischerTW , BurmeisterG , SchmidtHW , ElsnerP . Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. British Journal of Dermatology2004;150(2):341‐5. [PUBMED: 14996107] ">Fischer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Melatonin–alcohol solution versus alcohol solution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of our outcomes were addressed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0011" title="GuerreroAR , MedinaKR , KahnMC , GuerreroMJ . Usefulness and safety of 0.025 percent 17‐alpha‐estradiol versus 2 percent minoxidil in the treatment of androgenetic alopecia [Utilidad y seguridad del 17‐alfa‐estradiol 0,025 por ciento versus minoxidil 2 por ciento en el tratamiento de la alopecia androgenetica]. Revista Chilena de Dermatologia2009;25(1):21‐5. ">Guerrero 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minoxidil 2% versus 17α‐estradiol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> <p>No response from principal investigator</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0012" title="HongCK , HanTY , KangHC , AhnSW , AhnJY , SeoSJ . The efficacy and safety of a combination cytopurine/pentadecanoic glyceride topical solution on androgenetic alopecia: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(12):1233‐9. ">Hong 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cytopurine, pentadecanoic glyceride, 95% ethanol topical solution versus vehicle solution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0017" title="KimJH , YSM , ChoiJE , SonSW . Study of the efficacy of Korean red ginseng in the treatment of androgenic alopecia. Journal of Ginseng Research2009;33(3):223‐8. ">Kim 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Korean red ginseng versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> <p>No response from principal investigator</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0018" title="KimH , ChoiJW , KimJY , ShinJW , LeeSJ , HuhCH . Low‐level light therapy for androgenetic alopecia: a 24‐week, randomized, double‐blind, sham device‐controlled multicenter trial. Dermatologic Surgery2013;39(8):1177‐83. [PUBMED: 23551662] ">Kim 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low level light therapy versus sham device</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> <p>No response from principal investigator</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0022" title="MazzarellaF , LoconsoleF , CammisaA , MastrolonardoM , VenaGA . Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16‐month therapy course. Journal of Dermatological Treatment1997;8(3):189‐92. [EMBASE: 1997295968] ">Mazzarella 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Finasteride 0.005% lotion versus vehicle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> <p>No response from principal investigator</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0023" title="MinozziM , UnferV , ConstabileL . Androgenetic alopecia in postmenopausal women [Alopecia androgenetica in post‐menopausa]. Giornale Italiano di Ostetricia e Ginecologia1997;19(6):341‐4. [EMBASE: 1997225861] ">Minozzi 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethinyl estradiol (0.02 mg/day) versus transdermal estradiol (0.05 mg/day) with medroxyprogesterone acetate (MPA) versus ethinyl estradiol (0.02 mg/day) with cyproterone acetate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosis of female pattern hair loss (FPHL) was not clearly defined/stated. No response from principal investigator </p> <p>None of our outcomes were assessed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0024" title="MorgantiP , FabriziG , JamesB , BrunoC . Effect of gelatin‐cystine and serenoa repens extract on free radicals level and hair growth. Journal of Applied Cosmetology1998;16(3):57‐64. [EMBASE: 1998406625] ">Morganti 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active lotion (gelatine‐cystine and <i>Serenoa repens</i>) versus placebo lotion versus active diet supplement (gelatine‐cystine) versus placebo supplement versus active lotion and active supplement (n = 12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> <p>No response from principal investigator</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0026" title="NCT01189279 . Safety and pharmacokinetics study of new formulation of Bimatoprost in patients with alopecia. clinicaltrials.gov/ct2/show/NCT01189279 (accessed 14 January 2016). ">NCT01189279</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bimatoprost A versus bimatoprost B versus bimatoprost C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of our outcomes were addressed, no separate data for men and women. No response from Allergan </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0027" title="NCT01226459 . A Phase 3 Multi‐Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia). clinicaltrials.gov/ct2/show/NCT01226459 (accessed 14 January 2016). ">NCT01226459</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minoxidil 5% versus vehicle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Too many inconsistencies regarding numbers that dropped out and number of participants analysed, as well as in calculations made for mean changes from baseline. No response from principal investigators </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0038" title="RietschelML , DuncanSH . Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. Journal of the American Academy of Dermatology1987;16(3 Pt 2):677‐85. [EMBASE: 1987099274] ">Rietschel 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minoxidil 2% versus minoxidil 3% versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> <p>No response from principal investigator</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0041" title="ThomE . Efficacy and tolerability of Hairgain® in individuals with hair loss: a placebo‐controlled, double‐blind study. Journal of International Medical Research2001;29(1):2‐6. [EMBASE: 2001114261] ">Thom 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dietary supplement versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> <p>No response from principal investigator</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0042" title="ThomE . Nourkrin: objective and subjective effects and tolerability in persons with hair loss. Journal of International Medical Research2006;34(5):514‐9. [EMBASE: 2006563255] ">Thom 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dietary supplement versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> <p>No response from principal investigator</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0044" title="UkşalÜ , BayramF , UtaşS , ÇolakR , BorluM . Comparision of low dose finasteride, flutamide and spirolactone in female androgenetic alopecia. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S238. ">Ukşal 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spironolactone versus flutamide versus finasteride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poster, limited data, unclear how many participants in each group. No response from principal investigator </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: FPHL: female pattern hair loss, N: Number randomised</p> </div> </div> <p>We have categorised comparisons as follows.</p> <p> <ul id="CD007628-list-0009"> <li> <p>Treatments with topical minoxidil (comparisons 1 to 8).</p> </li> <li> <p>Other topical treatments (comparisons 9 to 15).</p> </li> <li> <p>Oral treatments (comparisons 16 to 18).</p> </li> <li> <p>Laser‐based treatments and electrostatic field (comparisons 19 to 22).</p> </li> </ul> </p> <section id="CD007628-sec-0100"> <h4 class="title">1. Minoxidil (1%, 2%, and 5%) versus placebo</h4> <p>Nine trials provided data for some outcomes for this comparison (<a href="./references#CD007628-bbs2-0005" title="DeVillezRL , JacobsJP , SzpunarCA , WarnerML . Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Archives of Dermatology1994;130(3):303‐7. [PUBMED: 8129407] ">DeVillez 1994</a>; <a href="./references#CD007628-bbs2-0013" title="JacobsJP , SzpunarCA , WarnerML . Use of topical minoxidil therapy for androgenetic alopecia in women. International Journal of Dermatology1993;32(10):758‐62. [PUBMED: 8225725] ">Jacobs 1993</a>; <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>; <a href="./references#CD007628-bbs2-0028" title="NCT01325350 . Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01325350 (accessed 14 January 2016). ">NCT01325350</a>; <a href="./references#CD007628-bbs2-0032" title="OlsenEA . Topical minoxidil in the treatment of androgenetic alopecia in women. Cutis1991;48(3):243‐8. [PUBMED: 1935254] ">Olsen 1991</a>; <a href="./references#CD007628-bbs2-0034" title="Pazoki‐ToroudiH , BabakoohiS , NilforoushzadehMA , Nassiri‐KashaniM , ShizarpourM , AjamiM , et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed2012;10(5):276‐82. [PUBMED: 23163069] ">Pazoki‐Toroudi 2012</a>; <a href="./references#CD007628-bbs2-0036" title="PriceVH , MenefeeE . Quantitative estimation of hair growth. I. androgenetic alopecia in women: effect of minoxidil. Journal of Investigative Dermatology1990;95(6):683‐7. [PUBMED: 2250110] ">Price 1990</a>; <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a>; <a href="./references#CD007628-bbs2-0046" title="WhitingDA , JacobsonC . Treatment of female androgenetic alopecia with minoxidil 2%. International Journal of Dermatology1992;31(11):800‐4. [PUBMED: 1428436] ">Whiting 1992</a>). Seven of these trials examined the effects of a 2% concentration of minoxidil, whereas <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a> compared a 1% concentration with placebo, one study included an additional 5% arm (<a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>), and one three‐armed study compared minoxidil 5% with placebo as one of the three comparisons within that study (<a href="./references#CD007628-bbs2-0034" title="Pazoki‐ToroudiH , BabakoohiS , NilforoushzadehMA , Nassiri‐KashaniM , ShizarpourM , AjamiM , et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed2012;10(5):276‐82. [PUBMED: 23163069] ">Pazoki‐Toroudi 2012</a>). See also 'Summary of findings' table 1 (<a href="./full#CD007628-tbl-0001">summary of findings Table for the main comparison</a>). </p> <section id="CD007628-sec-0101"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0102"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>Six studies (1148 participants) reported participant‐rated clinically significant (moderate to marked) hair regrowth (<a href="./references#CD007628-bbs2-0005" title="DeVillezRL , JacobsJP , SzpunarCA , WarnerML . Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Archives of Dermatology1994;130(3):303‐7. [PUBMED: 8129407] ">DeVillez 1994</a>; <a href="./references#CD007628-bbs2-0013" title="JacobsJP , SzpunarCA , WarnerML . Use of topical minoxidil therapy for androgenetic alopecia in women. International Journal of Dermatology1993;32(10):758‐62. [PUBMED: 8225725] ">Jacobs 1993</a>; <a href="./references#CD007628-bbs2-0028" title="NCT01325350 . Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01325350 (accessed 14 January 2016). ">NCT01325350</a>; <a href="./references#CD007628-bbs2-0032" title="OlsenEA . Topical minoxidil in the treatment of androgenetic alopecia in women. Cutis1991;48(3):243‐8. [PUBMED: 1935254] ">Olsen 1991</a>; <a href="./references#CD007628-bbs2-0034" title="Pazoki‐ToroudiH , BabakoohiS , NilforoushzadehMA , Nassiri‐KashaniM , ShizarpourM , AjamiM , et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed2012;10(5):276‐82. [PUBMED: 23163069] ">Pazoki‐Toroudi 2012</a>; <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a>). Pooled data, using a fixed‐effect model, from these studies indicated that a greater proportion of participants (157/593) treated with minoxidil reported a statistically significant moderate increase in hair regrowth when compared with placebo (77/555) (risk ratio (RR) 1.93, 95% confidence interval (CI) 1.51 to 2.47; six trials, 1148 participants; P &lt; 0.00001; I² statistic = 24%, <a href="./references#CD007628-fig-0007" title="">Analysis 1.1</a>). We compared the effect size and the precision estimates of 1% minoxidil versus placebo, 2% minoxidil versus placebo, and 5% minoxidil versus placebo. Thus, we conclude that although the difference would appear to favour minoxidil (2%), this was relatively small and provides no evidence of any genuine difference with the 1% concentration, whilst the higher concentration of 5% did not show a statistically significant difference compared to placebo. Although there was little suggestion of heterogeneity, we repeated this analysis using a random‐effects model to assess the extent of the between‐study heterogeneity (see <a href="#CD007628-tbl-0009">Table 5</a>). One other study, <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> (381 participants, data on 260 participants), which also reported data for this outcome, used a VAS rated zero to 100 to measure change in hair growth/scalp coverage, with a higher score indicating more scalp coverage. The VAS score was 58.3 (18.2 standard deviation (SD)) in the placebo group, 62.9 (16.7 SD) in the 2% minoxidil group, and 68.1 (17.9 SD) in the 5% minoxidil group. According to the principal investigators only the self assessments of 5% minoxidil versus placebo reached a statistically significant difference (P &lt; 0.001). </p> <div class="table" id="CD007628-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Table of random‐effects sensitivity analyses</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Concentration/subgroups</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% confidence interval</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>I² statistic</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chi² test (P value)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-fig-0007" title="">Analysis 1.1</a> </p> <p>Self‐rated hair regrowth</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.34 to 2.46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.00001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007628-fig-0008" title="">Analysis 1.2</a> </p> <p>Adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minoxidil (1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.61 to 2.06</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minoxidil (2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 to 1.79</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minoxidil (5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51 to 6.55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.10</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-fig-0009" title="">Analysis 1.3</a> </p> <p>Investigator‐rated hair regrowth</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.53 to 3.06</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.00001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.41</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-fig-0010" title="">Analysis 1.4</a> </p> <p>Increase in total hair count</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.80 to 15.65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.00001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-fig-0011" title="">Analysis 1.5</a> </p> <p>Increase in total hair count (sensitivity analysis)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.96</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.69 to 15.24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.00001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.76</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-fig-0012" title="">Analysis 2.1</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 to 1.30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.005</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-fig-0013" title="">Analysis 2.2</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 to 1.35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-fig-0014" title="">Analysis 2.3</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−2.12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−5.47 to 1.23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD007628-sec-0103"> <h6 class="title">Change in QoL</h6> <p><a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> rated the impact of hair loss on QoL on a VAS (data on 260 participants), and at 48 weeks the mean score in the 2% minoxidil group was 52.1 and 46.5 in the placebo group (study authors reported P = 0.04, Student t‐test), where a score of 50 indicates "neutral" impact, ranging up to 100 as "positive" impact. In the 5% minoxidil group, the mean VAS score was 54.4 (slightly more than no change) compared to 46.5 with placebo (study authors reported P = 0.004, Student t‐test). Although the study investigators reported these scores without SDs and stated them as being statistically significant, the mean differences (MDs) between intervention groups were marginal and can be considered not clinically important. The other included studies did not assess this outcome. </p> </section> <section id="CD007628-sec-0104"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>Comparison of the effect size and precision estimates for minoxidil (1%) versus placebo (RR 1.12, 95% CI 0.61 to 2.06; one trial, 280 participants), minoxidil (2%) versus placebo (RR 1.24, 95% CI 0.82 to 1.87), and minoxidil (5%) versus placebo (RR 2.05, 95% CI 0.96 to 4.37; four trials, 427 participants) reveals that although the difference between the adverse effects favours the minoxidil (1%) concentration, this is small and provides limited evidence of any genuine difference between the three concentrations (see <a href="./references#CD007628-fig-0008" title="">Analysis 1.2</a>). The interaction between the subgroups of dose and effect size did not provide adequate evidence to demonstrate a difference, but this is likely to be due to a lack of power (P value = 0.43). </p> <p>In most instances, the adverse events reported were mild and consisted of pruritus, skin irritation, and dermatitis. Additional hair growth on areas other than the scalp, e.g. sideburns and forehead, was reported in 71/153 participants in the minoxidil (5%) group compared to 34/154 in the minoxidil (2%) group and 12/74 in the placebo group (<a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>). The data for adverse events were incompletely reported in <a href="./references#CD007628-bbs2-0005" title="DeVillezRL , JacobsJP , SzpunarCA , WarnerML . Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Archives of Dermatology1994;130(3):303‐7. [PUBMED: 8129407] ">DeVillez 1994</a>, with the investigators indicating only that "no serious or unexpected medical events were reported during the study", and <a href="./references#CD007628-bbs2-0046" title="WhitingDA , JacobsonC . Treatment of female androgenetic alopecia with minoxidil 2%. International Journal of Dermatology1992;31(11):800‐4. [PUBMED: 1428436] ">Whiting 1992</a> reported that no serious side effects were encountered. </p> <p>Pooled adverse events data for all of the concentrations of minoxidil versus placebo showed a RR of 1.34 (95% CI 0.98 to 1.83; five trials, 1301 participants; I² statistic = 0%), with no statistically significant difference between groups. </p> </section> </section> <section id="CD007628-sec-0105"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0106"> <h6 class="title">Proportion of participants with investigator‐rated hair regrowth</h6> <p>Seven studies (1181 participants) comparing one or more of these interventions provided data for this outcome (<a href="./references#CD007628-bbs2-0005" title="DeVillezRL , JacobsJP , SzpunarCA , WarnerML . Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Archives of Dermatology1994;130(3):303‐7. [PUBMED: 8129407] ">DeVillez 1994</a>; <a href="./references#CD007628-bbs2-0013" title="JacobsJP , SzpunarCA , WarnerML . Use of topical minoxidil therapy for androgenetic alopecia in women. International Journal of Dermatology1993;32(10):758‐62. [PUBMED: 8225725] ">Jacobs 1993</a>; <a href="./references#CD007628-bbs2-0028" title="NCT01325350 . Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01325350 (accessed 14 January 2016). ">NCT01325350</a>; <a href="./references#CD007628-bbs2-0032" title="OlsenEA . Topical minoxidil in the treatment of androgenetic alopecia in women. Cutis1991;48(3):243‐8. [PUBMED: 1935254] ">Olsen 1991</a>; <a href="./references#CD007628-bbs2-0034" title="Pazoki‐ToroudiH , BabakoohiS , NilforoushzadehMA , Nassiri‐KashaniM , ShizarpourM , AjamiM , et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed2012;10(5):276‐82. [PUBMED: 23163069] ">Pazoki‐Toroudi 2012</a>; <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a>; <a href="./references#CD007628-bbs2-0046" title="WhitingDA , JacobsonC . Treatment of female androgenetic alopecia with minoxidil 2%. International Journal of Dermatology1992;31(11):800‐4. [PUBMED: 1428436] ">Whiting 1992</a>). The investigator‐rated assessments were in agreement with the participant self‐rated assessments, both of which reported and confirmed a statistically significant increase in moderate to marked hair regrowth with minoxidil (112/610) compared to placebo (44/571) (RR 2.35, 95% CI 1.68 to 3.28; seven trials, 1181 participants; P &lt; 0.00001 I² statistic = 2%; <a href="./references#CD007628-fig-0009" title="">Analysis 1.3</a>). A comparison of the effect size and precision of estimates for minoxidil (1%) versus placebo, and minoxidil (2%) versus placebo revealed that there was no appreciable difference between the two concentrations of minoxidil for this outcome. <a href="./references#CD007628-bbs2-0034" title="Pazoki‐ToroudiH , BabakoohiS , NilforoushzadehMA , Nassiri‐KashaniM , ShizarpourM , AjamiM , et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed2012;10(5):276‐82. [PUBMED: 23163069] ">Pazoki‐Toroudi 2012</a> showed no statistically significant difference between the minoxidil (5%) group and placebo, but the effect estimate was very imprecise with wide CIs, due to a lack of events in the placebo group. One other study, <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> (data on 260 participants), used a VAS, rated zero to 100, to evaluate change in hair growth/scalp coverage with a higher score indicating better coverage. The changes were 2.2 (17.9 SD) in the placebo group, 10.3 (17.0 SD) in the minoxidil (2%) group and 11.7 (17.2 SD) in the minoxidil (5%) group. </p> </section> <section id="CD007628-sec-0107"> <h6 class="title">Change from baseline in total hair count</h6> <p>Eight studies including 1242 participants reported data for the mean change in total hair count from baseline (<a href="./references#CD007628-bbs2-0005" title="DeVillezRL , JacobsJP , SzpunarCA , WarnerML . Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Archives of Dermatology1994;130(3):303‐7. [PUBMED: 8129407] ">DeVillez 1994</a>; <a href="./references#CD007628-bbs2-0013" title="JacobsJP , SzpunarCA , WarnerML . Use of topical minoxidil therapy for androgenetic alopecia in women. International Journal of Dermatology1993;32(10):758‐62. [PUBMED: 8225725] ">Jacobs 1993</a>; <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>; <a href="./references#CD007628-bbs2-0028" title="NCT01325350 . Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01325350 (accessed 14 January 2016). ">NCT01325350</a>; <a href="./references#CD007628-bbs2-0032" title="OlsenEA . Topical minoxidil in the treatment of androgenetic alopecia in women. Cutis1991;48(3):243‐8. [PUBMED: 1935254] ">Olsen 1991</a>; <a href="./references#CD007628-bbs2-0036" title="PriceVH , MenefeeE . Quantitative estimation of hair growth. I. androgenetic alopecia in women: effect of minoxidil. Journal of Investigative Dermatology1990;95(6):683‐7. [PUBMED: 2250110] ">Price 1990</a>; <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a>; <a href="./references#CD007628-bbs2-0046" title="WhitingDA , JacobsonC . Treatment of female androgenetic alopecia with minoxidil 2%. International Journal of Dermatology1992;31(11):800‐4. [PUBMED: 1428436] ">Whiting 1992</a>). The MD across the studies favoured minoxidil and ranged from eight to 42 hairs (total hair count). The pooled data illustrated that the increase in total hair count in the minoxidil group when compared to the placebo group was 13.18 (95% CI 10.92 to 15.44; eight trials, 1242 participants; P &lt; 0.00001; I² statistic = 9%; <a href="./references#CD007628-fig-0010" title="">Analysis 1.4</a>). A comparison of the effect size and precision of the estimates indicated that there was no evidence of any systematic difference between the three concentrations of minoxidil. In addition, we observed funnel plot asymmetry that was attributable to a single study of eight participants (<a href="./references#CD007628-bbs2-0036" title="PriceVH , MenefeeE . Quantitative estimation of hair growth. I. androgenetic alopecia in women: effect of minoxidil. Journal of Investigative Dermatology1990;95(6):683‐7. [PUBMED: 2250110] ">Price 1990</a>) (see <a href="#CD007628-fig-0006">Figure 6</a>). It remains unclear whether this asymmetry was the result of publication bias, small‐study effects, or an artefact of natural variability. The impact of excluding this study from <a href="./references#CD007628-fig-0010" title="">Analysis 1.4</a> had a marginal effect on the overall pooled result (RR 12.96, 95% CI 10.69 to 15.24; seven trials, 1108 participants; P &lt; 0.00001; I² statistic = 0%), which we report as a sensitivity analysis (see <a href="./references#CD007628-fig-0011" title="">Analysis 1.5</a>); however, it did remove any suggestion of heterogeneity. In an attempt to assess the between study heterogeneity, we repeated both of these analyses using a random‐effects model, and presented the results in <a href="#CD007628-tbl-0009">Table 5</a>. We found little difference between the two sets of analyses. </p> <div class="figure" id="CD007628-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Minoxidil versus placebo, outcome: 1.4 Mean increase in total hair count from baseline." data-id="CD007628-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Minoxidil versus placebo, outcome: 1.4 Mean increase in total hair count from baseline. </p> </div> </div> </div> </section> <section id="CD007628-sec-0108"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>Three studies reported data on this outcome (<a href="./references#CD007628-bbs2-0034" title="Pazoki‐ToroudiH , BabakoohiS , NilforoushzadehMA , Nassiri‐KashaniM , ShizarpourM , AjamiM , et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed2012;10(5):276‐82. [PUBMED: 23163069] ">Pazoki‐Toroudi 2012</a>; <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a>; <a href="./references#CD007628-bbs2-0046" title="WhitingDA , JacobsonC . Treatment of female androgenetic alopecia with minoxidil 2%. International Journal of Dermatology1992;31(11):800‐4. [PUBMED: 1428436] ">Whiting 1992</a>). In <a href="./references#CD007628-bbs2-0034" title="Pazoki‐ToroudiH , BabakoohiS , NilforoushzadehMA , Nassiri‐KashaniM , ShizarpourM , AjamiM , et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed2012;10(5):276‐82. [PUBMED: 23163069] ">Pazoki‐Toroudi 2012</a> there was a reduction in the number of shed hair of 38.32 (40.98 SD) in the minoxidil (5%) group (43 participants) compared to a reduction of 0.47 (23.50 SD) in the placebo group (18 participants) with a MD of −37.85 (95% CI −54.22 to −21.48; P &lt; 0.00001). </p> <p>Two thirds (10/17) of the participants in the minoxidil (2%) group reported a decrease in hair shedding compared with less than half (7/16) in placebo group, and that this was more noticeable at the second month of treatment in <a href="./references#CD007628-bbs2-0046" title="WhitingDA , JacobsonC . Treatment of female androgenetic alopecia with minoxidil 2%. International Journal of Dermatology1992;31(11):800‐4. [PUBMED: 1428436] ">Whiting 1992</a> (RR 1.34, 95% CI 0.68 to 2.66; one trial, 33 participants). </p> <p>However, there was no statistically significant difference in the number of participants in <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a> that reported a decrease in hair loss, and 98/140 participants in the minoxidil (1%) group compared to 87/140 demonstrated a large placebo effect (RR 1.13, 95% CI 0.95 to 1.33, one trial, 180 participants). </p> </section> <section id="CD007628-sec-0109"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>One study measured participants' satisfaction as a 'benefit of treatment' and rated it using a VAS (zero = no benefit, 50 = moderate benefit, and 100 = great benefit) (<a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>). Participant satisfaction in the two minoxidil groups compared to placebo was 18.2 for the minoxidil (5%) group (principal investigators reported P &lt; 0.001, Student t‐test) and 8.7 for the minoxidil (2%) group (P = 0.09, Student t‐test). The score for the minoxidil (5%) group was 60.0 (27.6 SD), for the (2%) group 50.5 (32.5 SD), and 41.8 (29.9 SD) for the placebo group, and was rated using a VAS score (0 = no benefit, 50 = moderate benefit, and 100 = great benefit). The investigators concluded that there was evidence of increased participant satisfaction with the higher, rather than with the lower, concentration. However, there was a 32% loss to follow‐up in this study and the data analysis was per‐protocol. </p> </section> <section id="CD007628-sec-0110"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>The mean change in hair density, assessed on the Savin Female Density scale at 48 weeks, was −0.9 in the minoxidil (2%) group compared to −0.4 in the placebo group (investigators reported P = 0.012, Student t‐test), and a lower score represented a more beneficial effect (<a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>). The mean change in hair density in the minoxidil (5%) group was −0.8 (P value = 0.015, Student t‐test) compared to placebo. In <a href="./references#CD007628-bbs2-0028" title="NCT01325350 . Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01325350 (accessed 14 January 2016). ">NCT01325350</a> the mean change from baseline in target area hair width was 0.87 (1.315) mm/cm² in the minoxidil (2%) group versus 0.07 (1.183) mm/cm² in the placebo group with a MD of 0.80 (95% CI 0.36 to 1.24; P = 0.0004) which favoured minoxidil (2%). </p> </section> </section> </section> <section id="CD007628-sec-0111"> <h4 class="title">2. Minoxidil (2%) versus minoxidil (5%)</h4> <p>Four studies compared these interventions (<a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>; <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>; <a href="./references#CD007628-bbs2-0025" title="DoshiU , IsraelM , KendallC , QuizaC , SacavageS , TyndallD , et al. Effectiveness of once daily 5% minoxidil topical foam in the treatment of women with thinning hair due to female pattern hair loss (FPHL). Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB112. [EMBASE: 71895204] NCT01145625 . A Phase 3 multi‐center parallel design clinical trial to compare the efficacy and safety of 5% Minoxidil Foam vs. 2% Minoxidil Solution in females for the treatment of female pattern hair loss ‐ androgenetic alopecia (MINALO3004, NCT01145625). clinicaltrials.gov/ct2/show/NCT01145625 (accessed 14 January 2016). ">NCT01145625</a>; <a href="./references#CD007628-bbs2-0039" title="ShengY‐Y , RuiW‐L , XuF , QiS‐S , HuR‐M , MiaoY , et al. A randomized controlled clinical study on 2% and 5% topical minoxidil solution in the treatment of female pattern hair loss [Chinese]. Journal of Clinical Dermatology2014;43(10):583‐5. [EMBASE: 2015699887] ">Sheng 2014</a>). One study, <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>, used a 2% concentration applied twice daily and the 5% concentration once daily, whereas <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> and <a href="./references#CD007628-bbs2-0039" title="ShengY‐Y , RuiW‐L , XuF , QiS‐S , HuR‐M , MiaoY , et al. A randomized controlled clinical study on 2% and 5% topical minoxidil solution in the treatment of female pattern hair loss [Chinese]. Journal of Clinical Dermatology2014;43(10):583‐5. [EMBASE: 2015699887] ">Sheng 2014</a> applied both concentrations twice daily. In <a href="./references#CD007628-bbs2-0025" title="DoshiU , IsraelM , KendallC , QuizaC , SacavageS , TyndallD , et al. Effectiveness of once daily 5% minoxidil topical foam in the treatment of women with thinning hair due to female pattern hair loss (FPHL). Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB112. [EMBASE: 71895204] NCT01145625 . A Phase 3 multi‐center parallel design clinical trial to compare the efficacy and safety of 5% Minoxidil Foam vs. 2% Minoxidil Solution in females for the treatment of female pattern hair loss ‐ androgenetic alopecia (MINALO3004, NCT01145625). clinicaltrials.gov/ct2/show/NCT01145625 (accessed 14 January 2016). ">NCT01145625</a> both treatment arms received a single dose each day. None of the four studies reported any significant difference in efficacy between either of the two concentrations of minoxidil. See also 'Summary of findings' table 2 (<a href="./full#CD007628-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD007628-sec-0112"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0113"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>Two of the studies did not assess this outcome (<a href="./references#CD007628-bbs2-0025" title="DoshiU , IsraelM , KendallC , QuizaC , SacavageS , TyndallD , et al. Effectiveness of once daily 5% minoxidil topical foam in the treatment of women with thinning hair due to female pattern hair loss (FPHL). Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB112. [EMBASE: 71895204] NCT01145625 . A Phase 3 multi‐center parallel design clinical trial to compare the efficacy and safety of 5% Minoxidil Foam vs. 2% Minoxidil Solution in females for the treatment of female pattern hair loss ‐ androgenetic alopecia (MINALO3004, NCT01145625). clinicaltrials.gov/ct2/show/NCT01145625 (accessed 14 January 2016). ">NCT01145625</a>; <a href="./references#CD007628-bbs2-0039" title="ShengY‐Y , RuiW‐L , XuF , QiS‐S , HuR‐M , MiaoY , et al. A randomized controlled clinical study on 2% and 5% topical minoxidil solution in the treatment of female pattern hair loss [Chinese]. Journal of Clinical Dermatology2014;43(10):583‐5. [EMBASE: 2015699887] ">Sheng 2014</a>). In <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a> 44% (25/57) of the participants in the minoxidil (2%) group, as opposed to 39% (22/56) of those in the minoxidil (5%) group, experienced moderate to greatly increased hair regrowth (RR 1.12, 95% CI 0.72 to 1.73; one trial, 113 participants). In <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> (209 participants for this comparison) the VAS score showed a change in hair growth/scalp coverage of 62.9 (16.7 SD) in the minoxidil (2%) group, compared to a score of 68.1 (17.9 SD) in the minoxidil (5%) group (investigators reported P = 0.062). </p> </section> <section id="CD007628-sec-0114"> <h6 class="title">Change in QoL</h6> <p>Only one study evaluated this outcome (<a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>). The trial investigators reported that at week 48 there was no statistically significant difference in impact of hair loss on QoL between the two intervention groups. </p> </section> <section id="CD007628-sec-0115"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>There was no statistically significant difference in the number of adverse events reported in either intervention group in three of the studies (<a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>; <a href="./references#CD007628-bbs2-0025" title="DoshiU , IsraelM , KendallC , QuizaC , SacavageS , TyndallD , et al. Effectiveness of once daily 5% minoxidil topical foam in the treatment of women with thinning hair due to female pattern hair loss (FPHL). Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB112. [EMBASE: 71895204] NCT01145625 . A Phase 3 multi‐center parallel design clinical trial to compare the efficacy and safety of 5% Minoxidil Foam vs. 2% Minoxidil Solution in females for the treatment of female pattern hair loss ‐ androgenetic alopecia (MINALO3004, NCT01145625). clinicaltrials.gov/ct2/show/NCT01145625 (accessed 14 January 2016). ">NCT01145625</a>; <a href="./references#CD007628-bbs2-0039" title="ShengY‐Y , RuiW‐L , XuF , QiS‐S , HuR‐M , MiaoY , et al. A randomized controlled clinical study on 2% and 5% topical minoxidil solution in the treatment of female pattern hair loss [Chinese]. Journal of Clinical Dermatology2014;43(10):583‐5. [EMBASE: 2015699887] ">Sheng 2014</a>). However, in <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> the number of participants that reported adverse events appeared to favour the lower concentration. These were reported by 10/154 participants in the minoxidil (2%) twice daily group compared to 22/153 in the minoxidil (5%) twice daily group (RR 0.45, 95% CI 0.22 to 0.92, one trial, 307 participants). Hypertrichosis (more hair growth on areas other than the scalp), dermatitis, and pruritus were also reported more frequently in the minoxidil (5%) group. Pooling of the data indicated a RR of 1.02 (95% CI 0.91 to 1.15; four trials, 1006 participants; I² statistic = 76%; <a href="./references#CD007628-fig-0012" title="">Analysis 2.1</a>). Exclusion of this single study, <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>, from the analysis slightly altered the pooled results and reduced the degree of heterogeneity (RR 1.10, 95% CI 0.99 to 1.23; three trials, 699 participants; I² statistic = 50%; <a href="./references#CD007628-fig-0013" title="">Analysis 2.2</a>). The twice daily dose of 5% in this study resulted in double the number of adverse events compared to the twice daily dosage of minoxidil (2%). We repeated the analyses using a random‐effects model and found little difference between the two sets of analyses (<a href="#CD007628-tbl-0009">Table 5</a>). </p> </section> </section> <section id="CD007628-sec-0116"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0117"> <h6 class="title">Proportion of participants with investigator‐rated clinically significant hair regrowth</h6> <p>The investigator‐ and participant‐rated assessments were largely in agreement in three of the studies, i.e. there was no evidence of a difference between the two concentrations of minoxidil for stimulating hair growth. In <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a> the investigator‐rated assessments revealed that 12/57 participants in the minoxidil (2%) group had moderate to greatly increased hair growth compared to 14/56 in the minoxidil (5%) group (RR 0.84, 95% CI 0.43 to 1.66; one trial 113 participants). These results were confirmed by the investigator‐rated VAS scores in <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>, which showed no statistically significant difference in efficacy between either concentration of minoxidil (principal investigators' reported P = 0.608). In <a href="./references#CD007628-bbs2-0039" title="ShengY‐Y , RuiW‐L , XuF , QiS‐S , HuR‐M , MiaoY , et al. A randomized controlled clinical study on 2% and 5% topical minoxidil solution in the treatment of female pattern hair loss [Chinese]. Journal of Clinical Dermatology2014;43(10):583‐5. [EMBASE: 2015699887] ">Sheng 2014</a> 27/132 participants in the minoxidil (2%) group had a moderate to marked improvement compared to 34/132 in the minoxidil (5%) group (RR 0.79, 95% CI 0.51 to 1.24; one trial 264 participants). <a href="./references#CD007628-bbs2-0025" title="DoshiU , IsraelM , KendallC , QuizaC , SacavageS , TyndallD , et al. Effectiveness of once daily 5% minoxidil topical foam in the treatment of women with thinning hair due to female pattern hair loss (FPHL). Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB112. [EMBASE: 71895204] NCT01145625 . A Phase 3 multi‐center parallel design clinical trial to compare the efficacy and safety of 5% Minoxidil Foam vs. 2% Minoxidil Solution in females for the treatment of female pattern hair loss ‐ androgenetic alopecia (MINALO3004, NCT01145625). clinicaltrials.gov/ct2/show/NCT01145625 (accessed 14 January 2016). ">NCT01145625</a> did not assess this outcome. </p> </section> <section id="CD007628-sec-0118"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>The pooled data from three studies (631 participants) (<a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>; <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>; <a href="./references#CD007628-bbs2-0025" title="DoshiU , IsraelM , KendallC , QuizaC , SacavageS , TyndallD , et al. Effectiveness of once daily 5% minoxidil topical foam in the treatment of women with thinning hair due to female pattern hair loss (FPHL). Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB112. [EMBASE: 71895204] NCT01145625 . A Phase 3 multi‐center parallel design clinical trial to compare the efficacy and safety of 5% Minoxidil Foam vs. 2% Minoxidil Solution in females for the treatment of female pattern hair loss ‐ androgenetic alopecia (MINALO3004, NCT01145625). clinicaltrials.gov/ct2/show/NCT01145625 (accessed 14 January 2016). ">NCT01145625</a>) indicated that there was no statistically significant difference in the change in total hair count from baseline to the end of study between the two treatment groups (MD −2.12, 95% CI −5.47 to 1.23; I² statistic = 0%; see <a href="./references#CD007628-fig-0014" title="">Analysis 2.3</a> and <a href="#CD007628-tbl-0009">Table 5</a>). </p> </section> <section id="CD007628-sec-0119"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>None of the studies assessed this outcome.</p> </section> <section id="CD007628-sec-0120"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>Almost three quarters of the participants in the minoxidil (2%) group were more satisfied with the appearance of their hair at the end of treatment compared to more than half of those in the minoxidil (5%) group (<a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>). Assessments of 'benefit of treatment' in <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> rated on a VAS scored 50.5 (32.5 SD) in the 2% group versus 60.0 (27.6 SD) in the 5% group (principal investigators' reported P = 0.29, Student t‐test). The two other studies did not assess this outcome (<a href="./references#CD007628-bbs2-0025" title="DoshiU , IsraelM , KendallC , QuizaC , SacavageS , TyndallD , et al. Effectiveness of once daily 5% minoxidil topical foam in the treatment of women with thinning hair due to female pattern hair loss (FPHL). Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB112. [EMBASE: 71895204] NCT01145625 . A Phase 3 multi‐center parallel design clinical trial to compare the efficacy and safety of 5% Minoxidil Foam vs. 2% Minoxidil Solution in females for the treatment of female pattern hair loss ‐ androgenetic alopecia (MINALO3004, NCT01145625). clinicaltrials.gov/ct2/show/NCT01145625 (accessed 14 January 2016). ">NCT01145625</a>; <a href="./references#CD007628-bbs2-0039" title="ShengY‐Y , RuiW‐L , XuF , QiS‐S , HuR‐M , MiaoY , et al. A randomized controlled clinical study on 2% and 5% topical minoxidil solution in the treatment of female pattern hair loss [Chinese]. Journal of Clinical Dermatology2014;43(10):583‐5. [EMBASE: 2015699887] ">Sheng 2014</a>). </p> </section> <section id="CD007628-sec-0121"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>There was no statistically significant difference in the non‐vellus cumulative target area hair width (mm/cm² between the minoxidil (2% and 5%) applications in <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>, and similarly in <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> for hair density, assessed as the mean change from baseline based on the Savin Female Density scale. The other two studies did not assess this outcome (<a href="./references#CD007628-bbs2-0025" title="DoshiU , IsraelM , KendallC , QuizaC , SacavageS , TyndallD , et al. Effectiveness of once daily 5% minoxidil topical foam in the treatment of women with thinning hair due to female pattern hair loss (FPHL). Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB112. [EMBASE: 71895204] NCT01145625 . A Phase 3 multi‐center parallel design clinical trial to compare the efficacy and safety of 5% Minoxidil Foam vs. 2% Minoxidil Solution in females for the treatment of female pattern hair loss ‐ androgenetic alopecia (MINALO3004, NCT01145625). clinicaltrials.gov/ct2/show/NCT01145625 (accessed 14 January 2016). ">NCT01145625</a>; <a href="./references#CD007628-bbs2-0039" title="ShengY‐Y , RuiW‐L , XuF , QiS‐S , HuR‐M , MiaoY , et al. A randomized controlled clinical study on 2% and 5% topical minoxidil solution in the treatment of female pattern hair loss [Chinese]. Journal of Clinical Dermatology2014;43(10):583‐5. [EMBASE: 2015699887] ">Sheng 2014</a>). </p> </section> </section> </section> <section id="CD007628-sec-0122"> <h4 class="title">3. Minoxidil 12.5% + azelaic acid + betamethasone 17‐valerate 0.025% versus placebo</h4> <p>One three‐armed study at unclear risk of bias conducted over a period of 24 weeks, which included 75 participants, evaluated this comparison (<a href="./references#CD007628-bbs2-0034" title="Pazoki‐ToroudiH , BabakoohiS , NilforoushzadehMA , Nassiri‐KashaniM , ShizarpourM , AjamiM , et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed2012;10(5):276‐82. [PUBMED: 23163069] ">Pazoki‐Toroudi 2012</a>). </p> <section id="CD007628-sec-0123"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0124"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>In the minoxidil high extra combination (MHEC) group, as named by the principal investigators, 21/57 of participants reported moderate to marked improvement compared to 0/18 in the placebo group (RR 14.09, 95% CI 0.90 to 221.58; one trial, 75 participants). </p> </section> <section id="CD007628-sec-0125"> <h6 class="title">Change in QoL</h6> <p>This study did not assess this outcome.</p> </section> <section id="CD007628-sec-0126"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>The number of adverse events were 14/57 in the MHEC group and 4/18 in the placebo group (RR 1.11, 95% 0.42 to 2.94; one trial, 75 participants). Adverse events included irritation, hypertrichosis, pruritus, and headache. </p> </section> </section> <section id="CD007628-sec-0127"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0128"> <h6 class="title">Proportion of participants with investigator‐rated clinically significant hair regrowth</h6> <p>The judgements regarding improvement (moderate and marked) were 100% in agreement with the participant assessments (RR 14.09, 95% CI 0.90 to 221.58; one trial 75 participants). </p> </section> <section id="CD007628-sec-0129"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>This study did not assess this outcome.</p> </section> <section id="CD007628-sec-0130"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>The mean decrease in number of shed hairs was 53.80 (40.94 SD) in the MHEC group versus 0.47 (23.50 SD) in the placebo group with a MD of −53.33 hairs (95% CI −68.66 to −38.00; P &lt; 0.00001) in favour of MHEC. </p> </section> <section id="CD007628-sec-0131"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>This study did not assess this outcome.</p> </section> <section id="CD007628-sec-0132"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>This study did not assess this outcome.</p> </section> </section> </section> <section id="CD007628-sec-0133"> <h4 class="title">4. Minoxidil 12.5% + azelaic acid + betamethasone 17‐valerate 0.025% versus minoxidil 5% </h4> <p>This is the third comparison, which included 106 participants, that <a href="./references#CD007628-bbs2-0034" title="Pazoki‐ToroudiH , BabakoohiS , NilforoushzadehMA , Nassiri‐KashaniM , ShizarpourM , AjamiM , et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed2012;10(5):276‐82. [PUBMED: 23163069] ">Pazoki‐Toroudi 2012</a> evaluated. </p> <section id="CD007628-sec-0134"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0135"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>In the MHEC group, 21/57 participants considered themselves to have moderate to marked improvement compared to 16/49 in the minoxidil (5%) group (RR 1.13, 95% CI 0.67 to 1.91; one trial, 106 participants). </p> </section> <section id="CD007628-sec-0136"> <h6 class="title">Change in QoL</h6> <p>This study did not assess this outcome.</p> </section> <section id="CD007628-sec-0137"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>There were 14 adverse events in 57 participants in the MHEC group and 11/49 in the minoxidil (5%) group (RR 1.09, 95% 0.55 to 2.18; one trial, 106 participants). Adverse events included irritation, hypertrichosis, pruritus, and headache. </p> </section> </section> <section id="CD007628-sec-0138"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0139"> <h6 class="title">Proportion of participants with investigator‐rated clinically significant hair regrowth</h6> <p>According to the investigators, 21/57 participants in MHEC group versus 16/49 in the minoxidil (5%) group showed a moderate to marked improvement of hair regrowth (RR 1.13, 95% CI 0.67 to 1.91; one trial, 106 participants), which is in concordance with the participants' assessments. </p> </section> <section id="CD007628-sec-0140"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>This study did not assess the outcome.</p> </section> <section id="CD007628-sec-0141"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>The mean decrease in number of shed hairs was 53.80 (40.94 SD) in the MHEC group, which was better than 38.32 (40.98 SD) in the minoxidil (5%) group with a MD of −15.48 hairs (95% CI −31.82 to 0.86). </p> </section> <section id="CD007628-sec-0142"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0143"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>The study did not assess this outcome.</p> </section> </section> </section> <section id="CD007628-sec-0144"> <h4 class="title">5. Minoxidil (2%) versus alfatradiol</h4> <p>One study (103 participants), which we assessed as at high risk of bias, reported limited data for this comparison (<a href="./references#CD007628-bbs2-0001" title="Blume‐PeytaviU , KunteC , KrispA , Garcia BartelsN , EllwangerU , HoffmannR . Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women [Vergleich der Wirksamkeit und Sicherheit von Minoxidil und Alfatradiol bei der topischen Behandlung der androgenetischen Alopezie der Frau]. Journal der Deutschen Dermatologischen Gesellschaft2007;5(5):391‐5. [PUBMED: 17451383] ">Blume‐Peytavi 2007</a>). </p> <section id="CD007628-sec-0145"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0146"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0147"> <h6 class="title">Change in QoL</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0148"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>No adverse effects were reported for either intervention in this study (<a href="./references#CD007628-bbs2-0001" title="Blume‐PeytaviU , KunteC , KrispA , Garcia BartelsN , EllwangerU , HoffmannR . Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women [Vergleich der Wirksamkeit und Sicherheit von Minoxidil und Alfatradiol bei der topischen Behandlung der androgenetischen Alopezie der Frau]. Journal der Deutschen Dermatologischen Gesellschaft2007;5(5):391‐5. [PUBMED: 17451383] ">Blume‐Peytavi 2007</a>). "Tolerability of treatment" was participant‐ and investigator‐assessed, and, although inadequately defined, the investigators referred to it in further similar studies as "pruritus and local intolerance". No relevant data were reported at 6 months, and the data at 12 months were incomplete and implausibly analysed (see the '<a href="#CD007628-sec-0091">Risk of bias in included studies</a>' section). Therefore, we have not included these in the meta‐analysis. </p> </section> </section> <section id="CD007628-sec-0149"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0150"> <h6 class="title">Proportion of participants with investigator‐rated clinically significant hair regrowth</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0151"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>At 12 months the increase in hair density was 17.20 (SD 32.95) hairs/cm² in the minoxidil group compared to 9.8 (SD 31.79) hairs/cm² in the alfatradiol group with a MD of 7.40 hairs/cm² (95% CI −8.98 to 23.78), which was not statistically significant. </p> </section> <section id="CD007628-sec-0152"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0153"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0154"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>The mean change in cumulative hair thickness from baseline to 12 months was 2.10 (3.10 SD) mm/cm² in the minoxidil group compared to 0.40 (3.31 SD) mm/cm² in the alfatradiol group with a MD of 1.70 mm/cm² (95% CI 0.07 to 3.33, P = 0.04). </p> </section> </section> </section> <section id="CD007628-sec-0155"> <h4 class="title">6. Intradermal applications (mesotherapy) with minoxidil 0.5% per 2 mL versus intradermal applications (mesotherapy) with saline 0.9% </h4> <p>A single study, <a href="./references#CD007628-bbs2-0029" title="NCT01655108 . Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients. clinicaltrials.gov/ct2/show/NCT01655108 (accessed 14 January 2016). ">NCT01655108</a>, at low risk of bias with 54 participants compared these interventions over 10 sessions and at weekly intervals. </p> <section id="CD007628-sec-0156"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0157"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>In the mesotherapy plus minoxidil group 7/27 participants reported a moderate to sharp increase in hair volume compared to 1/27 in the mesotherapy plus saline group (RR 7.00, 95% CI 0.92 to 53.10; one trial 54 participants). </p> </section> <section id="CD007628-sec-0158"> <h6 class="title">Change in QoL</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0159"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>All participants in both groups reported pain, but there were more reports in the mesotherapy plus minoxidil group (authors' reported P &lt; 0.10). The investigators also indicated that there was no difference between the groups regarding the nature of other adverse events such as headache, burning, and itching. </p> </section> </section> <section id="CD007628-sec-0160"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0161"> <h6 class="title">Proportion of participants with investigator‐rated clinically significant hair regrowth</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0162"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0163"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>In the mesotherapy plus minoxidil group 18/27 participants noticed a decrease in the extent of hair loss compared to 8/27 in the mesotherapy plus saline group (RR 2.25, 95% CI 1.19 to 4.27; one trial 54 participants; P = 0.01), which was in favour of mesotherapy plus minoxidil. </p> </section> <section id="CD007628-sec-0164"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0165"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>The study did not assess this outcome.</p> </section> </section> </section> <section id="CD007628-sec-0166"> <h4 class="title">7. Pantovigar one capsule three times a day plus minoxidil 2% twice daily versus minoxidil 2% twice daily </h4> <p>Pantovigar is a natural hair loss supplement. One study, at high risk of bias, evaluated it in combination with topical minoxidil versus minoxidil (2%) monotherapy (<a href="./references#CD007628-bbs2-0030" title="NCT01900041 . A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01900041 (accessed 14 January 2016). ">NCT01900041</a>). It was conducted over 26 weeks and included 74 participants. </p> <section id="CD007628-sec-0167"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0168"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0169"> <h6 class="title">Change in QoL</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0170"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>In the Pantovigar plus minoxidil group 15 adverse events were reported in 37 participants versus 19 adverse events in 37 participants in the minoxidil "only" group (RR 0.79, 95% CI 0.48 to 1.30; one trial 74 participants). </p> </section> </section> <section id="CD007628-sec-0171"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0172"> <h6 class="title">Proportion of participants with investigator‐rated clinically significant hair regrowth</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0173"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0174"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>The investigators reported that "changes in percentage telogen rate were comparable between both groups. No statistically significant difference was observed (P = 0.45)." </p> </section> <section id="CD007628-sec-0175"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0176"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>The study did not assess this outcome.</p> </section> </section> </section> <section id="CD007628-sec-0177"> <h4 class="title">8. Minoxidil and oral contraceptive pill (OCP) versus cyproterone acetate and OCP</h4> <p>One study, including 66 participants and assessed as high risk of bias, compared the effects of these interventions (<a href="./references#CD007628-bbs2-0045" title="VexiauP , ChaspouxC , BoudouP , FietJ , JouaniqueC , HardyN , et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12‐month randomized trial. British Journal of Dermatology2002;146(6):992‐9. [PUBMED: 12072067] ">Vexiau 2002</a>). </p> <section id="CD007628-sec-0178"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0179"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0180"> <h6 class="title">Change in QoL</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0181"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>Three participants in the minoxidil combined with OCP group reported pruritus, and one reported weight gain. A further participant in the cyproterone acetate group reported weight gain. </p> </section> </section> <section id="CD007628-sec-0182"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0183"> <h6 class="title">Proportion of participants with investigator‐rated clinically significant hair regrowth</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0184"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>Minoxidil combined with the OCP was more effective than cyproterone acetate. Mean change from baseline in the combination group was 7.7 hairs (9.3 SD) and in the cyproterone acetate group −0.2 hairs (6.7 SD). The MD in total number of hairs per 0.36 cm² between the minoxidil group was 7.90 (95% CI 3.70 to 12.10). </p> </section> <section id="CD007628-sec-0185"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>Both groups reported large decreases in self‐assessed mean hair loss; rated on a VAS, these were −28 (24 SD) for the minoxidil group versus −24 (26 SD) mm for the cyproterone acetate group. These found there was no difference in the reduction of hair loss between the 2 treatment groups (MD −4.00, 95% CI −17.52 to 9.52) </p> </section> <section id="CD007628-sec-0186"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0187"> <h6 class="title">Change in quality (or pattern) of hair regrowth (thickness and density)</h6> <p>The study did not assess this outcome.</p> </section> </section> </section> <section id="CD007628-sec-0188"> <h4 class="title">9. Estradiol valerate topical ointment (3%) for 12 weeks versus estradiol valerate topical ointment (3%) for 24 weeks versus placebo vehicle only for 24 weeks </h4> <p>A single study (75 participants) at unclear risk of bias provided minimal data for this comparison (<a href="./references#CD007628-bbs2-0010" title="GeorgalaS , KatoulisAC , GeorgalaC , MoussatouV , BoziE , StavrianeasNG . Topical estrogen therapy for androgenetic alopecia in menopausal females. Dermatology2004;208(2):178‐9. [PUBMED: 15057016] ">Georgala 2004</a>). </p> <section id="CD007628-sec-0189"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0190"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0191"> <h6 class="title">Change in QoL</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0192"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>Two of 25 participants in the 12‐week group reported mild pruritus itching on the scalp compared to 4/25 in the 24‐week group and 2/25 in the placebo group. In the 24‐week treatment group, two participants experienced postmenopausal uterine bleeding, which resulted in their withdrawal from the study. </p> </section> </section> <section id="CD007628-sec-0193"> <h5 class="title">Secondary outcomes</h5> <p>The study did not assess any of our secondary outcomes.</p> </section> </section> <section id="CD007628-sec-0194"> <h4 class="title">10. Octyl nicotinate (0.5%) and myristyl nicotinate (5%) versus placebo</h4> <p>A single study (60 participants) at unclear risk of bias compared the safety and efficacy of octyl nicotinate (0.5%) and myristyl nicotinate (5%) versus placebo over six months (<a href="./references#CD007628-bbs2-0006" title="DraelosZD , JacobsonEL , KimH , KimM , JacobsonMK . A pilot study evaluating the efficacy of topically applied niacin derivatives for treatment of female pattern alopecia. Journal of Cosmetic Dermatology2005;4(4):258‐61. [PUBMED: 17168873] ">Draelos 2005</a>). </p> <section id="CD007628-sec-0195"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0196"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0197"> <h6 class="title">Change in QoL</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0198"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p><a href="./references#CD007628-bbs2-0006" title="DraelosZD , JacobsonEL , KimH , KimM , JacobsonMK . A pilot study evaluating the efficacy of topically applied niacin derivatives for treatment of female pattern alopecia. Journal of Cosmetic Dermatology2005;4(4):258‐61. [PUBMED: 17168873] ">Draelos 2005</a> did not report data separately for adverse events for each intervention, only cumulatively as scalp stinging (9), scalp burning (2), scalp itching (12), scalp redness (4), and eye irritation (7). These occurred in both placebo and active intervention groups, and the study authors concluded that they were related to the volatile vehicle, and not the active constituent. </p> </section> </section> <section id="CD007628-sec-0199"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0200"> <h6 class="title">Proportion of participants with investigator‐rated clinically significant hair regrowth</h6> <p>At six months, 22/40 participants treated with the combination therapy showed an increase in hair fullness compared to 4/20 of those treated with placebo (RR 2.75, 95% CI 1.10 to 6.90; one trial, 60 participants). </p> </section> <section id="CD007628-sec-0201"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0202"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0203"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>Although no data were reported, the investigators referred to a "positive trend" in the participants' assessments of the appearance of their hair, but indicated that this did not reach significance (investigators' reported P value = 0.05). </p> </section> <section id="CD007628-sec-0204"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>The study did not assess this outcome.</p> </section> </section> </section> <section id="CD007628-sec-0205"> <h4 class="title">11. Fulvestrant 70 mg/mL versus placebo</h4> <p>A single study (70 participants) at low risk of bias provided limited outcome data for this comparison (<a href="./references#CD007628-bbs2-0008" title="GassmuellerJ , HoffmannR , WebsterA . Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof‐of‐concept studies. British Journal of Dermatology2008;158(1):109‐15. [PUBMED: 17986309] ">Gassmueller 2008</a>), and concluded that fulvestrant was ineffective after 16 weeks in the treatment of FPHL. </p> <section id="CD007628-sec-0206"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0207"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0208"> <h6 class="title">Change in QoL</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0209"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>There was no statistically significant difference in the number of adverse events between the interventions. These were mild, i.e. cold and headache, and similar in the fulvestrant group (10/34) and the placebo group (16/36) (RR 0.66, 95% CI 0.35 to 1.25; one trial, 70 participants). The study reported that both fulvestrant and the vehicle were well‐tolerated. </p> </section> </section> <section id="CD007628-sec-0210"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0211"> <h6 class="title">Proportion of participants with investigator‐rated clinically significant hair regrowth</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0212"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0213"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0214"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0215"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>No statistically significant differences were reported in terms of percentage change from baseline in cumulative hair thickness, nor in hair density. So there was no evidence in favour of fulvestrant over placebo. </p> </section> </section> </section> <section id="CD007628-sec-0216"> <h4 class="title">12. Adenosine versus placebo</h4> <p>Only one study, which was at unclear risk of bias and included 30 participants, evaluated the effect of this intervention in the treatment of FPHL for a 12‐month duration (<a href="./references#CD007628-bbs2-0033" title="OuraH , IinoM , IdetaR , NakazawaY , KishimotoJ , AraseS . Efficacy of adenosine on female pattern hair loss and male androgenetic alopecia. Journal of Investigative Dermatology2008;128(Suppl 1):S151. OuraH , IinoM , NakazawaY , TajimaM , IdetaR , NakayaY , et al. Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: a pilot, double‐blind, randomized, placebo‐controlled trial. Journal of Dermatology2008;35(12):763‐7. [PUBMED: 19239555] ">Oura 2008</a>). </p> <section id="CD007628-sec-0217"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0218"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>The study evaluated self‐assessments with a questionnaire, however the investigators only provided P values. These indicated that for hair growth there was no statistically significant difference between the two treatment groups at month 12 (investigators reported "P value = 0.081, Mann–Whitney U‐test") </p> </section> <section id="CD007628-sec-0219"> <h6 class="title">Change in QoL</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0220"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>There were no adverse events in either group.</p> </section> </section> <section id="CD007628-sec-0221"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0222"> <h6 class="title">Proportion of participants with investigator‐rated clinically significant hair regrowth</h6> <p>The dermatologist‐rated assessments indicated that four out of 15 participants in the adenosine treatment group improved compared to 2/15 in the placebo group (RR 2.00, 95% CI 0.43 to 9.32; one trial, 30 participants), and that these results were reasonably consistent with the investigator‐rated assessments. </p> </section> <section id="CD007628-sec-0223"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>The investigators reported that "hair density did not change significantly between the groups at any time point". </p> </section> <section id="CD007628-sec-0224"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>The investigators reported that at the end of the study there was a statistically significant difference in favour of the adenosine group regarding the prevention of hair loss (authors' reported "P value = 0.036, Mann–Whitney U‐test"). However, they did not provide any data to support this conclusion. </p> </section> <section id="CD007628-sec-0225"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>Although the 'change in appearance' at 12 months appeared to favour adenosine (investigators' reported "P value = 0.048, Mann–Whitney U‐test"), there was no statistically significant difference in satisfaction between the two groups at the end of the study. </p> </section> <section id="CD007628-sec-0226"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>The thick hair ratio (number of hairs thicker than 80 μm in diameter/thinner hairs) did not improve in the adenosine group over 12 months, but it did show a decrease in the placebo group (investigators reported "P value = 0.002, Student t‐test") with a difference between the two groups in favour of adenosine (investigators reported "P value = 0.04, Student t‐test"). </p> </section> </section> </section> <section id="CD007628-sec-0227"> <h4 class="title">13. Botanical tincture versus placebo</h4> <p>One study compared a botanical tincture (which contained <i>Thuja occidentalis</i> extract, <i>Swertia</i> extract, pantotenilethylether, 4‐pyrrolidine 2,6‐diaminopyrimidine 1‐oxide, cyanocobalamin, 95% ethanol, saline) to placebo (<a href="./references#CD007628-bbs2-0040" title="ShinHS , LeeSH , KimDH , AnJS , KwonOS , EunHC . The efficacy and safety of AP‐FHG0604T on female pattern hair loss: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(2):119‐26. ">Shin 2007</a>). Both were applied twice daily for 18 weeks in 33 participants. The limited data that were reported for this study, which we assessed as at unclear risk of bias, indicated a lack of efficacy for this treatment. </p> <section id="CD007628-sec-0228"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0229"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>The improvement score based on a VAS scale, rated from zero to 10, did not show a statistically significant difference between the groups (with a score of 4.4 (2.47 SD) in the botanical tincture group versus 4.5 (2.80 SD) in the placebo group. </p> </section> <section id="CD007628-sec-0230"> <h6 class="title">Change in QoL</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0231"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>There were no adverse events reported in either group.</p> </section> </section> <section id="CD007628-sec-0232"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0233"> <h6 class="title">Participants with investigator‐rated clinically significant hair regrowth</h6> <p>After 18 weeks the score in the botanical tincture group was 1.0 (0.82 SD) with a score of 1 representing a 0 to 25% improvement. In the placebo group the score was 0.8 (0.80 SD), which indicated no change or worse. </p> </section> <section id="CD007628-sec-0234"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>The investigators reported no statistically significant change in hair count compared to baseline for either group. </p> </section> <section id="CD007628-sec-0235"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>According to the investigators the degree of hair shedding, which was assessed using a VAS, was 5.0 (2.89 SD) in the botanical tincture group compared to 4.4 (3.20 SD) in the placebo group. There was no statistically significant difference between the groups. </p> </section> <section id="CD007628-sec-0236"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0237"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>The investigators reported no statistically significant change in hair diameter compared to baseline for either group. </p> </section> </section> </section> <section id="CD007628-sec-0238"> <h4 class="title">14. Bimatoprost different concentrations versus vehicle</h4> <p>One five‐armed study at unclear risk of bias, which included a total of 306 participants, evaluated the different concentrations of bimatoprost topical applications versus vehicle (<a href="./references#CD007628-bbs2-0028" title="NCT01325350 . Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01325350 (accessed 14 January 2016). ">NCT01325350</a>). Three arms included bimatoprost formulation A, B, and C without further specification, and the other two arms were minoxidil and vehicle. We have reported the comparisons versus minoxidil under comparison 22, and minoxidil versus vehicle under comparison 1. </p> <section id="CD007628-sec-0239"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0240"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>This was rated on a seven‐point scale of the Subject Self Assessment in Alopecia (SSA) score. Accordingly, 12/61 participants considered they had a moderate to great increase in hair regrowth in bimatoprost formulation A, 14/61 in formulation B, and 14/61 in formulation C versus 13/61 in the vehicle group. None of the comparisons showed a statistically significant difference compared to vehicle or compared to any of the bimatoprost concentration, which suggested that according to participants the treatment is ineffective. </p> </section> <section id="CD007628-sec-0241"> <h6 class="title">Change in QoL</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0242"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>In the bimatoprost formulation A group 21/61 participants reported adverse events, with five experiencing hypertrichosis; 21/61 in formulation B (one hypertrichosis), 18/61 in formulation C (no hypertrichosis); and 21/61 in the vehicle group (one hypertrichosis). There was no statistically significant difference between any of the treatment arms. </p> </section> </section> <section id="CD007628-sec-0243"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0244"> <h6 class="title">Proportion of participants with investigator‐rated clinically significant hair regrowth</h6> <p>Based on the Investigator's Global Assessment scale, the investigators judged that 10/61 in the bimatoprost formulation A group had a moderate to greatly increased hair regrowth, 8/61 in formulation B group, 10/61 in formulation C group, and 10/61 in the vehicle group, with no statistically significant difference between any of the groups. These assessments were in agreement with the participants' judgements. </p> </section> <section id="CD007628-sec-0245"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>The mean change in hair count was not clinically meaningful in any group. The mean change from baseline in hair count was 0.4 (17.10 SD) in the bimatoprost formulation A group, 3.5 (18.21 SD) in formulation B group, 4.3 (16.82 SD) in the formulation C group, and 1.1 (20.44 SD) in the vehicle group. </p> </section> <section id="CD007628-sec-0246"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0247"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0248"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>The mean change from baseline in target area hair width was 0.13 (1.198 SD) mm/cm² in the bimatoprost formulation A group, 0.19 (1.067 SD) mm/cm² in group B, 0.30 (1.263 SD) mm/cm² in group C, and 0.07 (1.1183 SD) mm/cm² in the vehicle group. No treatment arm showed a statistically significant difference of vehicle or against the other formulations. </p> </section> </section> </section> <section id="CD007628-sec-0249"> <h4 class="title">15. Bimatoprost different concentrations versus minoxidil</h4> <p>The same five‐armed study as in comparison 21 evaluated the different concentrations of topical applications versus minoxidil 2% (<a href="./references#CD007628-bbs2-0028" title="NCT01325350 . Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01325350 (accessed 14 January 2016). ">NCT01325350</a>). </p> <section id="CD007628-sec-0250"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0251"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>This was rated on a seven‐point scale of the SSA. Accordingly, 12/61 participants considered that they had a moderate to great increase in hair regrowth with the bimatoprost formulation A, 14/61 in formulation B, 14/61 in formulation C, versus 20/61 in the minoxidil group. Although the minoxidil group scored better on the SSA score, there was no statistically significant difference between any of the comparisons. </p> </section> <section id="CD007628-sec-0252"> <h6 class="title">Change in QoL</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0253"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>Adverse events reported were 21/61 in bimatoprost formulation A, with five experiencing hypertrichosis; 21/61 in formulation B (one hypertrichosis), 18/61 in formulation C (no hypertrichosis); and 25/62 in the minoxidil group (three hypertrichosis). There was no statistically significant difference between any of the treatment arms. </p> </section> </section> <section id="CD007628-sec-0254"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0255"> <h6 class="title">Proportion of participants with investigator‐rated clinically significant hair regrowth</h6> <p>Based on the Investigator's Global Assessment scale, the investigators judged that 10/61 in the bimatoprost formulation A group had a moderate to greatly increased hair regrowth, 8/61 in formulation B group, 10/61 in formulation C group, and 10/61 in the minoxidil group, with no statistically significant difference between any of the groups. This is in agreement with the participants judgements. </p> </section> <section id="CD007628-sec-0256"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>In the bimatoprost formulation A group, the mean change in hair count from baseline was 0.4 (17.10 SD) in the bimatoprost formulation A group, 3.5 (18.21 SD) in formulation B group, 4.3 (16.82 SD) in the formulation C group, and 13.6 (18.72 SD) in the minoxidil group. There was a statistically significant MD for each of the comparisons bimatoprost versus minoxidil in favour of minoxidil. The MD that compared formulation A versus minoxidil was −13.20 (95% CI −19.53, to −6.87; P &lt; 0.0001). For formulation B versus minoxidil the MD was −10.10 (95% CI −16.63 to −3.57; P = 0.002), and for formulation C versus minoxidil the MD was −9.30 (95% CI −15.59 to −3.01; P = 0.004). </p> </section> <section id="CD007628-sec-0257"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0258"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0259"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>The mean change from baseline in target area hair width was 0.13 (1.198 SD) mm/cm² in the bimatoprost formulation A group, 0.19 (1.067 SD) mm/cm² in group B, 0.30 (1.263 SD) mm/cm² in group C, and 0.87 (1.315 SD) mm/cm² in the minoxidil group. There was a statistically significant difference in favour of minoxidil in all comparisons. The MD of bimatoprost formulation A versus minoxidil was −0.74 (95% CI −1.18 to −0.30; P = 0.001), bimatoprost formulation B versus minoxidil MD −0.68 (95% CI −1.10 to −0.26; P = 0.002), and formulation C versus minoxidil MD −0.57 (95% CI −1.01 to −0.13; P = 0.01). </p> </section> </section> </section> <section id="CD007628-sec-0260"> <h4 class="title">16. Cyproterone versus flutamide versus finasteride</h4> <p>One study that included 36 participants examined these comparisons (<a href="./references#CD007628-bbs2-0004" title="CarminaE , LoboRA . Treatment of hyperandrogenic alopecia in women. Fertility and Sterility2003;79(1):91‐5. [PUBMED: 12524069] ">Carmina 2003</a>), but we assessed it as at high risk of bias. The investigators reported that flutamide at a dose of 250 mg daily provided a modest improvement in alopecia after one year, whereas cyproterone acetate 50 mg and finasteride 5 mg were not considered effective. </p> <section id="CD007628-sec-0261"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0262"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>Hair regrowth was participant‐assessed with a standardised questionnaire (<a href="./references#CD007628-bbs2-0109" title="BarberBL , KaufmanKD , KozloffRC , GirmanCJ , GuessHA . A hair growth questionnaire for use in the evaluation of therapeutic effects in men. Journal of Dermatological Treatment1998;9(3):181‐6. [EMBASE: 1998346166] ">Barber 1998</a>). Two of 12 participants in the cyproterone group reported improvement in hair growth compared to 3/12 in the flutamide group and 1/12 in the finasteride group. </p> </section> <section id="CD007628-sec-0263"> <h6 class="title">Change in QoL</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0264"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>No adverse events were reported for these comparisons; however, in the flutamide group, 2/12 participants had a slight increase in liver enzymes, which is considered to be a common side‐effect of this intervention. </p> </section> </section> <section id="CD007628-sec-0265"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0266"> <h6 class="title">Proportion of participants with investigator‐rated clinically significant hair regrowth</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0267"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0268"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>In the flutamide group, 8/12 participants reported an improvement in slowing down of hair loss versus 3/12 in the cyproterone acetate group and 1/12 in the finasteride group. </p> </section> <section id="CD007628-sec-0269"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>Improvement of hair appearance was reported by 3/12 participants in the flutamide group compared to 1/12 in the cyproterone acetate and none in the finasteride group. The flutamide participants were also more satisfied with their therapy (5/12) versus 3/12 in the cyproterone acetate and the finasteride group (1/12). </p> </section> <section id="CD007628-sec-0270"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>Baseline to end of study hair density was investigator‐assessed on a seven‐point scale (−3 = greatly decreased to 3 = greatly increased). In the cyproterone group, this scale was rated after 12 months as 0.5 (0.2 SD) in the flutamide group 0.9 (0.2 SD) and in the finasteride group 0.1 (0.2 SD). </p> </section> </section> </section> <section id="CD007628-sec-0271"> <h4 class="title">17. Finasteride (1 mg) versus placebo</h4> <p>Three studies examined this comparison (<a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a>; <a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a>; <a href="./references#CD007628-bbs2-0047" title="WhitingDA , WaldstreicherJ , SanchezM , KaufmanKD . Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women. Journal of Investigative Dermatology. Symposium Proceedings1999;4(3):282‐4. [PUBMED: 10674382] ">Whiting 1999</a>). We assessed <a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a> as at low risk of bias, <a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a> at unclear risk of bias, and <a href="./references#CD007628-bbs2-0047" title="WhitingDA , WaldstreicherJ , SanchezM , KaufmanKD . Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women. Journal of Investigative Dermatology. Symposium Proceedings1999;4(3):282‐4. [PUBMED: 10674382] ">Whiting 1999</a> at high risk of bias. See also 'Summary of findings' table 3 (<a href="./full#CD007628-tbl-0003">summary of findings Table 3</a>). </p> <section id="CD007628-sec-0272"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0273"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>Participant‐ and investigator‐rated assessments in <a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a> were largely in agreement that finasteride was no more effective than placebo. In the finasteride group, 30/67 participants considered themselves improved versus 33/70 in the placebo group (RR 0.95, 95% CI 0.66 to 1.37; one trial, 137 participants). <a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a> and <a href="./references#CD007628-bbs2-0047" title="WhitingDA , WaldstreicherJ , SanchezM , KaufmanKD . Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women. Journal of Investigative Dermatology. Symposium Proceedings1999;4(3):282‐4. [PUBMED: 10674382] ">Whiting 1999</a> did not assess this outcome. </p> </section> <section id="CD007628-sec-0274"> <h6 class="title">Change in QoL</h6> <p>None of the studies assessed this outcome.</p> </section> <section id="CD007628-sec-0275"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>Both groups in <a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a> reported a similar number of adverse events: 53/67 in the finasteride group versus 55/70 in the placebo group (RR 1.03, 95% CI 0.45 to 2.34; one trial, 137 participants). Several of the adverse events reported in this study are common in postmenopausal women and are not necessarily drug‐related. The placebo group reported more adverse events, such as headache and depression. <a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a> and <a href="./references#CD007628-bbs2-0047" title="WhitingDA , WaldstreicherJ , SanchezM , KaufmanKD . Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women. Journal of Investigative Dermatology. Symposium Proceedings1999;4(3):282‐4. [PUBMED: 10674382] ">Whiting 1999</a> did not assess this outcome. </p> </section> </section> <section id="CD007628-sec-0276"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0277"> <h6 class="title">Proportion of participants with investigator‐rated clinically significant hair regrowth</h6> <p>Only one study provided data for this outcome (<a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a>). The investigators reported that 10/67 participants in the finasteride group showed a moderate increase versus 13/70 in the placebo group, which included one participant with a greatly increased change in hair growth (RR 0.77, 95% CI 0.31 to 1.90; one trial, 137 participants). <a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a> and <a href="./references#CD007628-bbs2-0047" title="WhitingDA , WaldstreicherJ , SanchezM , KaufmanKD . Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women. Journal of Investigative Dermatology. Symposium Proceedings1999;4(3):282‐4. [PUBMED: 10674382] ">Whiting 1999</a> did not assess this outcome. </p> </section> <section id="CD007628-sec-0278"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>At 12 months, both treatment groups in <a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a> (data on 125 participants for this outcome) demonstrated a similar degree of hair loss by hair count, with a mean decrease from baseline in hair count of 8.7 hairs in the finasteride group versus 6.6 in the placebo group, but no SDs were reported. Individual patient data were provided in <a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a> for two different hair counts. The mean increase from baseline in hair count 1 was 17.86 hairs/cm², and 11.86 hairs/cm² in hair count 2 for seven participants on finasteride, and one hair, and ‐4.4 hairs for the two hair counts for the five participants on placebo. In <a href="./references#CD007628-bbs2-0047" title="WhitingDA , WaldstreicherJ , SanchezM , KaufmanKD . Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women. Journal of Investigative Dermatology. Symposium Proceedings1999;4(3):282‐4. [PUBMED: 10674382] ">Whiting 1999</a>, there was an increase of 0.2 (0.9 SD) in change from baseline in total hair count of terminal hairs in the finasteride group (44 participants) versus 1.1 (0.9 SD) in the placebo group (50 participants) (MD −0.90, 95% CI −1.2 to −0.54; P &lt; 0.00001), which was in favour of placebo. However, the difference of one hair in a 4 mm punch biopsy is not clinically important. </p> </section> <section id="CD007628-sec-0279"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>Although the investigators in <a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a> provided no data, they reported that there was no statistically significant difference in the slowing down of hair loss between the two groups at the end of the study. The other two studies did not assess this outcome. </p> </section> <section id="CD007628-sec-0280"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>Twelve out of 67 participants on finasteride were satisfied with their hair overall compared to 16/70 in the placebo group (RR 0.78, 95% CI 0.40 to 1.53; one trial, 137 participants), which was not a statistically significant difference (<a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a>). The other two studies did not assess this outcome. </p> </section> <section id="CD007628-sec-0281"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g thickness)</h6> <p>The studies did not assess this outcome</p> </section> </section> </section> <section id="CD007628-sec-0282"> <h4 class="title">18. Nutritional supplement versus no supplement</h4> <p>One study, which we assessed as at high risk of bias and included 120 participants, investigated the efficacy of a nutritional supplement that contained 460 mg fish oil, 460 mg black currant seed oil, 5 mg vitamin E, 30 mg vitamin C, and 1 mg lycopene versus no supplement during six months (<a href="./references#CD007628-bbs2-0020" title="LeFloc'hC , ChenitiA , ConnétableS , PiccardiN , VincenziC , TostiA . Effect of a nutritional supplement on hair loss in women. Journal of Cosmetic Dermatology2015;14(1):76‐82. [PUBMED: 25573272] ">Le Floc'h 2015</a>). </p> <section id="CD007628-sec-0283"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0284"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>Only data were reported for the group that received the supplement and 69/80 participants reported a moderate to large increase in hair density, and the investigators reported P &lt; 0.001. These data would suggest a huge beneficial effect for the supplement. However, these numbers are unusable without the data from the comparator group. As we were unable to retrieve these from the investigators, they cannot be further analysed. </p> </section> <section id="CD007628-sec-0285"> <h6 class="title">Change in QoL</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0286"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>There were no adverse events reported in either group.</p> </section> </section> <section id="CD007628-sec-0287"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0288"> <h6 class="title">Participants with investigator‐rated clinically significant hair regrowth</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0289"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0290"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>Hair loss according to the self‐assessments of the participants decreased in 71/80 women in the supplement group compared to 27/40 in the group that received no treatment (RR 1.31, 95% CI 1.05 to 1.65; one trial, 120 participants; P = 0.02) in favour of the supplement group. </p> </section> <section id="CD007628-sec-0291"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>Data were only reported for the supplement group, which indicated that 68/80 women were satisfied, but data for the untreated group were missing. </p> </section> <section id="CD007628-sec-0292"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>The study assessed hair density on a seven‐point Likert scale, rated from −3 to 3, and showed that 22 women had a moderate increase in hair density and just one patient in the supplement group experienced a "great increase" versus no improvement at all in the 'no‐treatment' group (RR 23.79, 95% CI 1.48 to 381.88; one trial, 120 participants; P = 0.03). </p> </section> </section> </section> <section id="CD007628-sec-0293"> <h4 class="title">19. Low level laser comb versus sham device</h4> <p>Two studies evaluated laser combs versus sham device therapy for three times a week for 12 minutes for a period of 26 weeks. <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a> (78 participants) used a nine‐beam laser comb, and <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a> (63 participants) used a dual 12‐beam laser comb. We assessed the studies as at high risk and unclear risk of bias, respectively. Although there appeared to be a statistically significant difference in the increase in hair count, this was not reflected in the participant assessments. See 'Summary of findings' table 4 (<a href="./full#CD007628-tbl-0004">summary of findings Table 4</a>). </p> <section id="CD007628-sec-0294"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0295"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>Both studies combined the data that reported minimally improved and improved hair regrowth, and therefore we cannot be certain to what extent participants considered these improvements to be clinically relevant. In <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a> 36/53 in the nine‐beam laser comb group reported minimal improvement of their hair loss versus 11/25 in the sham device group (RR 1.54, 95% CI 0.96 to 2.49; one trial, 78 participants). In <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a> 26/42 participants in the 12‐beam laser comb group considered their hair loss minimally improved or improved versus 11/21 in the sham device group (RR 1.18, 95% CI 0.74 to 1.89, one trial, 63 participants). </p> </section> <section id="CD007628-sec-0296"> <h6 class="title">Change in QoL</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD007628-sec-0297"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>The report in both studies also included two studies in men. The adverse events were not addressed per study, and the investigators reported that there were "no serious adverse events in any study and laser comb‐related adverse events consisted of dry skin (5.1 %), pruritus (2.5 %), scalp tenderness (1.3 %), irritation (1.3 %), and a warm sensation at the site (1.3 %)." </p> </section> </section> <section id="CD007628-sec-0298"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0299"> <h6 class="title">Participants with investigator‐rated clinically significant hair regrowth</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD007628-sec-0300"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>The mean change from baseline in the nine‐beam laser comb group was 20.2 (11.2 SD) hairs/cm² versus 2.8 (16.5 SD) in the sham device group with a MD of 17.40 hairs/cm² (95% CI 9.74, to 25.06; P &lt; 0.00001), which is a statistically significant difference (<a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>). The data in <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a> were similar with an increase of 20.6 (11.6 SD) hairs/cm² in the 12‐beam laser comb group and 3.0 (9.3 SD) in the sham device group (MD 17.60 hairs/cm², 95% CI 11.97, to 23.23; P &lt; 0.00001). </p> </section> <section id="CD007628-sec-0301"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD007628-sec-0302"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>At 26 weeks 31/53 participants in the nine‐beam laser comb group felt there was minimally improved or improved thickness or fullness of the hair compared to 10/25 in the sham device group (RR 1.46, 95% CI 0.86 to 2.49; one trial 78 participants) (<a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>). In <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a> 24/42 in the nine‐beam laser comb group experienced minimal improvement or improvement versus 9/21 in the sham device group (RR 1.33, 95% CI 0.76 to 2.33; one trial, 63 participants). </p> </section> <section id="CD007628-sec-0303"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>The studies did not assess this outcome.</p> </section> </section> </section> <section id="CD007628-sec-0304"> <h4 class="title">20. Low level laser in bicycle‐helmet like apparatus versus sham helmet</h4> <p>One study at low risk of bias in 47 participants evaluated these interventions for 25 minutes every other day over 16 weeks (<a href="./references#CD007628-bbs2-0019" title="LanzafameRJ , BlancheRR , ChiacchieriniRP , KazmirekER , SklarJA . The growth of human scalp hair in females using visible red light laser and LED sources. Lasers in Surgery and Medicine2014;46(8):601‐7. [PUBMED: 25124964] ">Lanzafame 2014</a>). The helmet in the active treatment group contained 21, 5 mW diode lasers (655 ± 5 nm) and 30 LEDS (655 ± 20 nm), and showed that the helmet with the low level laser improved hair count. </p> <section id="CD007628-sec-0305"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0306"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0307"> <h6 class="title">Change in QoL</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0308"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>No adverse events were reported in either intervention arm.</p> </section> </section> <section id="CD007628-sec-0309"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0310"> <h6 class="title">Participants with investigator‐rated clinically significant hair regrowth</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0311"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>The mean change from baseline was 100.3 hairs per 2.85 cm² (53.4 SD) in the laser helmet group versus 23.9 (30.1 SD) in the sham device group with a MD of 76.40 hairs per 2.85 cm² (95% CI 50.91 to 101.89; P &lt; 0.00001), which favours the laser helmet group </p> </section> <section id="CD007628-sec-0312"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0313"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0314"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>The study did not assess this outcome.</p> </section> </section> </section> <section id="CD007628-sec-0315"> <h4 class="title">21. Handi‐Dome laser versus incandescent red light source</h4> <p>One study in 44 women, which we assessed as at unclear risk of bias, compared these interventions which consisted of a single, 30 minute treatment, every other day over 16 weeks (<a href="./references#CD007628-bbs2-0031" title="NCT01967277 . A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy. clinicaltrials.gov/ct2/show/NCT01967277 (accessed 14 January 2016). ">NCT01967277</a>) . </p> <section id="CD007628-sec-0316"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0317"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0318"> <h6 class="title">Change in QoL</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0319"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>No adverse events were reported in either intervention arm.</p> </section> </section> <section id="CD007628-sec-0320"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0321"> <h6 class="title">Participants with investigator‐rated clinically significant hair regrowth</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0322"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>The Handi‐Dome laser group showed a larger increase in hair count than the red light group with a mean change of 89.9 (63.3 SD) in the Handi‐Dome laser group versus 18.5 (24.4 SD) in the red light group (MD 71.40, 95% CI 41.08 to 101.72; P &lt; 0.00001). </p> </section> <section id="CD007628-sec-0323"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0324"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0325"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>The study did not assess this outcome.</p> </section> </section> </section> <section id="CD007628-sec-0326"> <h4 class="title">22. Pulsed electrostatic field versus sham</h4> <p>One poorly reported trial, which we assessed as at unclear risk of bias, provided independent patient data (IPD) for the six female participants (<a href="./references#CD007628-bbs2-0035" title="PolicarpiF , GiorginiS , FarellaV , MelliMC , CampolmiP , PanconesiE . Effects of application of a pulsed electrostatic field in male and female androgenic alopecia [Efficacia dell'applicazione di un campo elettrostatico pulsato nell'alopecia androgenetica maschile e femminile]. Annali Italiani di Dermatologia Clinica e Sperimentale1993;47(3):227‐32. [EMBASE: 1993274287] ">Policarpi 1993</a>). </p> <section id="CD007628-sec-0327"> <h5 class="title">Primary outcomes</h5> <section id="CD007628-sec-0328"> <h6 class="title">Proportion of participants with self‐rated clinically significant hair regrowth</h6> <p>Two out of four participants in the active treatment group showed a "significant improvement" at 36 weeks compared to neither of the two participants in the sham group. </p> </section> <section id="CD007628-sec-0329"> <h6 class="title">Change in QoL</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0330"> <h6 class="title">Adverse effects, safety, and tolerability</h6> <p>The study did not assess this outcome.</p> </section> </section> <section id="CD007628-sec-0331"> <h5 class="title">Secondary outcomes</h5> <section id="CD007628-sec-0332"> <h6 class="title">Proportion of participants with investigator‐rated clinically significant hair regrowth</h6> <p>The investigator‐rated assessments indicated there was no clinically "significant hair growth" observed in the participants in both treatment arms. </p> </section> <section id="CD007628-sec-0333"> <h6 class="title">Change from baseline to study conclusion in total hair count</h6> <p>The percentage change in mean hair count from baseline at 36 weeks in the active group was 2.96 in the first participant, and 16.95%, 4.67%, and 3.37% in subsequent participants. In the two participants in the sham group, the percentage change was 1.15% and 1.45%. </p> </section> <section id="CD007628-sec-0334"> <h6 class="title">Degree of hair shedding from baseline to the end of the study</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0335"> <h6 class="title">Cosmetic appearance of the hair or participant satisfaction</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD007628-sec-0336"> <h6 class="title">Change in quality (or pattern) of hair regrowth (e.g. thickness)</h6> <p>The study did not assess this outcome.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007628-sec-0337" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007628-sec-0337"></div> <section id="CD007628-sec-0338"> <h3 class="title" id="CD007628-sec-0338">Summary of main results</h3> <p>Forty‐seven studies, which examined 5290 participants, met the inclusion criteria of this Cochrane review. Only one included study assessed one of our key patient‐preferred outcomes, 'quality of life' (QoL) (<a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>). Most included studies focused on change in total (non‐vellus) hair count. However, although this may provide a quantifiable, objective, and more readily intelligible outcome, it is considered to be physician‐preferred, rather than an outcome directed towards addressing participants' preferences. Other frequently‐reported outcomes included participant‐assessed improvement of hair regrowth, as well as physician‐assessed improvement, and adverse events. Female pattern hair loss (FPHL) can be distressing, and is known to impact on QoL. Thus, the importance of assessing the efficacy of interventions targeted at improving this key outcome should not be underestimated (<a href="./references#CD007628-bbs2-0112" title="BiondoS , SinclairR . Quality of life in Australian women with female pattern hair loss. The Open Dermatology Journal2010;4:90‐4. ">Biondo 2010</a>). Pooling of data was only feasible for a limited number of the outcomes reported in the included studies and was confined to those that evaluated the efficacy of minoxidil compared to placebo and minoxidil (2%) versus minoxidil (5%). </p> <p>Based on the findings of this review, the only interventions that appeared to demonstrate a measure of efficacy were minoxidil (2% and 5% concentrations) with the quality of evidence being mainly moderate to low ('Summary of findings' table 1; 'Summary of findings' table 2). Both concentrations illustrated a good safety profile, but there is wide acknowledgement that doses in excess of 60 mg a day may lead to an increase in the number of adverse effects. Therefore, the application of 1 mL minoxidil 2% (20 mg/mL) twice daily or 1 mL minoxidil 5% (50 mg/mL) once daily should not be exceeded and the threshold is reached quicker with the 5% dosage. After discontinuation of treatment, renewed hair loss is likely to reoccur within three months and all beneficial effects will have disappeared in six months (<a href="./references#CD007628-bbs2-0143" title="OlsenEA , MessengerAG , ShapiroJ , BergfeldWF , HordinskyMK , RobertsJL , et al. Evaluation and treatment of male and female pattern hair loss. Journal of the American Academy of Dermatology2005;52(2):301‐11. [PUBMED: 15692478] ">Olsen 2005</a>; <a href="./references#CD007628-bbs2-0156" title="TorresF , TostiA . Female pattern alopecia and telogen effluvium: figuring out diffuse alopecia. Seminars in Cutaneous Medicine and Surgery2015;34(2):67‐71. [PUBMED: 26176282] ">Torres 2015</a>). </p> <p>Finasteride appeared to have a limited to no effect, but the results were inconsistent across the three studies with the quality of evidence rated low ('Summary of findings' table 3). Finasteride is not approved for use in women and has well known side effects such as libido reduction, breast tenderness, depression, and abnormalities of the external genitalia of a male foetus when used in pregnant women. Low‐level laser therapy showed an increase in total hair count, but this was not supported by both the participant‐assessments of improvement ('Summary of findings' table 4; moderate to low quality evidence). </p> <p>For further details see the 'Summary of findings' tables (<a href="./full#CD007628-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD007628-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD007628-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD007628-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD007628-sec-0339"> <h3 class="title" id="CD007628-sec-0339">Overall completeness and applicability of evidence</h3> <p>The studies included in this review, which evaluated a range of interventions, did not provide sufficient data to enable fair and reliable comparisons to be made for any one single intervention against another for a specific outcome, with the exception of minoxidil 2% and 5%, which, based on the evidence available, appeared to be safe and effective in the treatment of FPHL. </p> <p>Most interventions were evaluated in a single study, and none of the studies addressed more than a very limited number of our outcomes, which illustrates gaps in the overall completeness of the evidence. The quality of data reporting and its analysis was variable across the included studies. </p> <p>Mean change in hair count and adverse events were the most commonly addressed outcomes, followed by participant‐ and physician‐assessments of improvement of hair regrowth. However, there was a lack of consistency in the choice and assessment of other outcomes across the studies. Although it is generally acknowledged that renewed hair shedding occurs relatively soon after discontinuation of treatment, none of the studies reported data on the sustainability of the treatment effect after the end of the study, which is an outcome of some considerable importance to participants. Furthermore, none of the studies, except <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>, reported the possible impact of hair regrowth reflected by a decrease in time spent by the women on hair styling, or the use of wigs. </p> <p>We identified several ongoing studies that may eventually help to fill in some of the gaps in the evidence for the efficacy or otherwise of some of the other interventions, e.g. spironolactone, plasma rich in growth factors, and injections of autologous dermal and epidermal cells into the balding scalp (see the '<a href="./references#CD007628-sec-0379" title="">Characteristics of ongoing studies</a>' section). However, the research institute that was conducting these 10 studies on these cell injections has gone into liquidation and we were unable to access further details. </p> </section> <section id="CD007628-sec-0340"> <h3 class="title" id="CD007628-sec-0340">Quality of the evidence</h3> <section id="CD007628-sec-0341"> <h4 class="title">Limitations in study design and implementation</h4> <p>Although the study design in the included studies appeared to have been at best adequate, our study‐level assessments of the risk of bias for a number of the domains in several of these studies revealed some of the limitations in their implementation, which we have reported in the '<a href="#CD007628-sec-0091">Risk of bias in included studies</a>' section of this review. </p> <p>There was considerable variation in how well the studies were reported, and in particular the methods trials used to generate the sequence, to conceal the allocation, and the measures taken to blind investigators and participants. These factors, compounded with our unsuccessful attempts to contact many of the investigators for additional information, created difficulties in making accurate assessments of the risk of bias in more than 60% of the included studies. </p> <p>In many instances, the key outcomes assessed in the included studies provided limited data, much of which we could not pool except for minoxidil 2% and 5%, and, consequently, did not allow any wider assessment or comparison of the effects of the interventions across the studies. </p> </section> <section id="CD007628-sec-0342"> <h4 class="title">Indirectness of the evidence</h4> <p>The participants in the included studies were, in general, a clinically representative sample matching the inclusion criteria; therefore, we did not have any significant concerns about the appropriateness of participants identified in the review (see the '<a href="./references#CD007628-sec-0376" title="">Characteristics of included studies</a>' section). </p> <p>Twenty‐nine of the 47 studies included in this review were placebo‐controlled trials, which may only provide limited evidence on the advantages or disadvantages of new relative to existing interventions. Physicians need to have access to information about the benefits and harms of individual treatments, as well as the comparative efficacy of these interventions, and direct comparison trials are more likely to provide additional evidence that is both relevant and direct. </p> <p>Patient‐reported outcomes (PROs) are a prerequisite for informing evidence‐based decision‐making, but the importance of PROs — specifically those used in evaluating the impact of interventions on QoL and which are of direct relevance to patients — appears to have been underestimated by the investigators in most included studies. A validated disease‐specific tool for the assessment of QoL in women with FPHL (<a href="./references#CD007628-bbs2-0120" title="DolteKS , GirmanCJ , HartmaierS , RobertsJ , BergfeldW , WaldstreicherJ . Development of a health‐related quality of life questionnaire for women with androgenetic alopecia. Clinical and Experimental Dermatology2000;25(8):637‐42. [PUBMED: 11167980] ">Dolte 2000</a>) has been available for many years, yet none of the included studies appear to have recognised its value as a reliable instrument that can be used for assessment of this crucially important outcome. The one study that evaluated the impact of the interventions on QoL utilised a simple questionnaire (<a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a>), and, as with most of the PROs assessed in the included studies, this did not satisfy some of the more fundamental criteria provided in the 'checklist for describing and assessing PROs in clinical trials' (see <a href="#CD007628-tbl-0007">Table 3</a>).  </p> </section> <section id="CD007628-sec-0343"> <h4 class="title">Inconsistency of the results</h4> <p>The low number of studies investigating similar interventions, with the exception of minoxidil versus placebo, and minoxidil (2%) versus minoxidil (5%) did not permit pooling of data for most of the comparisons. Therefore, any inferences about the inconsistency of the results could only be drawn from these comparisons. We investigated the heterogeneity between the studies for these comparisons and report these in the <a href="#CD007628-sec-0099">Effects of interventions</a> as well as in <a href="#CD007628-sec-0081">Sensitivity analysis</a>. sections of this review. </p> </section> <section id="CD007628-sec-0344"> <h4 class="title">Imprecision of the results</h4> <p>Of the 47 studies included in this review, nine studies provided data for the comparison of minoxidil versus placebo. We downgraded the quality of evidence for serious imprecision for three of the separate outcomes, i.e. QoL, adverse events and degree of hair shedding, due to low sample size or low occurrence of events. In the comparison minoxidil 2% versus minoxidil 5% that covered four studies, we downgraded the quality of evidence for serious imprecision for the proportion of participants with self‐rated clinically significant hair regrowth, QoL, and change from baseline to study conclusion in total hair count for having wide CIs or low sample size. In the comparison finasteride versus placebo and the comparison of low‐level laser comb versus sham device, we downgraded the quality of evidence several times for serious imprecision for not meeting the optimal information size (see the 'Summary of findings' tables; <a href="./full#CD007628-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD007628-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD007628-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD007628-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD007628-sec-0345"> <h4 class="title">Publication bias</h4> <p>Based on a visual assessment of funnel plots in each case, there was no evidence of asymmetry in <a href="./references#CD007628-fig-0007" title="">Analysis 1.1,</a><a href="./references#CD007628-fig-0008" title="">Analysis 1.2</a>, and <a href="./references#CD007628-fig-0009" title="">Analysis 1.3</a>. However, in <a href="./references#CD007628-fig-0010" title="">Analysis 1.4</a>, examination of the funnel plot (<a href="#CD007628-fig-0006">Figure 6</a>) revealed asymmetry, which was caused by the inclusion of one small study that randomised eight participants and reported extremely positive results favouring minoxidil (<a href="./references#CD007628-bbs2-0036" title="PriceVH , MenefeeE . Quantitative estimation of hair growth. I. androgenetic alopecia in women: effect of minoxidil. Journal of Investigative Dermatology1990;95(6):683‐7. [PUBMED: 2250110] ">Price 1990</a>). After we investigated the individual participant data from the study, it remained unclear if the large treatment effect was the result of publication bias, small‐study effects, or an artefact of natural variability (see Section 10.4.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, <a href="./references#CD007628-bbs2-0129" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. Chichester, UK: John Wiley &amp; Sons, Ltd. ">Higgins 2011</a>). To assess the impact of this study, we performed a sensitivity analysis, which, after exclusion of the study, resulted in little change to the overall treatment effect (see <a href="./references#CD007628-fig-0011" title="">Analysis 1.5</a>). </p> </section> </section> <section id="CD007628-sec-0346"> <h3 class="title" id="CD007628-sec-0346">Potential biases in the review process</h3> <p>We made every attempt to limit bias in the review process by ensuring a comprehensive search for potentially eligible studies. The review authors' independent assessments of eligibility of studies for inclusion in this review and extraction of data minimised the potential for additional bias beyond that detailed in the '<a href="#CD007628-sec-0091">Risk of bias in included studies</a>' tables. The incompleteness of some of the reports and our inability to obtain clarification of certain trial details or to resolve ambiguities in the reports may have contributed to some bias in their assessment, but, where these conditions applied, we explicitly stated this in the review text. The effects of language bias on the identification and selection of studies for inclusion in a systematic review is widely recognised; therefore, we ensured that any studies not in the English language were translated so that we could assess them for eligibility. </p> </section> <section id="CD007628-sec-0347"> <h3 class="title" id="CD007628-sec-0347">Agreements and disagreements with other studies or reviews</h3> <p>We retrieved one systematic review, <a href="./references#CD007628-bbs2-0128" title="HassaniM , GorouhiF , BabakoohiS , Moghadam‐KiaS , FiroozA . Treatment of female pattern hair loss. Skinmed2012;10(4):218‐27. [PUBMED: 23008939] ">Hassani 2012</a>, which although published in 2012 only searched up to August 2008, excluded studies with small sample size and studies not in the English language, and did not reflect the extent of our current up‐to‐date searches. The review also lacked methodological rigour i.e. did not report prespecified outcomes, included an incomplete 'Risk of bias' assessment, and lacked a rating of the quality of the evidence. </p> <p>We also identified several literature reviews (<a href="./references#CD007628-bbs2-0108" title="AvciP , GuptaGK , ClarkJ , WikonkalN , HamblinMR . Low‐level laser (light) therapy (LLLT) for treatment of hair loss. Lasers in Surgery and Medicine2014;46(2):144‐51. [PUBMED: 23970445] ">Avci 2013</a>; <a href="./references#CD007628-bbs2-0113" title="BirchMP , LallaSC , MessengerAG . Female pattern hair loss. Clinical and Experimental Dermatology2002;27(5):383‐8. [PUBMED: 12190638] ">Birch 2002</a>; <a href="./references#CD007628-bbs2-0117" title="Camacho‐MartínezFM . Hair loss in women. Seminars in Cutaneous Medicine and Surgery2009;28(1):19‐32. [PUBMED: 19341939] ">Camacho‐Martínez 2009</a>; <a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>; <a href="./references#CD007628-bbs2-0134" title="LeavittM . Understanding and management of female pattern alopecia. Facial Plastic Surgery2008;24(4):414‐27. [PUBMED: 19034818] ">Leavitt 2008</a>; <a href="./references#CD007628-bbs2-0143" title="OlsenEA , MessengerAG , ShapiroJ , BergfeldWF , HordinskyMK , RobertsJL , et al. Evaluation and treatment of male and female pattern hair loss. Journal of the American Academy of Dermatology2005;52(2):301‐11. [PUBMED: 15692478] ">Olsen 2005</a>; <a href="./references#CD007628-bbs2-0146" title="PriceVH . Androgenetic alopecia in women. Journal of Investigative Dermatology. Symposium Proceedings2003;8(1):24‐7. [PUBMED: 12894991 ] ">Price 2003</a>; <a href="./references#CD007628-bbs2-0160" title="TrüebRM . Systematic approach to hair loss in women [Systematisches Vorgehen bei Frauen mit Haarausfall]. Journal der Deutschen Dermatologischen Gesellschaft2010;8(4):284‐97. [PUBMED: 20105246] ">Trüeb 2010</a>; <a href="./references#CD007628-bbs2-0163" title="VarothaiS , BergfeldWF . Androgenetic alopecia: an evidence‐based treatment update. American Journal of Clinical Dermatology2014;15(3):217‐30. [PUBMED: 24848508] ">Varothai 2014</a>) and three guidelines (<a href="./references#CD007628-bbs2-0115" title="BlumeyerA , TostiA , MessengerA , ReygagneP , delMarmolV , SpulsPI , et al. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men. Journal of the German Society of Dermatology2011;9(Suppl 6):S1‐57. [PUBMED: 21980982] ">Blumeyer 2011</a>; <a href="./references#CD007628-bbs2-0121" title="DrakeLA , DinehartSM , FarmerER , GoltzRW , GrahamGF , HordinskyMK , et al. Guidelines of care for androgenetic alopecia. American Academy of Dermatology. Journal of the American Academy of Dermatology1996;35(3 Pt 1):465‐9. [PUBMED: 8784287] ">Drake 1996</a>; <a href="./references#CD007628-bbs2-0135" title="LeeWS , LeeHJ , ChoiGS , CheongWK , ChowSK , GabrielMT , et al. Guidelines for management of androgenetic alopecia based on BASP classification‐‐the Asian Consensus Committee guideline. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2013;27(8):1026‐34. [PUBMED: 23176122] ">Lee 2013b</a>) that covered aspects of the diagnosis and management of FPHL in women. Although the reviews were a valuable resource to answer background questions covering the pathogenesis, classification, and epidemiology of the condition, none included a systematic search of the literature, nor a critical appraisal of the studies cited as references in support of the various treatment options described. The two guidelines provided comprehensive clinical recommendations on the effectiveness of a range of interventions for both men and women. However, to ensure that a guideline provides balanced information on the benefits and limitations of the therapeutic interventions being evaluated, its process of development should be transparent, robust, and reproducible; it should also clearly demonstrate that the supporting evidence was systematically reviewed (<a href="./references#CD007628-bbs2-0141" title="NasserM , FedorowiczZ . Grading the quality of evidence and strength of recommendations: the GRADE approach to improving dental clinical guidelines. Journal of Applied Oral Science2011;19(1):pii: S1678‐77572011000100001. [PUBMED: 21437460] ">Nasser 2011</a>). </p> <p>The earlier of the three guidelines, <a href="./references#CD007628-bbs2-0121" title="DrakeLA , DinehartSM , FarmerER , GoltzRW , GrahamGF , HordinskyMK , et al. Guidelines of care for androgenetic alopecia. American Academy of Dermatology. Journal of the American Academy of Dermatology1996;35(3 Pt 1):465‐9. [PUBMED: 8784287] ">Drake 1996</a>, which was produced by the American Academy of Dermatology's Guidelines/Outcomes Committee, lacked transparency and reproducibility, in that it did not report on the methodological approach used by its developers but only that the guideline reflected the "best data available at the time the report was prepared". However, the developers wisely cautioned that "the results of future studies may require alteration of its conclusions and recommendations." </p> <p>The guideline by <a href="./references#CD007628-bbs2-0135" title="LeeWS , LeeHJ , ChoiGS , CheongWK , ChowSK , GabrielMT , et al. Guidelines for management of androgenetic alopecia based on BASP classification‐‐the Asian Consensus Committee guideline. Journal of the European Academy of Dermatology &amp; Venereology : JEADV2013;27(8):1026‐34. [PUBMED: 23176122] ">Lee 2013b</a> targeted Asian participants, both male and female, and provided little to no detail of how the evidence was gathered and summarized, and no indication of how the recommendations made were based on the evidence. </p> <p>The 'Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men' (<a href="./references#CD007628-bbs2-0115" title="BlumeyerA , TostiA , MessengerA , ReygagneP , delMarmolV , SpulsPI , et al. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men. Journal of the German Society of Dermatology2011;9(Suppl 6):S1‐57. [PUBMED: 21980982] ">Blumeyer 2011</a>) was commissioned by the European Dermatology Forum to evaluate the "efficacy of the currently available therapeutic options". Although its development relied heavily on a formal consensus process negotiated between members of the guideline group and was therefore deemed reasonably transparent, we are in disagreement over the robustness of the methodological approach used in its development. Lack of clarity in the process, and ultimately its reproducibility, was illustrated by the incomplete reporting of some important steps taken in study assessment, handling of missing trial data, analysis and interpretation of results, and summary of the adverse events. </p> <p>We recognise an important area of discord with the method of grading of evidence for this guideline, which was based on study design and "summarised in a level of evidence" that combined the study design with a quality measure described by the developers as "mainly consistent results". However, these consistencies or inconsistencies, or indeed how they were defined or assessed in any of the individual studies, were unreported. It remains unclear if these factors were a potential source of bias, because, unlike in our systematic review, no 'Risk of bias' assessments were undertaken and the guideline developers did not report anything. Critically, four of the key studies underpinning the guideline recommendations for minoxidil were graded as "A₂ evidence resulting in an evidence level 1", which was inconsistent with our judgment that they were all categorised as at high risk of bias. A further seven studies were graded as B level evidence ("randomised, clinical studies of lesser quality"), but these quality criteria were also not clearly reported. Also, from the rather limited detail provided by the developers, a number of these assessments were not in agreement with the 'Risk of bias' assessments performed in this Cochrane review (see the '<a href="#CD007628-sec-0071">Assessment of risk of bias in included studies</a>' section). </p> <p>In making their study level assessments of evidence, the guideline developers also did not appear to have taken into consideration the conceptual differences between methodological quality and reporting quality. Thus, the "level of evidence" in the guidelines was based solely on the methodological quality of the individual trial as reported, with no clear indication if the developers had attempted to contact investigators to clarify missing trial details and data, which would have enabled more robust and exhaustive 'Risk of bias' assessments to be carried out. </p> <p>We specifically question and are at variance with the guideline developers' decision to summarise studies that combine data from men and women and narratively describe the treatment efficacy directed towards women. More importantly, we draw attention to the data analysis for the efficacy of minoxidil that included only the participants within the active treatment arms, ignorant of any placebo effect, which we have demonstrated can be considerable and is a further point of disagreement with our review. The, possibly unintentional, effect of this (as reported in the guideline) is an implied superiority in efficacy of the minoxidil (2% and 5%) concentrations compared to minoxidil (1%). However, in our systematic review, after accounting for the placebo participants in the analysis, the study that evaluated minoxidil (1%) (<a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a>) provided results that were the fourth largest treatment effect out of the eight included studies in <a href="./references#CD007628-fig-0010" title="">Analysis 1.4</a> and, similarly, in <a href="./references#CD007628-fig-0009" title="">Analysis 1.3</a>. Notably, whilst the guideline provided a narrative synthesis of the data, the conclusions in this Cochrane review are inferences derived from a systematic and evidence‐based approach. </p> <p>In this systematic review, a closer examination of the primary research clearly indicated that the lower concentration of minoxidil was well‐tolerated and without the adverse events associated with the higher concentration (<a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a>). Benefits and harms are equally important for decision‐making; thus, we noted the rather limited emphasis placed on the discussion of harms in the S3 guideline, in which the adverse events were only reported in a generic narrative as "instruction for use/practicability", lacked a structured analysis, and was in sharp contrast with the more detailed exploration undertaken in this review. </p> <p>The strength of clinical recommendations in the S3 guideline was based on the level of evidence and a number of other factors, none of which were clearly defined, nor appeared to correspond to the widely‐recognised GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to developing and presenting recommendations for management of patients (<a href="./references#CD007628-bbs2-0126" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE; an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [PUBMED: 18436948] ">Guyatt 2008</a>). In contrast, we used this method in this review to examine and categorise the quality level of a body of evidence. </p> <p>Therefore, whilst we concur with the general conclusions reached in both guidelines in terms of direction of treatment effect, we express a level of disagreement with the magnitude, and, more specifically, as reported in the S3 guideline, where it underpins the relevant clinical recommendations for minoxidil. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007628-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/urn:x-wiley:14651858:media:CD007628:CD007628-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_t/tCD007628-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Stage 1 on Ludwig scale (mild female pattern hair loss). Copyright © 2011 Department of Dermatology, Leiden University Medical Centre: reproduced with permission." data-id="CD007628-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Stage 1 on Ludwig scale (mild female pattern hair loss). Copyright © 2011 Department of Dermatology, Leiden University Medical Centre: reproduced with permission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007628-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/urn:x-wiley:14651858:media:CD007628:CD007628-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_t/tCD007628-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Stage 3 on Ludwig scale (severe female pattern hair loss). Copyright © 2011 Department of Dermatology, Leiden University Medical Centre: reproduced with permission." data-id="CD007628-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Stage 3 on Ludwig scale (severe female pattern hair loss). Copyright © 2011 Department of Dermatology, Leiden University Medical Centre: reproduced with permission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007628-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/urn:x-wiley:14651858:media:CD007628:CD007628-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_t/tCD007628-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD007628-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007628-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/urn:x-wiley:14651858:media:CD007628:CD007628-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_t/tCD007628-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD007628-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007628-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/urn:x-wiley:14651858:media:CD007628:CD007628-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_t/tCD007628-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD007628-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007628-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/urn:x-wiley:14651858:media:CD007628:CD007628-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_t/tCD007628-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Minoxidil versus placebo, outcome: 1.4 Mean increase in total hair count from baseline." data-id="CD007628-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Minoxidil versus placebo, outcome: 1.4 Mean increase in total hair count from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007628-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/urn:x-wiley:14651858:media:CD007628:CD007628-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_t/tCD007628-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Minoxidil versus placebo, Outcome 1 Proportion of participants with self‐rated at least moderate hair regrowth." data-id="CD007628-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Minoxidil versus placebo, Outcome 1 Proportion of participants with self‐rated at least moderate hair regrowth. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/references#CD007628-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007628-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/urn:x-wiley:14651858:media:CD007628:CD007628-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_t/tCD007628-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Minoxidil versus placebo, Outcome 2 Proportion of participants with adverse events." data-id="CD007628-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Minoxidil versus placebo, Outcome 2 Proportion of participants with adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/references#CD007628-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007628-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/urn:x-wiley:14651858:media:CD007628:CD007628-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_t/tCD007628-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Minoxidil versus placebo, Outcome 3 Proportion of participants with investigator‐rated at least moderate hair regrowth." data-id="CD007628-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Minoxidil versus placebo, Outcome 3 Proportion of participants with investigator‐rated at least moderate hair regrowth. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/references#CD007628-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007628-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/urn:x-wiley:14651858:media:CD007628:CD007628-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_t/tCD007628-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Minoxidil versus placebo, Outcome 4 Mean increase in total hair count from baseline." data-id="CD007628-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Minoxidil versus placebo, Outcome 4 Mean increase in total hair count from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/references#CD007628-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007628-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/urn:x-wiley:14651858:media:CD007628:CD007628-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_t/tCD007628-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Minoxidil versus placebo, Outcome 5 Mean increase in total hair count from baseline (sensitivity analysis)." data-id="CD007628-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Minoxidil versus placebo, Outcome 5 Mean increase in total hair count from baseline (sensitivity analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/references#CD007628-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007628-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/urn:x-wiley:14651858:media:CD007628:CD007628-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_t/tCD007628-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Minoxidil 2% versus minoxidil 5%, Outcome 1 Number of adverse events." data-id="CD007628-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Minoxidil 2% versus minoxidil 5%, Outcome 1 Number of adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/references#CD007628-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007628-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/urn:x-wiley:14651858:media:CD007628:CD007628-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_t/tCD007628-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Minoxidil 2% versus minoxidil 5%, Outcome 2 Number of adverse events (sensitivity analysis)." data-id="CD007628-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Minoxidil 2% versus minoxidil 5%, Outcome 2 Number of adverse events (sensitivity analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/references#CD007628-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007628-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/urn:x-wiley:14651858:media:CD007628:CD007628-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_t/tCD007628-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Minoxidil 2% versus minoxidil 5%, Outcome 3 Mean increase in total hair count from baseline." data-id="CD007628-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Minoxidil 2% versus minoxidil 5%, Outcome 3 Mean increase in total hair count from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/references#CD007628-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/media/CDSR/CD007628/image_n/nCD007628-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD007628-tbl-0010"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Research recommendations based on a gap in the evidence of the effects of interventions for female pattern hair loss (FPHL)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Core elements</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Issues to consider</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Status of research for this review</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evidence (E)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>What is the current state of the evidence?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This systematic review included 47 RCTs. There is mainly moderate to low quality evidence for the efficacy and safety of topical minoxidil 2% and 5% in the treatment of FPHL. </p> <p>Minoxidil (2%) topical solution twice daily appears to be effective and safe, and minoxidil (5%) used once daily may be as effective as minoxidil (2%) used twice daily, which may result in improved adherence. However, the higher concentration (5%) of minoxidil is only registered for the therapeutic management of FPHL in a small number of countries around the world. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Population (P)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosis, disease stage, comorbidity, risk factors, gender, age, ethnic group, specific inclusion or exclusion criteria, clinical setting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The participants should be aged 18 to 89 years.</p> <p>A distinction between women with and without a hyperandrogenic profile should be made, and between ethnic groups as well as pre‐ and postmenopausal women. </p> <p><b>Inclusion criteria </b> </p> <p> <ul id="CD007628-list-0010"> <li> <p>Women with FPHL Ludwig (3‐point) classification (<a href="./references#CD007628-bbs2-0137" title="LudwigE . Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. British Journal of Dermatology1977;97(3):247‐54. [PUBMED: 921894] ">Ludwig 1977</a>) or the Sinclair (5‐point) scale (<a href="./references#CD007628-bbs2-0153" title="SinclairR , JolleyD , MallariR , MageeJ . The reliability of horizontally sectioned scalp biopsies in the diagnosis of chronic diffuse telogen hair loss in women. Journal of the American Academy of Dermatology2004;51(2):189‐99. [PUBMED: 15280836] ">Sinclair 2004</a>). </p> </li> </ul> </p> <p><b>Exclusion criteria </b> </p> <p> <ul id="CD007628-list-0011"> <li> <p>Local scalp treatments in prior 4 weeks.</p> </li> <li> <p>Systemic treatment three months prior to study that could interfere with the study medications. </p> </li> <li> <p>Chemotherapy, radiation therapy, or laser therapy (on the scalp) within the last 6 months. </p> </li> <li> <p>Concomitant medication for treatment of hair loss.</p> </li> <li> <p>Pregnant or lactating women.</p> </li> <li> <p>Hyper‐ or hypothyroidism.</p> </li> <li> <p>Malnutrition.</p> </li> <li> <p>Liver, renal, or metabolic disease.</p> </li> <li> <p>Wearing a wig or having had a hair transplant.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type, frequency, dose, duration, prognostic factor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study duration should be at least 6 months.</p> <p>High‐quality, well‐designed, and rigorously‐reported studies of other widely used treatments, e.g. spironolactone, finasteride (at different dosages), dutasteride, cyproterone acetate, and laser‐based therapy should be included. </p> <p>Information on direct and indirect costs of the interventions should be addressed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparison (C)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Type, frequency, dose, duration, prognostic factor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Direct comparison studies of the widely used treatments are warranted.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome (O)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Which clinical or patient‐related outcomes will the researcher need to measure, improve, influence, or accomplish? Which methods of </p> <p>measurement should be used?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant's assessment of the treatment efficacy and changes in quality of life using standardised questionnaires, e.g. the Women's Androgenetic Alopecia Quality of Life Questionnaire (WAA‐QOL) (<a href="./references#CD007628-bbs2-0112" title="BiondoS , SinclairR . Quality of life in Australian women with female pattern hair loss. The Open Dermatology Journal2010;4:90‐4. ">Biondo 2010</a>; <a href="./references#CD007628-bbs2-0120" title="DolteKS , GirmanCJ , HartmaierS , RobertsJ , BergfeldW , WaldstreicherJ . Development of a health‐related quality of life questionnaire for women with androgenetic alopecia. Clinical and Experimental Dermatology2000;25(8):637‐42. [PUBMED: 11167980] ">Dolte 2000</a>). Standardised and uniform scales should be developed and used for physicians' assessments, and these should reliably reflect proportion of participants with investigator‐rated clinically significant hair regrowth and mean change in total hair count from baseline to the end of the study. Studies should address the sustainability of hair regrowth after discontinuation of treatment. An important patient‐reported outcome should be the impact of the hair regrowth reflected by the time spent by women with FPHL on hair styling, including the use of wigs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time stamp (T)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Date of literature search or recommendation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 July 2015</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study type</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>What is the most appropriate study design to address the proposed question?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD007628-list-0012"> <li> <p>Randomised controlled trial (adequately powered/multicentred).</p> </li> <li> <p>Methods: concealment of allocation sequence.</p> </li> <li> <p>Blinding: participants, trialists, outcomes assessors, data analysts.</p> </li> <li> <p>Setting: hospital/university or general practice with adequate follow‐up.</p> </li> </ul> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Abbreviations: FPHL: female pattern hair loss.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Research recommendations based on a gap in the evidence of the effects of interventions for female pattern hair loss (FPHL)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007628-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Minoxidil versus placebo</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Minoxidil (1%, 2% and 5%) compared to placebo for female pattern hair loss (FPHL)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with FPHL<br/> <b>Intervention:</b> minoxidil (1%, 2% and 5%)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with minoxidil</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>The proportion of participants with self‐rated clinically significant hair regrowth at the end of the study</b> <br/> Assessed with: 3 to 7 point Likert scales<br/> Follow‐up: range 24 weeks to 32 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.93</b> <br/> (1.51 to 2.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1148<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26.5% versus 13.9% experienced moderate to marked hair regrowth</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>139 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>268 per 1000</b> <br/> (209 to 343) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b> <br/> Assessed with: VAS, 0 = negative, 50 = neutral and 100 = positive<br/> Scale from: 0 to 100 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard deviations (SDs) were missing, therefore we could not calculate mean difference (MD). The VAS score was 54.4 for 5% minoxidil, 52.1 for 2% minoxidil, and 46.5 for placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.24</b> <br/> (0.82 to 1.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>727<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>These are the data for the minoxidil 2% versus placebo. The RR for minoxidil 1% versus placebo was 1.12 (95% CI 0.61 to 2.06) and for minoxidil 5% versus placebo 2.05 (95% CI 0.96 to 4.37) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>88 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>109 per 1000</b> <br/> (72 to 164) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of participants with investigator‐rated clinically significant hair regrowth at the end of the study</b> <br/> Assessed with: 4 to 7 point Likert scales<br/> Follow‐up: range 24 weeks to 32 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.35</b> <br/> (1.68 to 3.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1181<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>18.4% versus 7.7% had at least moderate hair regrowth</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>181 per 1000</b> <br/> (129 to 253) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in total hair count</b> <br/> Follow‐up: range 24 weeks to 32 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in total hair count ranged from <b>−3.25 to 20.4 hairs/cm</b>² </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in total hair count in the intervention group was <b>13.18 hairs/cm</b> ²<b>higher</b> (10.92 higher to 15.44 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1242<br/> (8 RCTs)<sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The impact of excluding <a href="./references#CD007628-bbs2-0036" title="PriceVH , MenefeeE . Quantitative estimation of hair growth. I. androgenetic alopecia in women: effect of minoxidil. Journal of Investigative Dermatology1990;95(6):683‐7. [PUBMED: 2250110] ">Price 1990</a> from this analysis had a marginal effect on the overall pooled result (RR 12.96, 95% 10.69 to 15.24) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Degree of hair shedding from baseline to the end of the study</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>380<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> very low<sup>10,11,12</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD007628-bbs2-0034" title="Pazoki‐ToroudiH , BabakoohiS , NilforoushzadehMA , Nassiri‐KashaniM , ShizarpourM , AjamiM , et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed2012;10(5):276‐82. [PUBMED: 23163069] ">Pazoki‐Toroudi 2012</a>: MD ‐37.85 hairs, 95% CI −54.22 to −21.48; P &lt; 0.00001) in favour of minoxidil. Number of participants reporting decrease: <a href="./references#CD007628-bbs2-0046" title="WhitingDA , JacobsonC . Treatment of female androgenetic alopecia with minoxidil 2%. International Journal of Dermatology1992;31(11):800‐4. [PUBMED: 1428436] ">Whiting 1992</a>: RR 1.34, 95% CI 0.68 to 2.66; <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a>: RR 1.13, 95% CI 0.95 to 1.33 </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cosmetic appearance of the hair or participant satisfaction</b> <br/> Assessed with: VAS with 0 = no benefit, 50 = moderate benefit, and 100 = great benefit<br/> Scale from: 0 to 100 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VAS score was 60.0 (27.6) for 5% minoxidil, 50.5 (35.5) for 2% minoxidil and 41.8 (29.9) for placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality (or pattern) of hair regrowth (e.g. thickness)</b> <br/> Assessed with: Savin Female Density scale and target area hair width was 0.87 (1.315) mm/cm² </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>372<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>2,13</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Investigators in <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> reported statistically significant differences in hair density for both minoxidil concentrations compared to placebo. <a href="./references#CD007628-bbs2-0028" title="NCT01325350 . Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01325350 (accessed 14 January 2016). ">NCT01325350</a>: MD 0.80, 95% CI 0.36 to 1.24; P = 0.004 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio; <b>GRADE:</b> Grading of Recommendations Assessment, Development and Evaluation; <b>FPHL:</b> female pattern hair loss;<b>RCT</b> : randomised controlled trial; <b>MD:</b> mean difference; <b>VAS:</b> visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded 1 level for serious risk of bias as we judged 5/6 studies' key domains of risk of bias, i.e. sequence generation, allocation concealment, and blinding as 'unclear'. <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a> was at 'low risk'.<br/> <sup>2</sup>Downgraded 1 level for serious imprecision due to small sample size, not meeting optimal information size.<br/> <sup>3</sup>Downgraded 1 level for serious risk of bias due to high drop‐out rate and per‐protocol analysis.<br/> <sup>4</sup>Downgraded 1 level for serious risk of bias as all 4 studies were at unclear to high risk of bias.<br/> <sup>5</sup>Downgraded 1 level for serious imprecision due to low occurrence of events.<br/> <sup>6</sup><a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> had 3 treatment arms.<br/> <sup>7</sup>Downgraded 1 level for serious risk of bias as we judged 6/7 studies' key domains of risk of bias, i.e. sequence generation, allocation concealment, and blinding as 'unclear'. <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a> was at 'low risk'.<br/> <sup>8</sup>Downgraded 1 level for serious risk of bias as we judged 7/8 studies' key domains of risk of bias, i.e. sequence generation, allocation concealment, and blinding as 'unclear'. <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a> was at 'low risk'.<br/> <sup>9</sup><a href="./references#CD007628-bbs2-0036" title="PriceVH , MenefeeE . Quantitative estimation of hair growth. I. androgenetic alopecia in women: effect of minoxidil. Journal of Investigative Dermatology1990;95(6):683‐7. [PUBMED: 2250110] ">Price 1990</a> was an outlier, with a small sample size (N = 8). There was possible publication bias, single participant with large treatment effect, and the result may be due to natural sampling variation.<br/> <sup>10</sup>Downgraded 1 level for serious risk of bias as in 2/3 studies' key domains of risk of bias, i.e. sequence generation, allocation concealment, and blinding were judged 'unclear'. <a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a> was at 'low risk'.<br/> <sup>11</sup>Downgraded 1 level for serious inconsistency as only <a href="./references#CD007628-bbs2-0034" title="Pazoki‐ToroudiH , BabakoohiS , NilforoushzadehMA , Nassiri‐KashaniM , ShizarpourM , AjamiM , et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed2012;10(5):276‐82. [PUBMED: 23163069] ">Pazoki‐Toroudi 2012</a> showed a difference in favour of minoxidil whilst the other 2 studies did not.<br/> <sup>12</sup>Downgraded 1 level for serious imprecision due to wide CIs, and the optimal information size is not met.<br/> <sup>13</sup>Downgraded 1 level for serious risk of bias due to attrition bias in <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> and unclear risk of selection, performance, and detection bias in <a href="./references#CD007628-bbs2-0028" title="NCT01325350 . Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01325350 (accessed 14 January 2016). ">NCT01325350</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Minoxidil versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007628-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Minoxidil 2% versus minoxidil 5%</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Minoxidil 2% compared to minoxidil 5% for female pattern hair loss (FPHL)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with FPHL <br/> <b>Intervention:</b> minoxidil 2%<br/> <b>Comparison:</b> minoxidil 5% </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with minoxidil 5%</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with minoxidil 2%</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of participants with self‐rated clinically significant hair regrowth</b> <br/> Assessed with: 7 point Likert scale in <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>, VAS scale 0‐100 in <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> <br/> Follow‐up: range 24 weeks to 48 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>322<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a> moderate to greatly increased hair regrowth in minoxidil 2% group versus 5% RR 1.12, 95% CI 0.72 to 1.73. VAS in <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> 62.9 (16.7 standard deviation (SD)) versus 68.1 (17.9 SD), authors' reported P = 0.062 </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b> <br/> Assessed with: VAS<br/> Scale from: 0 to 100 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>209<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Investigators reported "no statistically significant difference in impact of hair loss on quality of life between the two intervention groups" </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.02</b> <br/> (0.91 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1006<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Excluding <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> from the analysis, reduced the degree of heterogeneity, with minimal impact on the pooled results </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>369 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>376 per 1000</b> <br/> (335 to 442) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of participants with investigator‐rated clinically significant hair regrowth</b> <br/> Assessed with: 7 point Likert scales in <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a> and <a href="./references#CD007628-bbs2-0039" title="ShengY‐Y , RuiW‐L , XuF , QiS‐S , HuR‐M , MiaoY , et al. A randomized controlled clinical study on 2% and 5% topical minoxidil solution in the treatment of female pattern hair loss [Chinese]. Journal of Clinical Dermatology2014;43(10):583‐5. [EMBASE: 2015699887] ">Sheng 2014</a>. VAS scale in <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> <br/> Follow‐up: range 24 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>586<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>These outcomes in the 3 studies were in agreement with the participant assessments that there was no difference between the 2 concentrations of minoxidil </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline to study conclusion in total hair count</b> <br/> Follow‐up: range 26 weeks to 52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline to study conclusion in total hair count ranged from <b>23.7 to 31.9 hairs/cm</b>² </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline to study conclusion in total hair count in the intervention group was <b>2.12 hairs/cm</b> ²<b>lower</b> (5.47 lower to 1.23 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>631<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference between the 2 concentrations of minoxidil</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Degree of hair shedding from baseline to the end of the study</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed in any of the studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cosmetic appearance of the hair or participant satisfaction</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>322<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3/4 in <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a> were more satisfied after minoxidil 2% versus &gt; 50% on 5%. In <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> the scores on the VAS were 50.5 (SD 32.5) in the 2% group versus 60.0 (SD 27.6) in the 5% group </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality (or pattern) of hair regrowth (e.g. thickness)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>322<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No differences in both studies between the treatment arms</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio; <b>GRADE:</b> Grading of Recommendations Assessment, Development and Evaluation; <b>FPHL:</b> female pattern hair loss;<b>RCT</b> : randomised controlled trial; <b>MD:</b> mean difference; <b>VAS:</b> visual analogue scale </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded 1 level for serious risk of imprecision, due to wide CIs in <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>.<br/> <sup>2</sup>Downgraded 1 level for serious risk of bias due to the fact participants were not blinded in <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a>.<br/> <sup>3</sup>Downgraded 1 level for serious risk of bias due to high drop‐out rate and per‐protocol analysis.<br/> <sup>4</sup>Downgraded 1 level for serious imprecision due to small sample size, and not meeting the optimal information size.<br/> <sup>5</sup>Downgraded 1 level for serious inconsistency, due to <a href="./references#CD007628-bbs2-0021" title="LuckyAW , PiacquadioDJ , DitreCM , DunlapF , KantorI , PandyaAG , et al. A randomized, placebo‐controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology2004;50(4):541‐53. [PUBMED: 15034503] ">Lucky 2004</a> showing (as only study) a statistically significant difference in favour of minoxidil 2%.<br/> <sup>6</sup>Downgraded 1 level for serious risk of bias as blinding was unclear in 3/4 studies.<br/> <sup>7</sup>Downgraded 1 level for serious risk of bias, due to the fact the blinding of the investigators was not assured in <a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a> and <a href="./references#CD007628-bbs2-0039" title="ShengY‐Y , RuiW‐L , XuF , QiS‐S , HuR‐M , MiaoY , et al. A randomized controlled clinical study on 2% and 5% topical minoxidil solution in the treatment of female pattern hair loss [Chinese]. Journal of Clinical Dermatology2014;43(10):583‐5. [EMBASE: 2015699887] ">Sheng 2014</a>.<br/> <sup>8</sup>Downgraded 1 level for serious risk of imprecision, due to wide CIs, and the optimal information size is not met.<br/> <sup>9</sup>Downgraded 1 level for serious risk of bias, due to the fact that outcome assessors in <a href="./references#CD007628-bbs2-0025" title="DoshiU , IsraelM , KendallC , QuizaC , SacavageS , TyndallD , et al. Effectiveness of once daily 5% minoxidil topical foam in the treatment of women with thinning hair due to female pattern hair loss (FPHL). Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB112. [EMBASE: 71895204] NCT01145625 . A Phase 3 multi‐center parallel design clinical trial to compare the efficacy and safety of 5% Minoxidil Foam vs. 2% Minoxidil Solution in females for the treatment of female pattern hair loss ‐ androgenetic alopecia (MINALO3004, NCT01145625). clinicaltrials.gov/ct2/show/NCT01145625 (accessed 14 January 2016). ">NCT01145625</a> were not blinded.<br/> <sup>10</sup>Downgraded 1 level for serious imprecision, due to low sample sizes not meeting optimal information sizes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Minoxidil 2% versus minoxidil 5%</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007628-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Finasteride versus placebo</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Finasteride compared to placebo for female pattern hair loss (FPHL)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with FPHL<br/> <b>Intervention:</b> finasteride<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with finasteride</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>The proportion of participants with self‐rated clinically significant hair regrowth at the end of the study</b> <br/> Assessed with: Questionnaire (Barber 1998)<br/> Follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.95</b> <br/> (0.66 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Finasteride was no more effective than placebo</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>471 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>448 per 1000</b> <br/> (311 to 646) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed in any of the studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> <br/> Follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.03</b> <br/> (0.45 to 2.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>786 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>809 per 1000</b> <br/> (354 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of participants with investigator‐rated clinically significant hair regrowth</b> <br/> Assessed with: 7‐point rating scale (‐3 = greatly decreased to +3 = greatly increased)<br/> Follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.77</b> <br/> (0.31 to 1.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Finasteride was no more effective than placebo, this is consistent with the assessments of the participants </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>186 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b> <br/> (58 to 353) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change from baseline to study conclusion in total hair count</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>231<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In two of the studies (<a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a> and <a href="./references#CD007628-bbs2-0047" title="WhitingDA , WaldstreicherJ , SanchezM , KaufmanKD . Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women. Journal of Investigative Dermatology. Symposium Proceedings1999;4(3):282‐4. [PUBMED: 10674382] ">Whiting 1999</a>) there was no clinically meaningful difference whilst in <a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a> there was a difference of around 17 hairs in favour of finasteride </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Degree of hair shedding from baseline to the end of the study</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>1,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Although the investigators in <a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a> provided no data, they reported that there was no statistically significant difference in the slowing down of hair loss between the two groups </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cosmetic appearance of the hair or participant satisfaction</b> <br/> Follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.78</b> <br/> (0.40 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>137<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>229 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>178 per 1000</b> <br/> (91 to 350) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality (or pattern) of hair regrowth (e.g. thickness)</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed in any of the studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio; <b>GRADE:</b> Grading of Recommendations Assessment, Development and Evaluation; <b>FPHL:</b> female pattern hair loss;<b>RCT</b>: randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded 1 level for serious risk of bias as we judged key domains of risk of bias, i.e. sequence generation, allocation concealment, and blinding as 'unclear'.<br/> <sup>2</sup>Downgraded 1 level for serious imprecision due to wide CIs, small sample size, and not meeting the optimal information size.<br/> <sup>3</sup>Downgraded 1 level for serious risk of bias as in 2 studies key domains of risk of bias, i.e. sequence generation, allocation concealment, and blinding were judged 'unclear'. Furthermore in <a href="./references#CD007628-bbs2-0047" title="WhitingDA , WaldstreicherJ , SanchezM , KaufmanKD . Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women. Journal of Investigative Dermatology. Symposium Proceedings1999;4(3):282‐4. [PUBMED: 10674382] ">Whiting 1999</a> the drop‐out ratio was &gt; 30% and the analysis was per‐protocol.<br/> <sup>4</sup>Downgraded 1 level for serious inconsistency as in <a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a> and <a href="./references#CD007628-bbs2-0047" title="WhitingDA , WaldstreicherJ , SanchezM , KaufmanKD . Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women. Journal of Investigative Dermatology. Symposium Proceedings1999;4(3):282‐4. [PUBMED: 10674382] ">Whiting 1999</a> there was no meaningful difference, while <a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a> did show a difference of around 19 hairs in favour of finasteride.<br/> <sup>5</sup>Downgraded 1 level for serious imprecision due to small sample size not meeting the optimal information size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Finasteride versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007628-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Low‐level laser comb versus sham device</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Low‐level laser comb compared to sham device for female pattern hair loss (FPHL)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with FPHL<br/> <b>Intervention:</b> low‐level laser comb<br/> <b>Comparison:</b> sham device </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with sham device</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with low‐level laser comb</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportion of participants with self‐rated clinically significant hair regrowth</b> <br/> Assessed with: 5 point Likert scale. However, minimally improved and improved data are combined by investigators<br/> Follow‐up: mean 26 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>141<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The participants did not consider the low‐level laser comb to be more effective than the sham device (RR 1.54, 95% CI 0.96 to 2.49 for <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a> and RR 1.18, 95% CI 0.74 to 1.89 for <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed in any of the studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> <br/> Follow‐up: mean 26 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>141<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The investigators reported that there were "laser comb‐related adverse events: dry skin (5.1%), pruritus (2.5%), scalp tenderness (1.3%), irritation (1.3%) &amp; a warm sensation at the site (1.3%)" </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants with investigator‐rated clinically significant hair regrowth</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed in any of the studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline to study conclusion in total hair count</b> <br/> Follow‐up: mean 26 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low<sup>2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were statistically significant differences in favour of low‐level laser comb. MD 17.40 hairs, 95% CI 9.74 to 25.06 (<a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>); MD 17.60 hairs, 95% CI 11.97 to 23.23 (<a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Degree of hair shedding from baseline to the end of the study</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed in any of the studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cosmetic appearance of the hair or participant satisfaction</b> <br/> Follow‐up: mean 26 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>141<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> moderate<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minimally improved or improved thickness or fullness of the hair: RR 1.46, 95% CI 0.86 to 2.49 for <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a> and RR 1.33, 95% CI 0.76 to 2.33 for <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality (or pattern) of hair regrowth (e.g. thickness)</b> ‐ not measured </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed in any of the studies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio; <b>ITT:</b> intention‐to‐treat; <b>GRADE:</b> Grading of Recommendations Assessment, Development and Evaluation; <b>FPHL:</b> female pattern hair loss;<b>RCT</b> : randomised controlled trial; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Not downgraded for risk of bias, due to the fact we recalculated the RR for the intention‐to‐treat (ITT) population, whilst in both studies (<a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>; <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>) these were analysed as per‐protocol.<br/> <sup>2</sup>Downgraded 1 level for serious imprecision, due to wide CIs for both studies, due to small sample size, and not meeting optimal information size.<br/> <sup>3</sup>Downgraded 1 level for serious risk of bias, due to the fact there was a drop‐out rate of 19.2% in <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a> and 9.5% in <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>, and data analysis was per‐protocol. Furthermore, the trials did not provide exact data of adverse events per treatment arm.<br/> <sup>4</sup>Downgraded 1 level for imprecision, due to small sample size, and not meeting optimal information size.<br/> <sup>5</sup>Downgraded 1 level for serious risk of bias, due to the fact there was a drop‐out rate of 19.2% in <a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a> and 9.5% in <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a>, and data analysis was per‐protocol. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Low‐level laser comb versus sham device</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007628-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of terms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Term</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alopecia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loss of hair from head or body</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anagen hair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active, growing hair</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anagen phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active growth phase of hair follicles (2 to 7 years)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Catagen phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Involution phase of the hair follicle</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ferritin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iron‐containing proteins that are widely distributed in animals, plants, and micro‐organisms. Their major function is to store iron in a non‐toxic bioavailable form </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follicular miniaturisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The follicles produce hair that is thinner and thinner, until they either stop producing hair or produce hair that is so fine it is barely noticeable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hepatotoxic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical‐driven liver damage</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperandrogenism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Condition characterised by excessive production/secretion of androgens</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypertrichosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excessive (terminal and vellus) hair in non‐androgen dependent body sites; varies in people with different ethnic background without any pathological findings </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hirsutism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excessive hairiness on women in those parts of the body where terminal hair does not normally occur or is minimal ‐ for example, beard or chest hair </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ludwig scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Classification of female pattern hair loss (FPHL) stages I to III (minimal, moderate, intense) (<a href="./references#CD007628-bbs2-0137" title="LudwigE . Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. British Journal of Dermatology1977;97(3):247‐54. [PUBMED: 921894] ">Ludwig 1977</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐alpha‐reductase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An enzyme that converts testosterone, the male sex hormone, into the more potent hormone, dihydrotestosterone </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sinclair scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐point scale (1 = normal, 5 = advanced hair loss) used to assess FPHL (<a href="./references#CD007628-bbs2-0119" title="DinhQQ , SinclairR . Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging2007;2(2):189‐99. [PUBMED: 18044135] ">Dinh 2007</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telogen hair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dormant, inactive hair</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telogen phase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resting phase of the hair follicle (3 months)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Telogen effluvium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Massive hair loss resulting from the early entry of hairs into the telogen phase</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terminal hair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thicker, longer, and pigmented hair</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tincture¹</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An alcoholic extract of a drug derived from a plant</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vasodilation¹</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Widening of the blood vessels</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vellus hair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short, fine, light‐coloured, and barely noticeable hair that develops on most of a person's body from childhood </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>Abbreviations: FPHL: female pattern hair loss.<br/> ¹Definition taken from: <a href="./references#CD007628-bbs2-0138" title="MartinA (editor) . Concise Colour Medical Dictionary. 2nd edition. Oxford University Press, 1998. ">Martin 1998</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of terms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007628-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Contact with investigators</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Response</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Additional</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0050" title="BezzolaP , SorbelliniE . The role of microinflammation and apoptosis in androgenic alopecia: New therapeutical strategies [Il ruolo della microinfiammazione e dell' apoptosi nella alopecia androgenetica: Nouve strategie terapeutiche]. Journal of Plastic Dermatology2009;5(1):47‐58. [EMBASE: 2009226819] ">Bezzola 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no separate data for women. The primary outcome was diameter of hair, not one of the outcomes for this review. We excluded this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0001" title="Blume‐PeytaviU , KunteC , KrispA , Garcia BartelsN , EllwangerU , HoffmannR . Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women [Vergleich der Wirksamkeit und Sicherheit von Minoxidil und Alfatradiol bei der topischen Behandlung der androgenetischen Alopezie der Frau]. Journal der Deutschen Dermatologischen Gesellschaft2007;5(5):391‐5. [PUBMED: 17451383] ">Blume‐Peytavi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IPD (individual patient data) were unavailable. We included this study.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0002" title="Blume‐PeytaviU , HillmannK , DietzE , CanfieldD , Garcia BartelsN . A randomized, single‐blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology2011;65(6):1126‐34.e.2. [PUBMED: 21700360] ">Blume‐Peytavi 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. </p> <p>We received a response on 16 November 2011: "The allocation concealment was performed using sequentially numbered, sealed, opaque envelopes, and kept by the project manager of the CRC." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0003" title="Bureau JP, GinouvesP , GuilbaudJ , RouxME . Essential oils and low‐intensity electromagnetic pulses in the treatment of androgen‐dependent alopecia. Advances in Therapy2003;20(4):220‐9. [PUBMED: 14669818] ">Bureau 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We could contact one of the investigators, who was unable to provide separate data on women. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0004" title="CarminaE , LoboRA . Treatment of hyperandrogenic alopecia in women. Fertility and Sterility2003;79(1):91‐5. [PUBMED: 12524069] ">Carmina 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0005" title="DeVillezRL , JacobsJP , SzpunarCA , WarnerML . Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Archives of Dermatology1994;130(3):303‐7. [PUBMED: 8129407] ">DeVillez 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0006" title="DraelosZD , JacobsonEL , KimH , KimM , JacobsonMK . A pilot study evaluating the efficacy of topically applied niacin derivatives for treatment of female pattern alopecia. Journal of Cosmetic Dermatology2005;4(4):258‐61. [PUBMED: 17168873] ">Draelos 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0056" title="FarellaV , MelliMC , GiorginiS . Mucopolysaccharides and depolymerized nucleic acids in the treatment of androgenic alopecia [Mucopolisaccaridi e acidi nucleici depolimerizzati nella alopecia androgenetica, studio clinico in doppio cieco]. Dermatologia Oggi1991;6(3):39‐46. [EMBASE: 1992071835] ">Farella 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Italian Cochrane Centre translated and assessed this study, but it was a controlled clinical trial (CCT), so we excluded it. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0007" title="FischerTW , BurmeisterG , SchmidtHW , ElsnerP . Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. British Journal of Dermatology2004;150(2):341‐5. [PUBMED: 14996107] ">Fischer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We received information that allowed a change in the assessment for several domains from unclear to low risk of bias. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0008" title="GassmuellerJ , HoffmannR , WebsterA . Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof‐of‐concept studies. British Journal of Dermatology2008;158(1):109‐15. [PUBMED: 17986309] ">Gassmueller 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We received information that allowed a change in assessment for several domains from unclear to low risk of bias. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0010" title="GeorgalaS , KatoulisAC , GeorgalaC , MoussatouV , BoziE , StavrianeasNG . Topical estrogen therapy for androgenetic alopecia in menopausal females. Dermatology2004;208(2):178‐9. [PUBMED: 15057016] ">Georgala 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0009" title="GehringW , GloorM . Use of the phototrichogram to assess the stimulation of hair growth ‐ An in vitro study of women with androgenetic alopecia [Das Phototrichogramm als Verfahren zur Beurteilung haarwachstumsfördernder Präparate am beispiel einer Kombination von Hirsefruchtextrakt, L‐Cystin und Calcium panthonthenat‐Ergebnisse einer in vivo Untersuchung bei Frauen mit androgenetischem Haarausfall]. H+G Zeitschrift fur Hautkrankheiten2000;75(7‐8):419‐23. [EMBASE: 2000344799] ">Gehring 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0058" title="GolpourM , RabbaniH , FarzinD , AziziF . Comparing the effectiveness of local solution of minoxidil and caffeine 2.5% with local solution of minoxidil 2.5% in treatment of androgenetic alopecia. Journal of Mazandaran University of Medical Sciences2013;23(106):29‐36. [EMBASE: 2014593395] ">Golpour 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. One review author, ZF, translated this study, which only included males, so we excluded this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0011" title="GuerreroAR , MedinaKR , KahnMC , GuerreroMJ . Usefulness and safety of 0.025 percent 17‐alpha‐estradiol versus 2 percent minoxidil in the treatment of androgenetic alopecia [Utilidad y seguridad del 17‐alfa‐estradiol 0,025 por ciento versus minoxidil 2 por ciento en el tratamiento de la alopecia androgenetica]. Revista Chilena de Dermatologia2009;25(1):21‐5. ">Guerrero 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. The data was mixed in terms of gender. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0012" title="HongCK , HanTY , KangHC , AhnSW , AhnJY , SeoSJ . The efficacy and safety of a combination cytopurine/pentadecanoic glyceride topical solution on androgenetic alopecia: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(12):1233‐9. ">Hong 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation/concealment and blinding. The data was mixed in terms of gender. We included this study. <a href="http://mailto:hongck@cau.ac.kr" target="_blank"><span class="__cf_email__" data-cfemail="452d2a2b22262e052624306b24266b2e37">[email protected]</span></a>; <a href="http://dermahan@gmail.com" target="_blank"><span class="__cf_email__" data-cfemail="cda9a8bfa0aca5aca38daaa0aca4a1e3aea2a0">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0013" title="JacobsJP , SzpunarCA , WarnerML . Use of topical minoxidil therapy for androgenetic alopecia in women. International Journal of Dermatology1993;32(10):758‐62. [PUBMED: 8225725] ">Jacobs 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were unable to contact the study investigators. We included this study.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0014" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014a</a>; <a href="./references#CD007628-bbs2-0015" title="JimenezJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJ , HamblinM , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss. Journal of Investigative Dermatology2014;134(Suppl 1):S100. [EMBASE: 71440974] JimenezJJ , WikramanayakeTC , BergfeldW , HordinskyM , HickmanJG , HamblinMR , et al. Efficacy and safety of a low‐level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device‐controlled, double‐blind study. American Journal of Clinical Dermatology2014;15(2):115‐27. [PUBMED: 24474647] ">Jimenez 2014b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation/concealment and blinding. We included this study. <a href="http://dm@hairmax.com" target="_blank"><span class="__cf_email__" data-cfemail="dcb8b19cb4bdb5aeb1bda4f2bfb3b1">[email protected]</span></a>; Leonard Stillman. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0016" title="GorenAO , TamPY , FrieD , KeeneSA . Epigenetic markers predict treatment response to finasteride in female androgenetic alopecia: Poster session. Experimental Dermatology2010;19(6):584. [EMBASE: 70193861] KeeneS , GorenA . Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. Dermatologic Therapy2011;24(2):296‐300. [PUBMED: 21410621] ">Keene 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation/concealment and blinding. We included this study. <a href="http://drkeene@hairrestore.com" target="_blank"><span class="__cf_email__" data-cfemail="86e2f4ede3e3e8e3c6eee7eff4f4e3f5f2e9f4e3a8e5e9eb">[email protected]</span></a>; <a href="http://andyg@appliedbiology.com" target="_blank"><span class="__cf_email__" data-cfemail="02636c667b65426372726e6b6766606b6d6e6d657b2c616d6f">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0017" title="KimJH , YSM , ChoiJE , SonSW . Study of the efficacy of Korean red ginseng in the treatment of androgenic alopecia. Journal of Ginseng Research2009;33(3):223‐8. ">Kim 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding.</p> <p><a href="http://skin4u@korea.ac.kr" target="_blank"><span class="__cf_email__" data-cfemail="20534b494e1455604b4f5245410e41430e4b52">[email protected]</span></a>. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0018" title="KimH , ChoiJW , KimJY , ShinJW , LeeSJ , HuhCH . Low‐level light therapy for androgenetic alopecia: a 24‐week, randomized, double‐blind, sham device‐controlled multicenter trial. Dermatologic Surgery2013;39(8):1177‐83. [PUBMED: 23551662] ">Kim 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation, but not for concealment and blinding. We did not receive separate data for women. We included this study. <a href="http://chhuh@snu.ac.kr" target="_blank"><span class="__cf_email__" data-cfemail="01626969746941726f742f60622f6a73">[email protected]</span></a>; <a href="http://seokjong@knu.ac.kr" target="_blank"><span class="__cf_email__" data-cfemail="562533393d3c393831163d3823783735783d24">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0019" title="LanzafameRJ , BlancheRR , ChiacchieriniRP , KazmirekER , SklarJA . The growth of human scalp hair in females using visible red light laser and LED sources. Lasers in Surgery and Medicine2014;46(8):601‐7. [PUBMED: 25124964] ">Lanzafame 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation, as well as losses to follow‐up.</p> <p><a href="http://raymond.lanzafame@gmail.com" target="_blank"><span class="__cf_email__" data-cfemail="9ae8fbe3f7f5f4feb4f6fbf4e0fbfcfbf7ffdafdf7fbf3f6b4f9f5f7">[email protected]</span></a>. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0020" title="LeFloc'hC , ChenitiA , ConnétableS , PiccardiN , VincenziC , TostiA . Effect of a nutritional supplement on hair loss in women. Journal of Cosmetic Dermatology2015;14(1):76‐82. [PUBMED: 25573272] ">Le Floc'h 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. <a href="http://npiccardi@rd.loreal.com" target="_blank"><span class="__cf_email__" data-cfemail="c8a6b8a1ababa9baaca188baace6a4a7baada9a4e6aba7a5">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0065" title="LiMC , ShuW , WangHY , WangXS . Randomized double‐blind placebo‐controlled evaluation of topical minoxidil in the treatment of female androgonetic alopecia. Chinese Journal of Dermatology1996;29:223‐5. ">Li 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We excluded this study as it was a CCT.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0022" title="MazzarellaF , LoconsoleF , CammisaA , MastrolonardoM , VenaGA . Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16‐month therapy course. Journal of Dermatological Treatment1997;8(3):189‐92. [EMBASE: 1997295968] ">Mazzarella 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. The data was mixed in terms of gender. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0023" title="MinozziM , UnferV , ConstabileL . Androgenetic alopecia in postmenopausal women [Alopecia androgenetica in post‐menopausa]. Giornale Italiano di Ostetricia e Ginecologia1997;19(6):341‐4. [EMBASE: 1997225861] ">Minozzi 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0033" title="OuraH , IinoM , IdetaR , NakazawaY , KishimotoJ , AraseS . Efficacy of adenosine on female pattern hair loss and male androgenetic alopecia. Journal of Investigative Dermatology2008;128(Suppl 1):S151. OuraH , IinoM , NakazawaY , TajimaM , IdetaR , NakayaY , et al. Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: a pilot, double‐blind, randomized, placebo‐controlled trial. Journal of Dermatology2008;35(12):763‐7. [PUBMED: 19239555] ">Oura 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0034" title="Pazoki‐ToroudiH , BabakoohiS , NilforoushzadehMA , Nassiri‐KashaniM , ShizarpourM , AjamiM , et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. Skinmed2012;10(5):276‐82. [PUBMED: 23163069] ">Pazoki‐Toroudi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study. <a href="http://hpazooki@farabi.tums.ac.ir" target="_blank"><span class="__cf_email__" data-cfemail="c2aab2a3b8adada9ab82a4a3b0a3a0abecb6b7afb1eca3a1ecabb0">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0036" title="PriceVH , MenefeeE . Quantitative estimation of hair growth. I. androgenetic alopecia in women: effect of minoxidil. Journal of Investigative Dermatology1990;95(6):683‐7. [PUBMED: 2250110] ">Price 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We received no response from the investigator. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0037" title="PriceVH , RobertsJL , HordinskyM , OlsenEA , SavinR , BergfeldW , et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology2000;43(5 Pt 1):768‐76. [PUBMED: 11050579] ">Price 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We received no response from the investigator. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0039" title="ShengY‐Y , RuiW‐L , XuF , QiS‐S , HuR‐M , MiaoY , et al. A randomized controlled clinical study on 2% and 5% topical minoxidil solution in the treatment of female pattern hair loss [Chinese]. Journal of Clinical Dermatology2014;43(10):583‐5. [EMBASE: 2015699887] ">Sheng 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation/concealment and blinding. We included this study. <a href="http://dxq93216@medmail.com.cn" target="_blank"><span class="__cf_email__" data-cfemail="680c1019515b5a595e28050d0c05090104460b0705460b06">[email protected]</span></a>; <a href="http://felix_sheng@medmail.com.cn" target="_blank"><span class="__cf_email__" data-cfemail="1f797a737667406c777a71785f727a7b727e7673317c7072317c71">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0040" title="ShinHS , LeeSH , KimDH , AnJS , KwonOS , EunHC . The efficacy and safety of AP‐FHG0604T on female pattern hair loss: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(2):119‐26. ">Shin 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation/concealment. We included this study. </p> <p><a href="http://hceun@snu.ac.kr" target="_blank"><span class="__cf_email__" data-cfemail="1e767d7b6b705e6d706b307f7d30756c">[email protected]</span></a>; <a href="http://reslab@naver.com" target="_blank"><span class="__cf_email__" data-cfemail="631106100f0201230d021506114d000c0e">[email protected]</span></a> (Dr Shin Hyoseung); <a href="http://oskwon@snu.ac.kr" target="_blank"><span class="__cf_email__" data-cfemail="79160a120e1617390a170c57181a57120b">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0077" title="SinclairR . Treatment of androgenetic alopecia in women with oral antiandrogen therapy. Annales de Dermatologie et de Venereologie2002;129(Suppl 1 Pt 1):1S324. ">Sinclair 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Information provided to us enabled a change from unclear to high risk of bias. We excluded this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0041" title="ThomE . Efficacy and tolerability of Hairgain® in individuals with hair loss: a placebo‐controlled, double‐blind study. Journal of International Medical Research2001;29(1):2‐6. [EMBASE: 2001114261] ">Thom 2001</a>/<a href="./references#CD007628-bbs2-0042" title="ThomE . Nourkrin: objective and subjective effects and tolerability in persons with hair loss. Journal of International Medical Research2006;34(5):514‐9. [EMBASE: 2006563255] ">Thom 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The data was mixed in terms of gender. We received no response from the investigator. We included this study. <a href="http://erling.thom@parexel.com" target="_blank"><span class="__cf_email__" data-cfemail="7712051b1e191059031f181a37071605120f121b5914181a">[email protected]</span></a>; <a href="http://info@pharmamedico.com" target="_blank"><span class="__cf_email__" data-cfemail="0b62656d644b7b636a79666a666e6f62686425686466">[email protected]</span></a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0043" title="TsuboiR , TanakaT , NishikawaT , UekiR , YamadaH , KatsuokaK , et al. A randomized, placebo‐controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. European Journal of Dermatology2007;17(1):37‐44. [PUBMED: 17324826] ">Tsuboi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The information we received allowed us to change the assessment for several domains from unclear to low risk of bias. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0044" title="UkşalÜ , BayramF , UtaşS , ÇolakR , BorluM . Comparision of low dose finasteride, flutamide and spirolactone in female androgenetic alopecia. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S238. ">Ukşal 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was unconfirmed, i.e. sequence allocation/concealment and blinding. We included this study, but there were missing data. We received no response from the investigator. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0045" title="VexiauP , ChaspouxC , BoudouP , FietJ , JouaniqueC , HardyN , et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12‐month randomized trial. British Journal of Dermatology2002;146(6):992‐9. [PUBMED: 12072067] ">Vexiau 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We received information regarding the hyperandrogenic profile of the women. We included this study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0094" title="ACTRN12607000027415 . Double blind placebo controlled trial into the treatment of female pattern hair loss with spironolactone and minoxidil. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=81787 (accessed 14 January 2016). ">ACTRN12607000027415</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date. <a href="http://yazdaa27@gmail.com" target="_blank"><span class="__cf_email__" data-cfemail="4d342c37292c2c7f7a0d2a202c2421632e2220">[email protected]</span></a>; <a href="http://Rod.SINCLAIR@svhm.org.au" target="_blank"><span class="__cf_email__" data-cfemail="9ccef3f8b2cfd5d2dfd0ddd5cedcefeaf4f1b2f3eefbb2fde9">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0095" title="EUCTR2013‐002740‐85‐ES . A Pilot Randomized, Double‐blind, Placebo‐controlled Clinical Trial to Obtain Preliminary Data on Efficacy and Safety in the Application of PRGF‐Endoret by Mesotherapy, in the Treatment of Male and Female Androgenetic Alopecia of Over 6 Months Duration. www.clinicaltrialsregister.eu/ctr‐search/search?query=EUCTR2013‐002740‐85‐ES (accessed 16 January 2016). ">EUCTR2013‐002740‐85‐ES</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date nor if these are the same studies. <a href="http://eduardoanitua@eduardoanitua.com" target="_blank"><span class="__cf_email__" data-cfemail="afcacbdaceddcbc0cec1c6dbdaceefcacbdaceddcbc0cec1c6dbdace81ccc0c2">[email protected]</span></a>; <a href="http://virginia.cuadrado@bti-implant.es" target="_blank">virginia.cuadrado@bti‐implant.es</a>; <a href="http://alopecia.ccdermatologico@gmail.com" target="_blank"><span class="__cf_email__" data-cfemail="8eefe2e1feebede7efa0ededeaebfce3effae1e2e1e9e7ede1cee9e3efe7e2a0ede1e3">[email protected]</span></a>. Are EUCTR2013‐002740‐85‐ES and NCT01885676 the same studies, as everything is the same, except contact persons (same inclusion, same number of patients, same treatments, same sponsor) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0096" title="NCT00175617 . Efficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT00175617 (accessed 14 January 2016). ">NCT00175617</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date. <a href="http://andreas.finner@vch.ca" target="_blank"><span class="__cf_email__" data-cfemail="066768627463677528606f686863744670656e286567">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0097" title="NCT00197379 . The Effect of 0.5% Roxithromycin Lotion for Androgenetic Alopecia. clinicaltrials.gov/ct2/show/NCT00197379 (accessed 14 January 2016). ">NCT00197379</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date. <a href="http://itoutai@hama-med.ac.jp" target="_blank">itoutai@hama‐med.ac.jp</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0098" title="NCT00418249 . Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women. clinicaltrials.gov/ct2/show/NCT00418249 (accessed 14 January 2016). ">NCT00418249</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date. <a href="http://mailto:rlurie%40bezeqint.net" target="_blank"><span class="__cf_email__" data-cfemail="5c2e30292e35391c3e3926392d35322872323928">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0025" title="DoshiU , IsraelM , KendallC , QuizaC , SacavageS , TyndallD , et al. Effectiveness of once daily 5% minoxidil topical foam in the treatment of women with thinning hair due to female pattern hair loss (FPHL). Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB112. [EMBASE: 71895204] NCT01145625 . A Phase 3 multi‐center parallel design clinical trial to compare the efficacy and safety of 5% Minoxidil Foam vs. 2% Minoxidil Solution in females for the treatment of female pattern hair loss ‐ androgenetic alopecia (MINALO3004, NCT01145625). clinicaltrials.gov/ct2/show/NCT01145625 (accessed 14 January 2016). ">NCT01145625</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation/concealment. LinkedIn Professor Kendall, and U Doshi and website Johnson &amp; Johnson. Received from both Johnson &amp; Johnson international as NL reply they forwarded it to responsible party, however, no response </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0026" title="NCT01189279 . Safety and pharmacokinetics study of new formulation of Bimatoprost in patients with alopecia. clinicaltrials.gov/ct2/show/NCT01189279 (accessed 14 January 2016). ">NCT01189279</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date. <a href="http://clinicaltrials@allergan.com" target="_blank"><span class="__cf_email__" data-cfemail="43202f2a2d2a20222f37312a222f3003222f2f263124222d6d202c2e">[email protected]</span></a>, international and Dutch website </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0027" title="NCT01226459 . A Phase 3 Multi‐Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia). clinicaltrials.gov/ct2/show/NCT01226459 (accessed 14 January 2016). ">NCT01226459</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0028" title="NCT01325350 . Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01325350 (accessed 14 January 2016). ">NCT01325350</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allergan through website twice, no reply.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0029" title="NCT01655108 . Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients. clinicaltrials.gov/ct2/show/NCT01655108 (accessed 14 January 2016). ">NCT01655108</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation/concealment and blinding and received all possible data of the submitted paper. <a href="http://izelda@unb.br" target="_blank"><span class="__cf_email__" data-cfemail="cba2b1aea7afaa8bbea5a9e5a9b9">[email protected]</span></a>, Barbara Uzel: <a href="http://barbara.uzel@gmail.com" target="_blank"><span class="__cf_email__" data-cfemail="076566756566756629727d626b47606a666e6b2964686a">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0100" title="NCT01662089 . The Efficacy in Treatment of Female Pattern Hair Loss Using 5% Minoxidil Solution Combinded With Zinc Supplement. clinicaltrials.gov/ct2/show/NCT01662089 (accessed 14 January 2016). ">NCT01662089</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date. <a href="http://mailto:rattapongthuangtong%40yahoo.com?subject=NCT01662089, SirirajH-004, The Efficacy in Treatment of Female Pattern Hair Loss Using 5% Minoxidil Solution Combinded With Zinc Supplement" target="_blank"><span class="__cf_email__" data-cfemail="7c0e1d08081d0c13121b0814091d121b0813121b3c051d141313521f1311">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0101" title="NCT01686295 . 24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness. clinicaltrials.gov/ct2/show/NCT01686295 (accessed 14 January 2016). ">NCT01686295</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date. <a href="http://mailto:candresen%40tklresearch.com?subject=NCT01686295, CS940112, 24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness" target="_blank"><span class="__cf_email__" data-cfemail="0d6e6c63697f687e68634d7966617f687e686c7f6e65236e6260">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0102" title="NCT01885676 . Plasma Rich in Growth Factors (PRGF‐Endoret) in the Treatment of Androgenetic Alopecia. clinicaltrials.gov/ct2/show/NCT01885676 (accessed 14 January 2016). ">NCT01885676</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No further information regarding publication date. <a href="http://mailto:eduardoanitua%40eduardoanitua.com?subject=NCT01885676, BTI-01D-EC/12/ALO, Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia" target="_blank"><span class="__cf_email__" data-cfemail="e68382938794828987888f929387a68382938794828987888f929387c885898b">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0030" title="NCT01900041 . A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss. clinicaltrials.gov/ct2/show/NCT01900041 (accessed 14 January 2016). ">NCT01900041</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. sequence allocation and flow chart. We included this study. </p> <p><a href="http://Larissa.Cheredeeva@merz.ru" target="_blank"><span class="__cf_email__" data-cfemail="460a27342f35352768052e2334232223233027062b23343c683433">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0031" title="NCT01967277 . A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy. clinicaltrials.gov/ct2/show/NCT01967277 (accessed 14 January 2016). ">NCT01967277</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial conduct was confirmed, i.e. concealment and blinding (but not sequence generation). We included this study. <a href="http://pschnoor@capillus.com" target="_blank"><span class="__cf_email__" data-cfemail="8dfdfeeee5e3e2e2ffcdeeecfde4e1e1f8fea3eee2e0">[email protected]</span></a>, <a href="http://mailto:info@capillus.com" target="_blank"><span class="__cf_email__" data-cfemail="f69f989099b69597869f9a9a8385d895999b">[email protected]</span></a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0103" title="NCT02074943 . Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia. clinicaltrials.gov/ct2/show/NCT02074943 (accessed 14 January 2016). ">NCT02074943</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no further information regarding publication date, and the study is not yet finished. <a href="http://mailto:Jerry.Shapiro%40vch.ca?subject=NCT02074943, H13-03126, Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia" target="_blank"><span class="__cf_email__" data-cfemail="5e143b2c2c27700d363f2e372c311e283d36703d3f">[email protected]</span></a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Abbreviations: CCT: controlled clinical trial (quasi‐randomised).</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Contact with investigators</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007628-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Checklist for describing and assessing patient‐reported outcomes (PROs) in clinical trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. What were PROs measuring?<br/> a. What concepts were the PROs used in the study measuring?<br/> b. What rationale (if any) for selection of concepts or constructs did the authors provide?<br/> c. Were patients involved in the selection of outcomes measured by the PROs? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2. Omissions<br/> a. Were there any important aspects of health (e.g. symptoms, function, perceptions) or quality of life (e.g. overall evaluation, satisfaction with life) that were omitted in this study from the perspectives of the patient, clinician, significant others, payers, or other administrators and decision‐makers? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3. If randomised trials and other studies measured PROs, what were the instruments' measurement strategies?<br/> a. Did investigators use instruments that yield a single indicator or index number, a profile, or a battery of instruments?<br/> b. If investigators measure PROs, did they use specific or generic measures, or both? <br/> c. Who exactly completed the instruments? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4. Did the instruments work in the way they were supposed to work ‐ validity?<br/> a. Had the instruments used been validated previously (provide reference)? Was evidence of prior validation for use in this population presented?<br/> b. Were the instruments re‐validated in this study? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5. Did the instruments work in the way they were supposed to work ‐ ability to measure change?<br/> a. Are the PROs able to detect change in patient status, even if those changes are small? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6. Can you make the magnitude of effect (if any) understandable to readers?<br/> a. Can you provide an estimate of the difference in patients achieving a threshold of function or improvement, and the associated number needed to treat (NNT)? </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Table 17.6.a </p> <p>Patrick D, Guyatt GH, Acquadro C. Chapter 17: Patient‐reported outcomes. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="1"> <div class="table-footnote"> <p>Abbreviations: PRO: patient‐reported outcome.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Checklist for describing and assessing patient‐reported outcomes (PROs) in clinical trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007628-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Included studies with no usable or irretrievable data</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interventions and comparisons</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0003" title="Bureau JP, GinouvesP , GuilbaudJ , RouxME . Essential oils and low‐intensity electromagnetic pulses in the treatment of androgen‐dependent alopecia. Advances in Therapy2003;20(4):220‐9. [PUBMED: 14669818] ">Bureau 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Essential oil solution (E2F7) and electromagnetic pulses versus placebo solution and electromagnetic pulses </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> <p>Investigators unable to provide these</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0007" title="FischerTW , BurmeisterG , SchmidtHW , ElsnerP . Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. British Journal of Dermatology2004;150(2):341‐5. [PUBMED: 14996107] ">Fischer 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Melatonin–alcohol solution versus alcohol solution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of our outcomes were addressed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0011" title="GuerreroAR , MedinaKR , KahnMC , GuerreroMJ . Usefulness and safety of 0.025 percent 17‐alpha‐estradiol versus 2 percent minoxidil in the treatment of androgenetic alopecia [Utilidad y seguridad del 17‐alfa‐estradiol 0,025 por ciento versus minoxidil 2 por ciento en el tratamiento de la alopecia androgenetica]. Revista Chilena de Dermatologia2009;25(1):21‐5. ">Guerrero 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minoxidil 2% versus 17α‐estradiol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> <p>No response from principal investigator</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0012" title="HongCK , HanTY , KangHC , AhnSW , AhnJY , SeoSJ . The efficacy and safety of a combination cytopurine/pentadecanoic glyceride topical solution on androgenetic alopecia: A randomized double‐blind placebo‐controlled clinical trial. Korean Journal of Dermatology2007;45(12):1233‐9. ">Hong 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cytopurine, pentadecanoic glyceride, 95% ethanol topical solution versus vehicle solution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0017" title="KimJH , YSM , ChoiJE , SonSW . Study of the efficacy of Korean red ginseng in the treatment of androgenic alopecia. Journal of Ginseng Research2009;33(3):223‐8. ">Kim 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Korean red ginseng versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> <p>No response from principal investigator</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0018" title="KimH , ChoiJW , KimJY , ShinJW , LeeSJ , HuhCH . Low‐level light therapy for androgenetic alopecia: a 24‐week, randomized, double‐blind, sham device‐controlled multicenter trial. Dermatologic Surgery2013;39(8):1177‐83. [PUBMED: 23551662] ">Kim 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low level light therapy versus sham device</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> <p>No response from principal investigator</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0022" title="MazzarellaF , LoconsoleF , CammisaA , MastrolonardoM , VenaGA . Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16‐month therapy course. Journal of Dermatological Treatment1997;8(3):189‐92. [EMBASE: 1997295968] ">Mazzarella 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Finasteride 0.005% lotion versus vehicle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> <p>No response from principal investigator</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0023" title="MinozziM , UnferV , ConstabileL . Androgenetic alopecia in postmenopausal women [Alopecia androgenetica in post‐menopausa]. Giornale Italiano di Ostetricia e Ginecologia1997;19(6):341‐4. [EMBASE: 1997225861] ">Minozzi 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ethinyl estradiol (0.02 mg/day) versus transdermal estradiol (0.05 mg/day) with medroxyprogesterone acetate (MPA) versus ethinyl estradiol (0.02 mg/day) with cyproterone acetate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosis of female pattern hair loss (FPHL) was not clearly defined/stated. No response from principal investigator </p> <p>None of our outcomes were assessed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0024" title="MorgantiP , FabriziG , JamesB , BrunoC . Effect of gelatin‐cystine and serenoa repens extract on free radicals level and hair growth. Journal of Applied Cosmetology1998;16(3):57‐64. [EMBASE: 1998406625] ">Morganti 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active lotion (gelatine‐cystine and <i>Serenoa repens</i>) versus placebo lotion versus active diet supplement (gelatine‐cystine) versus placebo supplement versus active lotion and active supplement (n = 12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> <p>No response from principal investigator</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0026" title="NCT01189279 . Safety and pharmacokinetics study of new formulation of Bimatoprost in patients with alopecia. clinicaltrials.gov/ct2/show/NCT01189279 (accessed 14 January 2016). ">NCT01189279</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bimatoprost A versus bimatoprost B versus bimatoprost C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of our outcomes were addressed, no separate data for men and women. No response from Allergan </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0027" title="NCT01226459 . A Phase 3 Multi‐Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia). clinicaltrials.gov/ct2/show/NCT01226459 (accessed 14 January 2016). ">NCT01226459</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minoxidil 5% versus vehicle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Too many inconsistencies regarding numbers that dropped out and number of participants analysed, as well as in calculations made for mean changes from baseline. No response from principal investigators </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0038" title="RietschelML , DuncanSH . Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. Journal of the American Academy of Dermatology1987;16(3 Pt 2):677‐85. [EMBASE: 1987099274] ">Rietschel 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minoxidil 2% versus minoxidil 3% versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> <p>No response from principal investigator</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0041" title="ThomE . Efficacy and tolerability of Hairgain® in individuals with hair loss: a placebo‐controlled, double‐blind study. Journal of International Medical Research2001;29(1):2‐6. [EMBASE: 2001114261] ">Thom 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dietary supplement versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> <p>No response from principal investigator</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0042" title="ThomE . Nourkrin: objective and subjective effects and tolerability in persons with hair loss. Journal of International Medical Research2006;34(5):514‐9. [EMBASE: 2006563255] ">Thom 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dietary supplement versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No separate data for men and women</p> <p>No response from principal investigator</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-bbs2-0044" title="UkşalÜ , BayramF , UtaşS , ÇolakR , BorluM . Comparision of low dose finasteride, flutamide and spirolactone in female androgenetic alopecia. Journal of the European Academy of Dermatology &amp; Venereology1999;12(Suppl 2):S238. ">Ukşal 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spironolactone versus flutamide versus finasteride</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Poster, limited data, unclear how many participants in each group. No response from principal investigator </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Abbreviations: FPHL: female pattern hair loss, N: Number randomised</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Included studies with no usable or irretrievable data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007628-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Table of random‐effects sensitivity analyses</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysis</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Concentration/subgroups</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95% confidence interval</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>I² statistic</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chi² test (P value)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-fig-0007" title="">Analysis 1.1</a> </p> <p>Self‐rated hair regrowth</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.34 to 2.46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.00001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD007628-fig-0008" title="">Analysis 1.2</a> </p> <p>Adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minoxidil (1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.61 to 2.06</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minoxidil (2%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 to 1.79</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minoxidil (5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51 to 6.55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.10</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-fig-0009" title="">Analysis 1.3</a> </p> <p>Investigator‐rated hair regrowth</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.53 to 3.06</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.00001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.41</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-fig-0010" title="">Analysis 1.4</a> </p> <p>Increase in total hair count</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.80 to 15.65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.00001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-fig-0011" title="">Analysis 1.5</a> </p> <p>Increase in total hair count (sensitivity analysis)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.96</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.69 to 15.24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.00001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.76</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-fig-0012" title="">Analysis 2.1</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 to 1.30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.005</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-fig-0013" title="">Analysis 2.2</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 to 1.35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007628-fig-0014" title="">Analysis 2.3</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−2.12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−5.47 to 1.23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Table of random‐effects sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/full#CD007628-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007628-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Minoxidil versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Proportion of participants with self‐rated at least moderate hair regrowth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [1.51, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion of participants with adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.98, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Topical minoxidil solution (1%) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.61, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Topical minoxidil solution (2%) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>727</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.82, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Topical minoxidil solution (5%) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [0.96, 4.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Proportion of participants with investigator‐rated at least moderate hair regrowth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.35 [1.68, 3.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mean increase in total hair count from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.18 [10.92, 15.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Topical (1% to 2%) minoxidil versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.97 [10.58, 15.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Topical (5%) minoxidil versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.1 [7.96, 22.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mean increase in total hair count from baseline (sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.96 [10.69, 15.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Topical (1% to 2%) minoxidil versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.72 [10.33, 15.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Topical (5%) minoxidil versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.1 [7.96, 22.24]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Minoxidil versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/references#CD007628-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007628-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Minoxidil 2% versus minoxidil 5%</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.91, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of adverse events (sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.99, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean increase in total hair count from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.12 [‐5.47, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Minoxidil 2% versus minoxidil 5%</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007628.pub4/references#CD007628-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007628.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD007628-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD007628-note-0009">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007628-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007628-note-0007">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD007628-note-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD007628-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD007628-note-0004">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD007628-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD007628-note-0023">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007628-note-0002">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007628-note-0008">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007628\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007628\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007628\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007628\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007628\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007628\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007628\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007628\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007628\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007628\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007628\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007628\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007628\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007628\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007628\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007628\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007628\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007628\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007628.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007628.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007628.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007628.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007628.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715079976"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007628.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715079981"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007628.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7e5749f71bde',t:'MTc0MDcxNTA4MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 